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Bioconjugation chemistry generally refers to the covalent derivatisation of 
biomolecules. Derivatisation of cysteine’s thiol of peptides and proteins is a 
common method in bioconjugation chemistry as the thiolate is an excellent 
nucleophile in aqueous conditions. 
The propensity for thiols to oxidise in an aqueous environment necessitates the 
need for a disulfide reduction step prior to the addition of ligands derivatised with 
thiol alkylating linkers. Disulfide reducing agents such as tris(2-
carboxyethyl)phosphine (TCEP) and tris(3-hydroxypropyl)phosphine (THPP) are 
disulfide reducing agents that are often marketed as being non-reactive with thiol 
alkylating reagents. The reaction of TCEP and THPP with thiol alkylation linkers was 
therefore investigated. Characterisation of reaction products and mechanistic 
studies revealed that TCEP and THPP both react with thiol alkylation reagents. A 
novel protocol was, therefore, developed utilising the Staudinger reaction to 
oxidise excess TCEP and THPP prior to the addition of thiol alkylating reagents. The 
protocol offers a simple “one-pot” method for effecting conjugate production via 
thiol alkylation, without the need for an intermediate purification step for the 
removal of excess disulfide reducing agents. 
4-Vinyl pyridine (4-VP) derivatives were developed and explored as an alternative 
Michael acceptor class for thiol alkylation of peptides and proteins. The 4-VP 
derivatives exhibited high reactivity and specificity for thiol alkylation between pH = 
7 and pH = 8. A selection of 4-VP linkers were subsequently functionalised with 
either carbohydrates or polyethylene glycol (PEG) and successfully utilised to 
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Chapter 1: Introduction 
1.0) History and Development of Bioconjugation Chemistry 
The early application of chemistry for the modification of proteins relied mostly on 
empirical evidence, with a minimal understanding of the chemistry behind the 
outcomes. An example was the use of formaldehyde in the tanning industry. 
Formaldehyde was utilised for the hardening of leather products, which was due to 
the cross-linking of proteins and at the time was not clearly understood [1]. The 
early use of formalin to convert toxic proteins into non-toxic (toxoid) products was 
also not clearly understood but was essential for the progress of vaccination 
experiments [1]. The formalin-treated toxoid protein products retained much of 
their antigenic determinants and provided a safer method for inoculating patients. 
It was during the 1920’s when formalin induced toxoid variants of diphtheria toxin 
were developed for immunisation studies and is a method still utilised for the 
production of toxoid protein products [2]. Over the following two decades more 
detailed research was conducted into characterising the chemistry of modification 
of proteins by chemical reagents, which culminated in an review by Olcott and 
Fraenkel-Conrat in 1947 [3]. The accumulated evidence over this period provided 
the foundations for chemical techniques utilised to modify proteins today. 
The evolution of protein modification chemistry has been accelerated by the 
accumulating evidence that the vast majority of eukaryotic proteins undergo some 
form of chemical modification after ribosomal synthesis. The protein modifications 
are generally achieved through hydrolytic cleavage by proteases or the attachment 
of a ligand to the side chain of an amino acid [4]. These modifications are termed 
post-translational modifications (PTM) and may be transient or permanent 
alterations to the protein’s structure. The chemical alteration of the protein, which 
is usually a specific modification is regulated by enzymes and serves to impart 
specific physiological and/or functional properties to the protein: including the 
2 
 
protein’s structure, function, stability and cellular localisation. PTM’s of proteins 
include glycosylation, phosphorylation, nitrosation, acylation, methylation and 
ubiquitylation amongst many others and are essential for diverse biological 
processes (Figure 1.1). The ability of biological processes to specifically modify 
biomolecules such as proteins to impart a particular physiological and/or functional 
property is an idea that has sparked much scientific interest in replicating or 
inventing new methods for the chemical modification of biomolecules, which has 
resulted in the flourishing field of bioconjugate chemistry. 
 
Figure 1.1: Illustration of a number of potential protein PTMs which can affect the 
localisation and function of a protein. 
Bioconjugate chemistry involves the covalent attachment of appropriate ligands 
functionalised with suitable linker functional groups to biomolecules such as 
proteins. The linker functional group which is attached to the ligand is usually 
chosen to effect a chemoselective and stable chemical reaction with the 
biomolecule. Linkers are chosen with respect to the type of functional group 
targeted on the biomolecule (Figure 1.2). Linker derivatised ligands may be 
synthetic or biological and vary from polyethylene glycol (PEG) [5], nanoparticles 
[6], carbohydrates [7], fluorescent probes [8], peptides [9], proteins [10], RNA [11] 
and DNA [12]. The biomolecule may be a peptide, protein, RNA or DNA. The 
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development of specialised chemical coupling methods to achieve site-specific, 
covalent modifications has had major contributions in areas such as diagnostics, 
imaging, drug delivery, drug stability and biopharmaceutical production such as 
antibody drug conjugates (ADC’s) and conjugate vaccines [13-16]. 
 
Figure 1.2: A) Ligands can be derivatised with a variety of linkers to effect a 
chemoselective linkage on biomolecules. B) An iodoacetamide 
functionalised ligand can react selectively with a thiol functional group [17, 
18]. C) A cyclic diazocarboxamide can be used to selectively functionalise 






1.1) Applications of Bioconjugation Chemistry 
1.1.1) Diagnostics and Imaging 
The physiological concentration of most biomolecules such as DNA, RNA and 
proteins are often only present in µM levels in cells. The low concentration of most 
biomolecules in vivo, therefore, requires highly sensitive diagnostic tools to ensure 
detection in assays. A biodiagnostic often utilises bioconjugate chemistry to 
generate products that are able to improve screening and detection of low 
abundance analytes present in a heterogeneous sample. An example of such a 
biodiagnostic tool is the covalent attachment of a ligand with high affinity (e.g., 
biotin) for an affinity matrix (e.g. streptavidin) to a biomolecular probe (e.g. 
antibody) which exhibits specific binding potential to an analyte in a sample (Figure 
1.3) [20]. Incubation of the bioconjugate in a complex sample solution results in the 
binding of the biomolecular probe to a specific analyte. The bound analyte is 
enriched for detection by the elution of the sample solution through an affinity 
matrix, specific for binding the affinity tag to which the probe and analyte are 
attached (Figure 1.3). This principle has been utilised to develop a microfluidic 
immunosensor for the detection of the food-borne pathogen Staphylococcus 
enterotoxin B (SEB) [21] as well as the enzyme-linked immunosorbent assay (ELISA). 
ELISA is an analytical assay that is utilised for the detection and quantification of 





Figure 1.3: Bioconjugates comprised of molecular probes and affinity tags are useful 
tools for enriching a sample for specific analyte detection. 1) Incubation of 
the conjugate with a sample results in specific analyte-conjugate complex 
formation. 2) Incubation with an affinity matrix “captures” the conjugate-
analyte complex. 3) A washing step removes all unbound compounds from 
the affinity matrix. 
An example of a Federal Drug Administration (FDA) approved biodiagnostic is the 
Hybrid Capture 2 (HC2) assay for the diagnosis of 5 low-risk and 13 high-risk Human 
Papilloma virus (HPV) types (Figure 1.4) [23]. The HC2 assay utilises an RNA probe 
to bind complementary DNA sequences in a sample that originate from the HPV 
virus. The RNA/DNA hybrids are subsequently captured by a RNA/DNA hybrid-
specific antibody that is usually coated on a microtitre plate. After a washing 
procedure to remove the unbound analytes from the sample, a second RNA/DNA-
specific antibody is added, which has been synthetically conjugated to an alkaline 
phosphatase enzyme. A chemiluminescent substrate for the alkaline phosphatase 
enzyme is subsequently added as a method to indirectly confirm the presence of 




Figure 1.4: Illustration of the HC2 assay for detection of HPV DNA. 1) Denature DNA in 
sample and hybridise HPV DNA with complementary RNA probe. 2) Capture 
of DNA/RNA by antibody attached to microtitre plate. 3) A second 
RNA/DNA hybrid-specific antibody is added that is conjugated to the 
enzyme alkaline phosphatase. 4) A chemiluminescent substrate for alkaline 
phosphatase is added. Substrate consumption results in the emission of 
light, which provides indirect evidence for the presence of HPV DNA. 
In some cases sample preparation for imaging or diagnosis is not possible and 
analysis needs to be performed in vivo using techniques such as magnetic 
resonance imaging (MRI) and positron emission tomography (PET). MRI is a non-
invasive method for the internal imaging of an organism by detecting 
radiofrequencies emitted by excited hydrogen nuclei (Figure 1.5, A). Relaxation 
rates of these excited nuclei vary according to their location which allows tissue 
differentiation during image construction (Figure 1.5, A). The use of contrast agents 
in MRI such as Gd(III) greatly improves the sensitivity of the technique. Contrast 
agents such as Gd(III) function by increasing the relaxation rate of water protons in 
the surrounding tissue due to their paramagnetic properties [25]. The covalent 
attachment of contrast agents to molecular probes such as antibodies enhances the 
in vivo targeting of the contrast agents to specific areas of disease requiring 
evaluation [26]. 
PET imaging is a technique utilised to produce internal images of patients by using 
radiopharmaceuticals (Figure 1.5, B). PET imaging reagents are compounds that 
have been functionalised with a positron-emitting radionuclide. Positron emitters 
are neutron deficient and achieve stability by transmutation of a proton to a 
neutron with subsequent emission of a neutrino and a positron. The positron 
undergoes annihilation through contact with an electron to emit gamma rays that 
can be detected to generate an internal image of the patient (Figure 1.5, B) [27]. 
Positron emitters such as 18F are currently incorporated into compounds such as 
7 
 
deoxyglucose and administered to the patient. The radioactive drug enters the 
circulatory system and is subsequently metabolised and incorporated into various 
tissues within the body which can then be imaged. Radionuclides used usually have 
very short half-lives (18F = 109.8 minutes), therefore the synthesis of the 
radiopharmaceutical needs to be rapid and followed by immediate administration 
and detection procedures. Improved imaging can be achieved by the conjugation of 
the radionuclide to antibodies to improve targeting [28]. 
 
Figure 1.5: Images generated using MRI and PET imaging techniques. A) MRI image of 
a human head. Taken from [29]. B) PET image of a human brain. Taken 
from [30]. 
Bioconjugate techniques have also been developed for the structural 
characterisation of protein, DNA and RNA, as well as investigating biomolecular 
interactions (Figure 1.6). Förster resonance energy transfer (FRET) is a technique 
that utilises a pair of fluorescent molecules that are covalently attached to different 
locations of the biomolecule. A donor fluorophore transfers energy to an acceptor 
fluorophore, which subsequently emits radiation at a characteristic emission 
frequency. FRET experiments can serve as a nanoscale ruler, where distances 
between the fluorophores can be determined. A variety of fluorophores have been 
developed for this area of research including synthetic fluorophores, quantum dots 




Figure 1.6: FRET imaging to detect protein-protein interactions. The association of 
protein x-cyan fluorescent protein (CFP) conjugate with protein Y-yellow 
fluorescent protein (YFP) conjugate results in a transfer of energy from CFP 
to YFP, resulting in a FRET emission at 535 nm [34]. 
1.1.2) PEGylation 
PEGylation, first developed by Abuchowski et al. refers to the covalent attachment 
of one or more polyethylene glycol (PEG) chains (Figure 1.7, A) to a biomolecule or 
particle surface (Figure 1.7, B) [35, 36]. PEGylation with respect to 
biopharmaceutical manufacture often offers many advantages over non-PEGylated 
products. PEG is hydrophilic, non-immunogenic, available as linear or branched 
derivatives, available as a variety of molecular weights and is FDA approved [37]. 
PEGylation imparts a number of improved pharmacodynamics and pharmacokinetic 
properties to the derivatised biomolecule. It improves solubility, hinders proteolytic 
degradation, improves circulatory half-life and improves stability of the 
biomolecule. In 1990 Adagen became the first FDA approved PEGylated 
biopharmaceutical to appear on the market. Adagen is a PEGylated form of the 
enzyme adenosine deaminase (ADA). ADA is responsible for the conversion of 
deoxyadenosine from DNA breakdown and is toxic to leucocytes to non-toxic 
deoxyinosine. ADA deficiency, therefore, results in the toxic build-up of 
deoxyadenosine resulting in a diminished lymphocyte population and greater 
susceptibility to infection [29]. Administration of Adagen provides patients with 
adenosine deaminase to ensure clearance of deoxyadenosine. PEGylation of ADA 
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improves the half-life of the enzyme’s circulation from 2.8 hours to 50 hours, which 
offers the advantage of a reduced dosing regime [38]. 
 
Figure 1.7: PEGylation of proteins offers improved stability and longer circulation times 
in vivo. A) Repeat unit of a PEG chain. B) Illustration of a PEGylated protein. 
1.1.3) Glycosylation 
Glycosylation of proteins is a common post translational modification performed in 
eukaryotic cells. It is an enzyme mediated process occurring in the endoplasmic 
reticulum (ER) and Golgi apparatus of cells, whereby oligosaccharides are covalently 
attached to the side chains of ether asparagine (N-linked) or serine/threonine (O-
linked), as shown in (Figure 1.8) [39]. Glycosylation of proteins has been implicated 
in aiding protein folding, protein trafficking, ligand recognition, protein stabilisation, 
regulation of serum half-life and regulation of proteins biological activity [40]. It is, 
therefore, often crucial that protein based therapeutics are glycosylated to 
potentiate the functional activity and stability of the drug. Eukaryotic expression 
systems have the necessary cellular machinery to glycosylate proteins and can be 
used for large scale production of glycosylated protein-based therapeutics [39]. 
There are, however, a few problems associated with the utilisation of eukaryotic 
expression systems to glycosylate proteins, including the introduction of non-
human glycoforms and batchwise variation in glycoform production [39]. Chemical 
conjugation of synthetic oligosaccharides to the protein is an alternative approach 
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for the production of glycosylated protein-based therapeutics. Reductive amination 
is the most common technique to achieve chemical coupling of carbohydrates to 
proteins [41]. The chemical attachment of carbohydrates to proteins is utilised in 
the production of carbohydrate based cancer vaccines [42] and conjugate vaccines 
towards pathogens [43]. 
 
Figure 1.8: Illustration of O and N-linked oligosaccharides attached to a protein. Taken 
from [44]. 
1.1.4) Biotherapeutics 
Biotherapeutics are medicinal products that are manufactured utilising biological 
sources. Numerous biotherapeutics have been developed which also require 
bioconjugation chemistry during production. An example is antibody drug 
conjugates (ADC’s), which are generated through the covalent attachment of 
cytotoxic drugs to antibodies for the treatment of cancer (Figure 1.9). The highly 
selective delivery of the cytotoxic drug by the antibody offers the potential of 
improved efficacy and tolerability of the treatment. A number of factors contribute 
to the effectiveness of the ADC. The antibody should possess selectivity for antigens 
expressed on tumor cells, the linker chemistry and payload should not affect the 
activity of the antibody and the linker should be stable during circulation and only 
release the cytotoxic payload at the targeted site. ADC’s have been produced with 
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cleavable (hydrazone, disulfide and peptide-based) and non-cleavable (thioether) 
linkers [14]. Both strategies rely on tumor localisation, internalisation and lysosomal 
processing to release the payload to effect cell death. The first FDA approved ADC 
was in 2000 for Mylotarg, towards treatment for acute myeloid leukaemia. It was 
voluntarily removed from the U.S. market in 2010 due to its unacceptable toxicity. 
This was largely attributed to the labile hydrazone linkage coupling the antibody to 
the cytotoxic payload [14, 45]. This proved a valuable lesson regarding the 
manufacture of stable ADC’s. In 2013 the FDA approved Kadcyla, an ADC for the 
treatment of metastatic breast cancer. The projected annual sales for this particular 
ADC are in the region of US$ 2-5 billion per anum [46]. 
 
Figure 1.9: Representation of an ADC. An ADC is produced by the covalent attachment 
of a cellular toxin to an antibody. Adapted from [47]. 
1.1.5) Vaccines 
A vaccine is a prophylactic formulation that consists of antigen derived from a 
pathogen or an epitope specific to an unhealthy cell such as a tumor cell. 
Administration of the vaccine enables the immune system to generate long-lived 
memory cells and plasma cells, capable of producing protective antibodies against 
the antigenic material (Figure 1.10). Priming the immune system with antigen 
enables a rapid and specific immune response to either the development of the 




Figure 1.10: Illustration of how a vaccine functions. 1) Vaccination with a formulation 
containing antigen from a pathogen, 2) Recognition of antigen by a specific 
B-lymphocyte population, 3) Proliferation of the B-lymphocyte population 
specific for antigen recognition, 4) Maturation of B-lymphocytes to memory 
cells and antibody producing plasma cells, 5) Plasma cells produce 
antibodies specific for antigen binding, 6) Antibodies bind to pathogen-
specific antigen to effect clearance from the host. Adapted from [48]. 
The identification and characterisation of tumor-associated antigens provides 
specific targets for cancer vaccine design (Figure 1.11). Carbohydrate-based cancer 
vaccines are a potential class of prophylactics requiring the use of bioconjugate 
techniques. Many tumor cells have been identified to express cancer-specific 
carbohydrate epitopes on the cell surface. Research has characterised many of 
these tumor associated carbohydrate antigens (TACA’s), particularly in breast 
cancer, where the overexpression sLea, sLex and sTn epitopes (Figure 1.11) are 
indicative of tumor progression [49]. Priming the immune system with a vaccine 
formulated from TACA’s offers could result in the clearance of any developing TACA 
expressing carcinoma cells. 
13 
 
Carbohydrates, however, are poorly immunogenic and lead to a T-cell independent 
immune response. T-cell participation in an immune response is necessary for the 
development of long-lived plasma cells which are capable of generating antigen 
specific antibodies [50]. A T-cell independent immune response implies only 
transient protection to antigenic epitopes. An effective strategy to generate long-
lived memory to antigens is via covalent coupling of the TACA’s to antigenic carrier 
proteins. The glycoprotein conjugates are engulfed by B-cells and hydrolysed into 
smaller glycopeptide fragments. The glycopeptides are presented to T-helper cells, 
which subsequently produce cytokines that promote the maturation of B-cells into 
antibody producing plasma cells capable of targeting the carcinogenic epitopes 
[51]. An example of a carbohydrate-based vaccine is Theratope (Biomira Inc.). 
Theratope is a vaccine produced by the covalent attachment of the breast cancer 
associated sTn antigen to the carrier protein keyhole limpet hemocyanin (KLH). 
Theratope initially showed promising results in phase 1 and phase 2 clinical trials 
for the treatment of breast cancer. The much anticipated phase 3 trials however, 
were disappointing. Although high antigen-specific antibody titres were detected, 
there was no significant difference in median survival time between treatment and 




Figure 1.11: Structures of the cancer-associated glycans, sLea, sLex and sTn. 
The conjugation of pathogen associated carbohydrates to antigenic carrier proteins 
has proven successful in the development of conjugate vaccines towards Neisseria 
meningitis (Menactra and Menveo), Streptococcus pneumonia (Synflorix and 
Prevnar-13) and Haemophilus influenza type B (Hiberix and ActHIB). The 
above mentioned pathogens are often epidemic in developing countries with 
infants, elderly and immunocompromised individuals being the most susceptible to 
infection. Conjugate vaccines are manufactured through the covalent attachment 
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of pre-purified oligosaccharides derived from the cellular membranes of the most 
virulent pathogen strains to antigenic carrier proteins such as toxoid diphtheria and 
tetanus protein and antigenic outer membrane proteins [54]. The conjugate 
vaccines induce a T cell dependant immune response, which results in long term 
protection and memory to the administered pathogen derived carbohydrate-based 
epitopes [55, 56]. 
1.2) Chemical Linkages used in Bioconjugation 
A variety of linkages have been explored to effect bioconjugation between an 
appropriate ligand and a biomolecule. 
1.2.1) Amide Bond Conjugation 
Bioconjugation through the generation of an amide bond is a common and useful 
strategy due to the stability of the amide bond at neutral pH. The amide bond is 
usually generated between an amine-containing molecule and a reagent possessing 
an activated ester. Targeting amine-containing amino acids on peptides and 
proteins to generate bioconjugates via amide bond formation can generate 
heterogeneous products due to the general abundance of primary and secondary 
amines present in the amino acid sequence. Amide bond formation can occur at the 
side chain of lysine amino acids, the amine present on the amino acid at the N-
terminus of the of the peptide/protein sequence and the imidazole side chain of 
histidine that may be present in the amino acid sequence. The multiple sites for 
potential amide bond formation can complicate purification protocols and increase 




Native chemical ligation offers another route to amide bond generation between 
peptide and proteins [57] and has been utilised for the site specific attachment of 
fluorescent molecules to proteins (Figure 1.12) [58]. The thiol of a terminal 
cysteine-containing peptide is reacted with a thioester-containing peptide in a 
trans-thioesterification reaction. A subsequent SN acyl transfer generates an 
amide bond (Figure 1.12). Native chemical ligation method, however, also 
generates a free thiol functional group after amide bond formation. The presence 
of a thiol may be advantageous, offering an additional functional group for 
subsequent bioconjugation reactions. The presence of a thiol may also be 
disadvantageous as it could offer a site for unwanted side reactions and 
dimerisation of the bioconjugate by disulfide bond formation. Chemical 
desulfurisation offers a solution to the problem if the peptide or protein does not 
contain addition cysteine residues necessary for its structure or function [59]. 
 
Figure 1.12: Amide bond formation using the native chemical ligation method. 
Staudinger ligation offers an alternative route to generating bioconjugates via 
amide bond formation. Staudinger ligation is based on the original Staudinger 
reaction where an azide is reduced to the amine through the use of a phosphine 
[60]. The Staudinger ligation method of amide bond formation is achieved by 
conjugating a ligand derivatised with an azide functional group to a second ligand 
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containing a phosphine functional group and an acyl donor, which is necessary for 
the amide bond generation [61]. Staudinger ligation can been used to generate 
both non-traceless (presence of a phosphine oxide derivative in the product, Figure 
1.13, A) and traceless (absence of phosphine oxide derivative in the product, Figure 
1.13, B) bioconjugates. Staudinger ligation has been previously utilised to introduce 
glycans onto cell surfaces [61, 62]. Staudinger ligation provides an opportunity for a 
very specific reaction to produce homogenous bioconjugates that can simplify 
purification and characterisation of the products. A potential disadvantage of this 
method is the incorporation of non-natural azide-containing amino acids or 
carbohydrates into the cellular structure. 
 
Figure 1.13: (A) Non-traceless Staudinger ligation and (B) Traceless Staudinger ligation 





1.2.2)  C-N Double Bond Conjugation 
The generation of a carbon-nitrogen double bond can be achieved in an aqueous 
environment which is attractive for bioconjugation chemistry. The linkage is 
generated by reaction of an amine with either an aldehyde or ketone functional 
group to generate an imine bond. The reaction is reversible, rendering the bond 
fairly labile. The imine is can be reduced to render a more stable linkage and is a 
strategy that has been utilised to link carbohydrates to proteins [64]. 
Hydrazone (C=N-N) and oxime (C=N-O) linkages can be generated by the reaction of 
hydrazine or alkoxyamine functional groups with an aldehyde or ketone functional 
group. Hydrazones and oximes are more stable than imine linkages but are also 
prone to hydrolysis. They have, however, found applicability in bioconjugation 
chemistry, especially were long term stability is not a concerning priority. 
Hydrazone and oxime linkages have been utilised to attach peptides to glass slides 
to generate microarrays for the detection of antibodies in blood samples and cell-
adhesion assays [65, 66]. 
 
1.2.3) Linkages by Cycloaddition 
The Cu() accelerated Huisgen azide-alkyne 1,3-dipolar cycloaddition (“click”) 
reaction to generate a stable 1,4-disubstituted(1,2,3)triazole linkage has become a 
very useful reaction to generate bioconjugates (Figure 1.14, A). The click reaction is 
a versatile, reaction, tolerant to a wide range of temperatures, a variety of solvents, 
a wide pH range and often purified by simple product filtration [67]. The azide and 
alkyne functional groups are unreactive to most functional groups, which aids in the 
production of homogenous conjugates. The triazole linkage is water soluble and 
rigid, which minimises interaction of the connected ligands, minimising aggregation 
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and any potential reaction between the two ligands. The presence Cu() can be 
cytotoxic which can limit the use of click chemistry in vivo [63]. Catalyst free click 
reactions are, however, possible with the use of a ring strained alkyne such as 
cyclooctyne (Figure 1.14, B). The click reaction has been utilised in a diverse range 
of bioconjugations including labelling of peptides, proteins and DNA [68]. 
 
Figure 1.14: (A) Cu()-catalysed Huisgen 1,3-dipolar azide-alkyne cycloaddition and (B) 
strain-induced Huisgen 1,3-dipolar azide-alkyne cycloaddition. 
The Diels-Alder reaction between a diene and a dienophile is an alternative 
cycloaddition reaction utilised in bioconjugation chemistry. Diene derivatised 
peptides have been successfully immobilised onto dienophile functionalised glass 
slides for peptide chip production [69]. Diene derivatised proteins have also been 





1.2.4) Thioether Linkages 
The thiol functional group is naturally present in peptides and proteins as the 
terminal functional group of cysteine’s side chain. The hydrogen bonding 
interactions within a protein can greatly affect the pKa of the thiol, with a range of 
4-10 reported [71]. Deprotonation of the thiol generates a thiolate, which is an 
excellent nucleophile for thioether bond formation. Generally, cysteine accounts 
for 3 % of a proteins constitution [72]. The low thiol abundance provides a 
possibility of producing a small number of bioconjugate derivatives, which can 
simplify purification protocols and decrease production costs of the bioconjugate. 
There are some important considerations to address before performing 
bioconjugations based on thioether formation. Thiols are important functional 
groups in the mechanism of catalysis for enzymes such as cysteine proteases [73]. 
Covalent modification of the thiol at the catalytic site may affect the activity of 
bioconjugate. Thiol functional groups also exist in peptides and proteins as disulfide 
bonds. Disulfide bonds play an important role in the tertiary structure, and hence, 
function of the peptide or protein [74]. If thiols are not available for bioconjugation 
due to their functional roles within the peptide or protein, it is possible to 
biochemically or chemically introduce thiol functional groups. Site directed 
mutagenesis is a biochemical method for the introduction of a cysteine residue into 
a protein [75]. Synthetic methods are also possible through functionalisation of a 
pre-existing amino acid residue to display a thiol. Cystamine (Figure 1.15 A, 1.3) is 
utilised to introduce a thiol (existing as a disulfide) through derivatisation of 
carboxylic acids (Figure 1.15 A) or phosphates. As an example, a general carboxylic 
acid is initially reacted with a water soluble carbodiimide 1.1 to yield an activated 
ester 1.2. The intermediate is then incubated with cystamine (1.3), which yields a 
urea by-product 1.4 and a disulfide derivative 1.5. Incubation of derivative 1.5 with 
a thiol-containing biomolecule can generate a mixed disulfide product. The disulfide 
bond of 1.5 can also be reduced to access the thiol functional group for conjugation 
to a biomolecule derivatised with a thiol-alkylating reagent.  
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The -amino group of lysine may also be derivatised to display a thiol functional 
group through the use of 2-iminothiolane (1.6, Figure 1.15 B) [76, 77]. 
 
Figure 1.15: Functionalisation of amino acid side chains to introduce a thiol functional 
group. A) Introduction of a thiol via derivatisation of a carboxylic acid. B) 
Introduction of a thiol via derivatisation of a primary amine. 
The attachment of ligands to thiols on peptides or proteins is often performed 
under aqueous conditions. There is a tendency for free thiols under aqueous 
conditions to oxidise and form disulfide bonds. A prerequisite regarding 
conjugations utilising the thiol functional group is the necessary step of pre-
reduction of disulfide bonds to thiol functional groups. A number of reducing 
agents have been developed for the reduction of disulfides under aqueous 
conditions and are either alkyl-thiols or trialkylphosphines [18]. Alkyl-thiol reducing 
agents need to be removed from the solution prior to bioconjugation reactions 
since the thiol-based reducing agents have the capacity to compete with the thiols 
present on the peptide or protein for the thiol-reactive ligands. Reducing agent 
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removal requires rapid and efficient protocols by dialysis or gel filtration 
chromatography, under oxygen depleted conditions to avoid re-oxidation of the 
thiols to disulfide bonds. The process of removing the excess reducing agent can 
contribute significantly to reducing the yield of bioconjugation reactions.  
Commercial sources for the trialkylphosphine-based disulfide reducing agent tris(2-
carboxyethyl)phosphine (TCEP) report that TCEP does not need to be removed from 
solution after the disulfide reduction step and prior to the addition of thiol-selective 
modification reagents [78, 79]. The potential to leave the trialkylphosphine in 
solution and subsequently add a thiol-alkylating reagent offers a simple “one-pot” 
protocol to generate conjugates, while minimising the exposure of the thiols to 
oxidative conditions during a reducing agent removal step. There is, however, some 
reports claiming that TCEP does react with thiol alkylating reagents and can reduce 
conjugate yields if not removed post disulfide reduction [8, 80]. 
Post disulfide reduction, a ligand derivatised with a thiol-alkylating linker is 
generally added to effect a conjugation reaction. There are a variety of reagents 
currently available that will alkylate a thiol functional group rapidly and fairly 
selectively, though each reagent possesses individual strengths and limitations. 
1.2.4.1) -Halocarbonyls 
Alkyl halides based on iodoacetic acid or iodoacetamide (Figure 1.16) are often 
used for the alkylation of sulfhydryls [18, 81]. -Halocarbonyls are fairly unstable 
compounds that require careful storage and are also light sensitive. -
Halocarbonyls irreversibly alkylate thiols through a nucleophilic substitution 
reaction, which is optimal at alkaline pH, where the thiolate is an excellent 
nucleophile towards the alkyl halide [18]. The -halocarbonyls may also react, in a 
pH dependant manner, with the hydroxyl group of tyrosine, the -amino group of 
lysine, the imidazole group of histidine and the N terminus of proteins. Generally, 
the thiolate on the cysteine side chain reacts much faster with the -halocarbonyl 
than the functional groups of tyrosine, lysine and imidazole [18]. The alkylating 
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reagent is often required in high concentration to ensure sufficient conjugation 
which may promote the non-specific modification of other amino acid functional 
groups. The alkaline conditions necessary for optimal alkylation may also be 
detrimental to the stability of the protein. 
 
Figure 1.16: Thiol alkylation via an iodoacetamide derivative. 
1.2.4.2) Michael Acceptors 
Maleimide is by far the most common reagent used for thiol alkylation of a cysteine 
residue. Ligands can be functionalised with maleimide using a maleimido-N-
hydroxysuccinimide ester. Maleimide-based alkylation is achieved through the 
conjugate addition of the thiolate at the activated alkene of the maleimide ring and 
results in a diastereomeric mixture of thioether derivatives (Figure 1.17). This may 
be problematic in terms of meeting potential purity standards in some therapeutic 
applications [82]. Maleimide is specific for thiols between pH = 6.5 and pH = 7.5 and 
at pH = 7 is 1000 more reactive towards thiols than amines [83]. Reactions with 
amines are more prevalent at a pH greater than 7 [18]. Maleimide is about 20 fold 
more reactive than iodoacetic acid or iodoacetamide derivatives and also has 
membrane permeability capacity [18]. The alkylation can be followed 
spectrophotometrically at 300 nm, with conjugation resulting in the disappearance 





Figure 1.17: Thiol alkylation via a maleimide derivative. 
Maleimide derivatives are fairly stable at or below pH = 6. At pH = 7, they exhibit a 
half-life of 45 hours yet at pH = 9 it decreases to less than 1 hour [18]. The 
shortened stability is attributed to the hydrolysis of the maleimide ring to yield 
maleamic acid (Figure 1.18, A). A similar ring opening reaction may occur to a thiol-
maleimide adduct, which may be unfavourable when producing therapeutics 
requiring prolonged storage in an aqueous environment. The alkene of maleimide is 
highly electrophilic and is susceptible to nucleophilic attack from amines. This is a 
major disadvantage when considering the potential purification complexity. At 
alkaline pH the maleimide addition products can undergo transamidation reactions 
to form a cyclic compound, which can complicate product purification and 
characterisation (Figure 1.18, B) [18]. There is the added potential of hydrolysis of 
the maleimide-thioconjugate to regenerate the free thiol (Figure 1.18, C). The 
limitations of the maleimide functional group must be considered before being 




Figure 1.18: Potential limitations associated with the use of maleimide as a thiol 
alkylating reagent. (A) Alkaline conditions can cause ring opening of the 
maleimide ring to generate maleamic acid derivatives. (B) Transamidation 
reaction on the maleimide ring. (C) Hydrolysis of the thioether linkage on 
the maleimide ring. Adapted from [18]. 
Vinyl sulfone is an additional Michael acceptor utilised in the production of 
bioconjugates via thioether bond formation (Figure 1.19). Vinyl sulfone offers an 
advantage over the use of maleimide due to irreversible formation of an achiral 
thioether bond. Vinyl sulfone is predominantly used for the alkylation of thiols but 
is also reactive towards amine nucleophiles, which can potentially lead to the 
production of heterogeneous conjugates, which can complicate purification 
protocols and reduce yields of the desired products. [84]. Vinyl sulfone has been 
utilised to attach various ligands to thiol containing biomolecules such as PEG, 




Figure 1.19: Thiol alkylation via a vinyl sulfone derivative 
1.3) Aims and Objectives 
This thesis seeks to utilise the thiolate of cysteine present in peptides and proteins 
for the attachment of ligands via suitable linker chemistry towards the production 
of bioconjugates. Key areas of optimisation include the reduction of disulfide bonds 
to generate free thiols in the biomolecule and developing protocols suited for high 
yielding bioconjugation reactions between the biomolecule and the linker-
functionalised ligand. An additional area of optimisation is the development of 
linkers chemoselective for thiol alkylation for generating high yielding, homogenous 
bioconjugate products. 
Chapter 2 describes the reaction of trialkylphosphine reducing agents with thiol-
alkylating reagents. Water soluble trialkylphosphines such as TCEP and THPP have 
emerged as popular and very effective disulfide reducing agents. Chapter 2 aims to 
investigate the reaction of the trialkylphosphine reducing agents with the Michael 
acceptor thiol alkylating reagents: maleimide and vinyl sulfone through product 
characterisation and mechanistic studies. The aim is to provide some clear 
conclusions regarding the potential reaction between TCEP/THPP and 
maleimide/vinyl sulfone in the hope of standardising the necessary reduction 
protocol prior to synthesis of bioconjugates via thiol alkylation. 
Chapter 3 describes the development of a novel, “one-pot” method for effecting 
thiol-alkylation reactions after a reduction step by trialkylphosphines. Reductant 
removal is usually possible using techniques such as dialysis, gel filtration and spin 
filtration, but may lead to the reoxidation of the thiols to disulfide bonds and lead 
to loss in conjugate yield. It also adds extra time and cost into the production of the 
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conjugate. The aim is, therefore, to remove the excess reducing agent in situ in the 
hope of developing a “one-pot” method for the production of conjugates utilising 
thiol alkylation chemistry. The addition of a water soluble alkyl azide offers a 
possible route to achieve this objective. The addition of a water soluble alkyl azide 
to quench excess TCEP or THPP should yield products (phosphine oxide, alkyl-amine 
and nitrogen gas) compatible with the subsequent conjugation step. The protocol 
offers the potential of a simple and novel method for the production of conjugates 
and is validated through the derivatisation of cysteine containing amino acids and 
peptides by maleimide functionalised ligands. 
Chapter 4 describes the development of 4-vinyl pyridine (4-VP) derivatives as 
linkers for thiol-alkylation as an alternative to popular maleimide-based chemistry. 
Maleimide offers excellent reactivity and sufficient selectivity for thiols at neutral 
pH. Disadvantages, however, include potential reactions with amines, production of 
a diastereomeric mixtures, reversibility of the reaction and maleimide ring 
instability at an alkaline pH. The aim is to develop an alternative class of thiol 
alkylating reagents to overcome some of the pitfalls of maleimide chemistry. 4-
Vinyl pyridine has been previously used to exclusively alkylate thiols of peptides and 
proteins prior to mass spectrometric analysis. The aim is to utilise the selectivity of 
4-VP for broader applications in bioconjugate chemistry. It was envisaged to 
synthesise suitably derivatised 4-VP derivatives to facilitate the covalent 
attachment to ligands such as PEG and carbohydrates. The development of 4-VP as 
a thiol alkylating reagent involved the synthesis of a variety of 4-VP derivatives, 
characterisation of the reactions between the 4-VP derivatives and thiol containing 
peptides, pH-rate determination for the 4-VP derivatives and investigating the 
potential for derivatising thiol-containing proteins by glycation and PEGylation. 
Chapter 5 describes the development of a novel method for thiol alkylation of S-
nitrosated (SNO) proteins. Nitrosation of cysteinyl thiols of peptides and proteins is 
a transient post translational modification that is implicated in many biological 
processes such as vasodilation and cell signalling. A number of techniques have 
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been developed for the identification of the nitrosation sites, the most common 
being the biotin switch technique (BST). There are some pitfalls associated with this 
technique, which can lead to low yielding isolates or the isolation of false positives. 
The key to functionalising and identifying correct nitrosation sites are mild sample 
preparation protocols and a chemoselective reaction with the thio-nitroso 
functional group. The research aim is to develop a novel, one-step method that 
allows for the selective functionalisation of a thio-nitroso group, followed by 
sample enrichment using biotin affinity tag chemistry. There is precedence in the 
literature of 4-VP reacting with a nitrosated thiol to generate an oxime product, 
although no product characterisation was published. The method was repeated to 
validate the chemistry. The chemistry proved successful but an additional product 
via Michael addition of thiols was also isolated, rendering the method unsuitable 
for the specific targeting of nitrosated thiols. The allyl functional group was 
subsequently explored as method for specifically reacting with a nitrosated thiol. 
The method was successfully validated. The technique, however, proved to be low 
yielding but was successful in identifying nitrosated thiols in a model protein. 
Appendix 1 describes the reduction of ,β-unsaturated 1,4-dicarbonyl substrates by 
THPP. The discovery of rapid maleimide reduction to succinimide by THPP under 
aqueous conditions prompted the investigation of THPP as a potential general 
reductant of ,β-unsaturated 1,4-dicarbonyls. Characterisation and mechanistic 
studies of the reduction reaction were performed on a variety of ,β-unsaturated 
1,4-dicarbonyls, proving that THPP can be utilised as an effective reducing agent for 
,β-unsaturated 1,4-dicarbonyl substrates. 
Appendix 2 explores the potential of a TCEP-maleimide ylene adduct, isolated in 
Chapter 2, to react with Selctflour, an electrophilic fluorine source. This was 
pursued to validate the hypothesis of a TCEP-maleimide ylene adduct. The ylene 
was predicted to react with Selectfluor, analogous to the Wittig reaction where an 




Chapter 2: Reaction of Trialkylphosphine 
Reducing Agents with Thiol-Alkylating Reagents 
2.0) Disulfide Reducing Agents 
The thiol functional group of cysteine’s side chain in peptides and proteins is usually 
oxidised and exists predominantly as a disulfide bond. The disulfide bond is not 
reactive towards most reagents designed for thiol alkylation. A prerequisite, 
therefore, for thiol alkylation strategies on proteins is the necessary step of pre-
reduction of disulfides to thiol functional groups.  
A number of reducing agents have been developed for the reduction of disulfides 
under aqueous conditions. The choice of reducing agent is often dictated by the 
limitations of the reducing agent as well as the biomolecule of choice. A particular 
limitation of a biomolecule is typified by the requirement to often only partially 
reduce disulfides of antibodies prior to bioconjugation to necessitate the 
maintenance of tertiary structure of the protein, which is facilitated by the 
numerous disulfide bridges [83]. 
2.0.1) Mono Thiol Containing Disulfide Reductants 
β-Mercapatoethanol (BME, 2.1) is a water soluble liquid that is often utilised as a 
disulfide reducing agent. BME requires use in a ventilated hood because of its very 
strong odour and toxicity, which are principle reasons for its decline in use. BME is a 
powerful disulfide reducing agent and can be used if complete disulfide reduction 
within the protein is required. BME is often used to aid in protein denaturation for 
sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) of proteins [85]. 
BME is utilised in bioconjugation protocols, for example, to reduce disulfides in 
proteins and reduce mixed disulfides of ligands prior to attachment to gold 
nanoparticles [86, 87]. BME has also been utilised to react with excess maleimidyl 
groups after a bioconjugation reaction to prevent the attachment of potential 
nucleophiles to the synthesised conjugate [88]. 
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β-Mercaptoethylamine hydrochloride (BMEA, 2.2) is a weaker disulfide reducing 
agent compared to BME. BMEA is a water soluble solid that can be used for the 
partial disulfide reduction of antibodies for the production of antibody-ligand 
conjugates [89]. BMEA has also been used to introduce thiols into biomolecules to 
enable the synthesis of conjugate vaccines by thiol alkylation [90].  
 
The mechanism of disulfide reduction by mono thiol-containing reductants is a 2 
step process, with an intermediate mixed disulfide existing before complete 
reduction of the target disulfide (Figure 2.1). The rate of disulfide reduction is 
relatively slow due to the rate of mixed disulfide exchange being approximately 
equal to the rate of the target disulfide reduction. Mono thiol-containing reducing 
agents are, therefore, needed in large excesses, require long incubation periods 
and, importantly, need to be removed prior to bioconjugation reactions. 
 
Figure 2.1: Mechanism of disulfide reduction by a mono thiol-containing disulfide 
reductant such as BME (R = (CH2)2OH) and BMEA (R = (CH2)2NH2). 
2.0.2) Dithiol Containing Disulfide Reductants 
The use of dithiothreitol (DTT, 2.3) and dithioerythritol (DTE, 2.4) as disulfide 
reducing agents was first described by Cleland in 1964 [91]. DTT and DTE are water 
soluble compounds, have a reduced offensive odour and are stronger disulfide 
reducing agents compared to BME and BMEA and so quickly replaced the mono-




The driving force for disulfide reduction in proteins is the ability of DTT and DTE to 
form intramolecular ring structures (4,5-dihydroxy-1,2-dithiane) [92]. The reducing 
agent initially acts as a nucleophile on the disulfide of the protein, reducing one of 
the target sulfur atoms and generating a mixed disulfide intermediate on the 
second sulfur atom of the protein. The remaining free thiol of DTT or DTE 
nucleophilically attacks the mixed disulfide bond to reduce the second target 
sulphur atom, and in the process, generating a disulfide-containing 6-membered 
ring. The generation of a disulfide containing cyclic by-product drives the 
equilibrium towards disulfide reduction in the protein (Figure 2.2). DTT and DTE are 
able to reduce most solvent accessible disulfides in proteins [83]. In the absence of 
denaturants such a SDS or urea, DTT and DTE are often not able to reduce all 
disulfides in the protein as they are unable to access the core of the protein’s 
folded structure due to steric hindrance [93]. Very rarely a DTT mixed disulfide may 
be formed with the biomolecule. The two sulfur atoms of DTT may also form 
disulfide bonds to two different sulfur atoms. This prevents the DTT molecule from 
cyclising and may complicate purification of the biomolecule and reduce yields 
during the bioconjugation reaction [93]. It is essential to remove DTT and DTE from 
the reaction before conjugation chemistry is pursued as the thiol-based reducing 
agents have the capacity to react with thiol-alkylating reagents, reducing yields of 
alkylation at the target thiol. This class of disulfide reductant has been successfully 
utilised in many bioconjugation protocols, including the reduction of antibodies 
[77], reduction of cytokines prior to PEGylation [94], activation of nanoparticles [95] 




Figure 2.2: Mechanism of disulfide reduction by DTT or DTE. 
2.0.3) Water Soluble Trialkylphosphines 
Triphenylphosphine was the first phosphine-based reagent utilised for the 
reduction of simple disulfide-containing compounds in the presence of water and 
was reported in 1935 [97]. A more water soluble phosphine: tris(hydroxymethyl) 
phosphine was later developed and utilised to reduce the disulfides of 
immunoglobulins [98]. 
Trialkylphosphine reducing agents do possess a few advantages over thiol-based 
disulfide reducing agents. The phosphorus atom of commercial water-soluble 
phosphines have pKa’s of 7-8. This is a common pH range to perform 
bioconjugations, therefore, the trialkylphosphines are more effective nucleophiles 
than thiol-based reducing agents to effect disulfide reduction within this pH range. 
Disulfide reduction utilising trialkylphosphines is irreversible, unlike the reversible 
mechanism of disulfide reduction observed with thiol-containing reducing agents. 
The driving force for the irreversible reduction of disulfides by trialkyphosphines is 
the generation of the strong P-O bond as the trialkylphosphine is oxidised to 
trialkylphosphine oxide (Figure 2.3). Trialkylphosphines, therefore, do not need to 
be utilised in vast excess as required by thiol-based reducing agents. Optimised 
conditions theoretically allow for stoichiometric use of trialkylphosphines in 
disulfide reduction, however, trialkylphosphines are susceptible to oxidation to 
trialkylphosphine oxides in the presence of molecular oxygen and so need to be 




Figure 2.3: Mechanism of disulfide reduction by trialkylphosphines. R = alkyl. 
Tributylphosphine (TBP, 2.5) has a pKa of 8.43 (phosphorus atom) and has been 
utilised for the reduction of protein disulfides for many decades [92, 99-102]. TBP is 
very sensitive to oxidation and, therefore, needs to be utilised as a fresh solution 
and stored under inert conditions. There is also the added disadvantages of TBP 
possessing a foul odour and poor water solubility, which tends to limit its use in 
bioconjugation chemistry, although it is still a commercially available product 
marketed for biological applications [103, 104]. TBP has generally been replaced by 
less odorous, more stable and water soluble derivatives such as tris(2-
carboxyethy)phosphine (TCEP, 2.6) to reduce disulfides in proteins. 
The first use of TCEP for disulfide reduction was reported in 1969 for the reduction 
of immunoglobulins [98] and eventually became commercially available in 1992 [80, 
105]. The use of TCEP has gained in popularity since its introduction as a biological 
disulfide reducing agent. TCEP offers many advantages over DTT. TCEP has a pKa of 
7.68 (phosphorus atom), is an odourless and water soluble crystalline solid that is 
relatively stable to oxidation and is stable in an aqueous environment over a wide 
pH range [106, 107]. TCEP is a weaker chelator of metal ions than DTT so, therefore, 
has less potential to interfere in bioinorganic systems [107]. TCEP does not form 
mixed disulfides during disulfide reduction, which is especially favourable when 
producing therapeutics which require strict characterisation protocols, for example, 
antibody-drug conjugates [108]. There are, however, a few potential limitations to 
be considered. Co-elution of TCEP with peptides and proteins during gel filtration 
purification has been reported, which can complicate purification protocols [109]. 
TCEP is fairly impermeable to the hydrophobic protein core so may only cause 
selective reduction of proteins [110]. TCEP has the potential to cause 
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desulfurisation of cysteine [111] and cleave cysteine containing peptide bonds 
[112]. The cost of TCEP is also generally 2-3 times more than DTT. Despite the 
potential disadvantages, TCEP has been successfully utilised in bioconjugate 
production, including the reduction of disulfides in RNA [113], peptides[114] and 
proteins [80, 115]. 
Tris(3-hydroxypropyl)phosphine (THPP, 2.7) is a relatively new commercially 
available, water soluble phosphine that is emerging as an alternative disulfide 
reducing agent to TCEP [116]. THPP is a viscous liquid of relatively low odour. The 
phosphorus atom of THPP has a pKa of 7.22, is stable to oxygen dependant 
oxidation over a wide pH range and has shown superior reducing qualities when 
compared to TCEP [18, 117, 118]. THPP and has been utilised in bioconjugation 
chemistry for reducing plasma proteins [119]. 
 
2.1) Reaction of TCEP with the Thiol-Alkylating Reagent Maleimide 
The maleimide functional group is a Michael acceptor and is the most widely used 
thiol-alkylating reagent in bioconjugation chemistry due to its specificity for 
sulfhydryl nucleophiles at neutral pH [18]. There is conflicting data in the literature 
with regards to the potential for reaction of the maleimide functional group with 
TCEP during bioconjugation reactions. The debate has not been completely 
resolved and needs to be addressed to ensure high bioconjugation yields and 
prevent unwanted side reactions that may compromise the purity of bioconjugates. 
A number of commercial sources for TCEP report that TCEP does not react with 
maleimide and, therefore, does not need to be removed before introduction of the 
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maleimide functionalised ligand to alkylate the reduced disulfides of the 
biomolecule [120, 121]. Literature protocols have also been published where TCEP 
is claimed to be non-reactive towards maleimide when TCEP is not removed prior 
to addition of maleimide-based reagents [108, 122]. The potential reaction of TCEP 
with maleimide can be overlooked if the maleimide functionalised ligand is used in 
significant excess to TCEP [108]. 
There is, however, also literature claiming that TCEP does react with maleimide and 
therefore, needs to be removed in a similar manner to thiol-based disulfide 
reducing agents before the maleimide-based bioconjugation chemistry is pursued 
[8, 80, 109]. The presence of TCEP in bioconjugation reactions between maleimide 
and cysteinyl proteins has been reported to reduce conjugation yields [8]. TCEP 
was, therefore, proposed to compete with thiols for addition to maleimide, 
however, no product characterisation has been performed [8, 80, 109, 123]. Mass 
spectrometry of bioconjugation reactions where maleimide and TCEP have been 
utilised have identified a potential phosphonium ion adduct between TCEP and 
maleimide as the likely product [124, 125], which is consistent with earlier 
literature reporting a phosphonium ion adduct between a trisubstituted phosphine 
and maleimide [126]. There is also additional literature where triphenylphosphine 
has been used to reduce maleimide to succinimide under reflux conditions [127]. 
As such, we first sought to investigate the ambiguity in the literature regarding the 
reaction of TCEP with Michael acceptors such as maleimide. The possible reaction 
between THPP and maleimide was also investigated. The possible reaction of 
trialkylphosphines TCEP or THPP with the Michael acceptor vinyl sulfone is also 
included in the investigation. It is envisaged to provide evidence that may 
standardise protocols utilising trialkylphosphines to reduce disulfide bonds and 
Michael acceptors to effect bioconjugation by thiol alkylation. 
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2.1.1) Characterisation of the Reaction Product between TCEP and Maleimide 
The reaction of TCEP (2.6) and the maleimide functional group was initially 
investigated by incubation of TCEP with N-ethyl maleimide (2.8) in aqueous sodium 
phosphate (0.1 M, pH = 7) for 1 hour (Figure 2.4). Purification of the reaction by 
reverse phase (C-18) chromatography yielded a TCEP-maleimide adduct in a 73 % 
yield, which could exist as a resonance hybrid of an ylene 2.9 or an ylide 2.10. NMR 
and MS spectroscopy could not aid in distinguishing the TCEP-maleimide product as 
either 2.9 or 2.10. Infrared spectroscopy was more useful in postulating the 
structure for the TCEP-maleimide adduct as being N-ethyl-3-
(tris(carboxyethyl)phosphorylidene)pyrrolidine-2,5-dione (2.9). The identification of 
a band at 1229 cm-1 in the infrared spectrum could be indicative of a P=C bond as a 
P=C bond stretching frequency is expected in the region 1180-1230 cm-1 [128]. The 
isolation of product 2.9 in good yield is clear evidence that TCEP does react with 
maleimide. The ylene adduct 2.9 has not been reported in the literature, although a 
phosphonium ion adduct has been previously proposed based on mass 
spectrometry methods [124, 125]. 
 
Figure 2.4: Reaction of TCEP (2.6) with N-ethyl maleimide (2.8) to form a covalent 
adduct 2.9. 
The reaction between TCEP and a maleimide-functionalised amino acid was 
subsequently investigated. The reaction was performed to isolate and characterise 
any potential reaction products in a model system that more closely resembled a 
bioconjugation reaction. TCEP was incubated with the maleimide functionalised 
amino acid N6-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl]-L-lysine (2.11) in 
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aqueous sodium phosphate (0.1 M, pH = 7) for 1 hour (Figure 2.5). Purification of 
the reaction by reverse phase (C-18) chromatography yielded a TCEP-maleimide 
adduct in 70 % yield, which could exist as a resonance hybrid of the ylene product 
2.12 or the ylide 2.13. Unfortunately NMR and MS spectroscopy could not aid in 
distinguishing the TCEP-maleimide product as either 2.12 or 2.13. Infrared red 
spectroscopy was utilised to suggest the structure for the TCEP-maleimide adduct 
as the ylene derivative 2.12. The identification of a band at 1164 cm-1 in the infrared 
spectrum could be indicative of a P=C bond. The ylene structure is, therefore, 
postulated as the product from the reaction of TCEP with 2.12. Results suggest that 
trialkylphosphines are likely to react with maleimide functionalised biomolecules 
under typical conditions used for bioconjugation. 
 
Figure 2.5: Reaction of maleimide derivatised lysine (2.11) with TCEP to form a 
covalent adduct. 
2.1.2) Mechanism of the Reaction between TCEP and Maleimide 
We next sought to investigate the mechanism of reaction for TCEP-maleimide 
adduct formation by repeating the original reaction of TCEP (2.6) with N-ethyl 
maleimide (2.8), this time using a deuterated buffer (Figure 2.6). NMR and MS 
analysis of deuterated products aids in determining the sites on the substrates 
where hydrogen atoms may have been added or lost during the reaction. This can 
assist in the formulation of a mechanism for the reaction. A racemic deuterium 
containing TCEP-maleimide ylene adduct 2.14 was isolated as the major product of 
the reaction after reverse phase (C-18) chromatography in a 79 % yield. The ylene 
structure was suggested through analysis of the infrared spectrum. The 
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identification of a band at 1233 cm-1 in the infrared spectrum could be indicative of 
a P=C bond stretching frequency. 
 
Figure 2.6: Reaction of TCEP (2.6) with N-ethyl maleimide (2.8) in a deuterated buffer 
to yield the product 2.14. 
The isolation and characterisation of 2.14 allowed postulation of a mechanism for 
the formation of the product (Figure 2.7). Nucleophilic attack of the phosphorus 
atom of TCEP at the conjugated alkene of maleimide initially forms a phosphonium 
ion adduct. The acidic -proton attached to the carbon atom bearing the 
phosphonium cation is lost to neutralise the positive charge of the phosphonium 
ion intermediate, resulting in an ylene product. It is postulated that the three 
electron withdrawing 2-carboxyethyl groups attached to the phosphorus atom of 
TCEP destabilises the phosphonium ion associated with an ylide and instead favour 






Figure 2.7: A proposed mechanism for TCEP-maleimide adduct formation. R = 
(CH2)2CO2H 
2.2) Reaction of THPP with the Thiol-Alkylating Reagent Maleimide 
THPP is a relatively new commercial disulfide reducing agent that can be utilised as 
a substitute for TCEP. The above observation of a reaction between TCEP and 
maleimide derivatives (Figure 2.4-Figure 2.6) prompted an investigation into the 
potential reaction of THPP with maleimide derivatives. 
2.2.1) Characterisation of the Reaction Product between THPP and Maleimide 
The potential for reaction between THPP (2.7) and maleimide was investigated by 
incubating THPP with N-ethyl maleimide (2.8) for 1 hour in a buffered solution 
(phosphate, 0.1 M, pH = 7). Purification of the reaction by silica gel chromatography 
yielded the product N-ethyl succinimide (2.15) in 61 % yield (Figure 2.8). This was a 
surprising result as we initially anticipated ylide or ylene products analogous to the 
TCEP reactions with maleimide derivatives (Figure 2.4 and Figure 2.5). There is, 
however, evidence in the literature of triphenylphosphine reducing maleimide to 
succinimide, although reflux conditions were utilised [127]. Here, THPP appears to 
have the capacity to rapidly reduce α,β-unsaturated 1,4-dicarbonyl substrates 




Figure 2.8: Reaction of THPP (2.7) with N-ethyl maleimide (2.8). 
The reaction between THPP and a maleimide-functionalised amino acid was 
subsequently investigated. The reaction was performed to isolate and characterise 
any potential reaction products in a model system that more closely resembled a 
typical bioconjugation reaction. As such, THPP (2.7) was incubated with the 
maleimide functionalised amino acid N6-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoyl]-L-lysine (2.11) in aqueous sodium phosphate (0.1 M, pH = 7) for 1 
hour. The reduced product N6-[3-(2,5-dioxopyrrolidin-1-yl)propanoyl]-L-lysine (2.16) 









Figure 2.9: Reaction of maleimide derivatised lysine (2.11) with THPP (2.7) to yield the 
succinimide-lysine derivative (2.16). 
2.2.2) Mechanism of the Reaction between THPP and Maleimide 
The mechanism of maleimide reduction by THPP was investigated by repeating the 
reaction of THPP (2.7) with N-ethyl maleimide (2.8) in deuterated aqueous sodium 
phosphate (0.1 M, pH = 7) for 1 hour. A racemic mixture of 1-ethyl-3-dideutero-
(4R,S)-deutero-pyrrolidine-2,5-dione (2.17), which was confirmed by NMR and 
HRMS analysis, was isolated by silica gel chromatography in a 52 % yield (Figure 
2.10). 
 
Figure 2.10: Reaction of THPP (2.7) with N-ethyl maleimide (2.8) in deuterated buffer to 





The deuterated succinimide product 2.17 allowed postulation of a mechanism for 
the reduction of maleimide by THPP. Nucleophilic attack by the phosphorus atom of 
THPP at the alkene carbon of maleimide results in a phosphonium cation adduct as 
an intermediate. The acidic α-proton attached to the carbon atom bearing the 
phosphonium cation is lost to neutralise the positive charge of the phosphonium 
ion intermediate, which results in a resonance hybrid of an ylene and an ylide 
intermediate. The ylide intermediate and aqueous conditions facilitate oxidation of 
the phosphorus atom of the ylide intermediate to generate THPP oxide and N-ethyl 
succinimide (Figure 2.11). 
 






2.3) Reaction of TCEP with Vinyl Sulfone: a Thiol-Alkylating 
Functional group 
Vinyl sulfone is an alternative Michael acceptor thiol alkylating reagent which has 
been developed and used successfully in bioconjugation reactions. The vinyl sulfone 
functional group has been functionalised with poly(ethylene)glycol (PEG) for 
generating PEGylated biomolecules via thiol alkylation [129]. A variety of different 
ligands such as fluorophores and affinity tags have also been functionalised with 
vinyl sulfone for bioconjugate applications [84]. 
The reaction of TCEP with vinyl sulfone has not been previously explored and 
requires investigation, especially in light of our previous findings that the ylene 
product 2.9 is generated by the reaction of TCEP with maleimide. Vinyl sulfone, 
similar to maleimide, is a Michael acceptor so it is very probable that a reaction 
between TCEP and vinyl sulfone may occur. 
As such, phenyl vinyl sulfone (2.18) was incubated with TCEP (2.6) in aqueous 
sodium phosphate (0.1 M, pH = 7) for 1 hour (Figure 2.12). Purification of the 
reaction by reverse phase (C-18) chromatography yielded a TCEP-vinyl sulfone-
adduct in 84 % yield. NMR spectroscopy was ineffective in distinguishing the 
product as either the phosphonium ion adduct 2.19 or the penta co-ordinate 
phosphorus product 2.20. However, the identification of a peak at 1153 cm-1 (P-O-
ethyl = 1155-1165 cm-1) in the infrared spectrum suggests the penta co-ordinate 
derivative 2.20 as the product [130]. This product may be generated by the 
nucleophilic attack of TCEP at the vinylic terminal carbon of phenyl vinyl sulfone to 
yield a phosphonium cation. The charged intermediate may be neutralised by the 
formation of a five membered ring via attack of one of the carboxylate functional 
groups of TCEP on the phosphonium cation. The isolation of 2.20 confirms that 
TCEP does react with vinyl sulfone and, therefore, should be removed prior to 




Figure 2.12: Reaction of TCEP (2.6) with phenyl vinyl sulfone (2.18). 
2.4) Reaction of THPP with Vinyl Sulfone: a Thiol-Alkylating 
Functional Group 
The evidence of TCEP’s reaction with a vinyl sulfone functional group also prompted 
an investigation into the reaction of THPP with a vinyl sulfone functional group 
(Figure 2.13). THPP (2.7) was incubated with phenyl vinyl sulfone (2.18) for 1 hour 
at neutral pH. The reaction resulted in a large number of products and it was not 
possible to isolate anything from the mixture. On the basis of these results it is 
suggested to avoid THPP when using vinyl sulfone chemistry in bioconjugation 






Figure 2.13: Reaction of THPP (2.7) with phenyl vinyl sulfone (2.18) yielded a complex 
mixture of products. 
2.5) Reaction of the TCEP-Maleimide Adduct 2.9 with Thiols 
The aim of the following investigation was to investigate the potential of the 
product 2.9 to react with a thiol functional group. The investigation was performed 
to test if the TCEP-maleimide adduct 2.9 could still be a potentially productive 
intermediate and facilitate thiol alkylation in bioconjugation protocols. 
The potential turnover of the TCEP-maleimide ylene adduct 2.9 by thiols was 
investigated over a wide pH range and monitored by either 31P NMR spectroscopy 
or high resolution mass spectrometry (Figure 2.14). The phosphorus signal in the 
31P NMR spectrum of TCEP displays a characteristic peak between  -15 and -20 
ppm compared to the ylene adduct ( -35 to -40 ppm) and TCEP oxide ( -55 to -60 
ppm). 31P NMR spectroscopy, therefore, provides a rapid method for monitoring 
the potential reaction of 2.9 with a thiol functional group. 
The adduct 2.9 was synthesised in conditions mentioned previously and confirmed 
by 31P NMR spectroscopy against an authentic sample. Reduced glutathione (2.21), 
a thiol-containing tripeptide, was subsequently added and the reaction was left at 
room temperature overnight in a buffered solution (pH = 7). The reaction was 
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subsequently analysed by 31P NMR and HRMS. No change was observed by 31P NMR 
and the HRMS only detected unreacted glutathione and 2.9. The absence of a 
glutathione-maleimide product demonstrated that the ylene 2.9 is stable at neutral 
pH, in the presence of nucleophilic thiols. The same experiment was performed at 
pH = 8 to increase the nucleophilic thiolate anion concentration. Again, no change 
was observed by NMR or HRMS spectroscopy. The results confirmed the inability of 
a thiolate to turnover the ylene 2.9 under neutral or basic conditions and at 
ambient temperature. The same reaction was performed in an acidic environment 
(pH = 4) to access the stability of the ylene. Reduced glutathione was, again, unable 
to turnover the maleimide-TCEP adduct 2.9. The above evidence demonstrated the 
stability of 2.9 towards thiol-based nucleophiles over a wide pH range and is, 
therefore, a non-productive species when considering nucleophilic orientated 
chemical bioconjugations. These results would suggest, therefore, that TCEP should 
be removed prior to the introduction of maleimide functionalised ligands, to 
prevent the consumption of the thiol alkylating reagent by the disulfide reducing 
agent. 
 
Figure 2.14: Incubation of 2.9 with glutathione (2.21) over a pH range. The reactions 
were monitored by either NMR or HRMS spectroscopy for any potential 





2.6) Impact of the TCEP-Maleimide Reaction in Bioconjugations 
The discovery of the adducts between TCEP and maleimide (2.9, 2.12 & 2.14) and 
the reduction of maleimide derivatives by THPP (2.15, 2.16 & 2.17) have 
implications with regards to bioconjugation chemistry. If the reducing agents (TCEP 
or THPP) are not removed prior to the addition of a maleimide-functionalised 
ligand, the yield for the bioconjugation process may be reduced. Conjugate-TCEP 
adducts may also be generated, which may be problematic during the synthesis of 
conjugate vaccines.  
2.6.1) The Effect of Not Removing TCEP or THPP Prior to Maleimide PEGylation of 
a Model Protein 
The effect of not removing the reducing agents TCEP or THPP from bioconjugation 
reactions utilising a protein relying on thiol alkylation by maleimide-derivatised 
ligands was initially investigated. 
Yeast enolase was used as a model protein to investigate the effect of reducing 
agents on thiol alkylation by maleimide functionalised ligands. Yeast enolase (47 
kDa) is a commercially available protein containing a single cysteine (Cys248) 
residue and is, therefore, an excellent model protein to perform thiol alkylation 
experiments. The cysteine residue, however, is buried in the core of the protein’s 
structure and so it is first necessary to denature the protein (8 M urea) to expose 
the cysteine to facilitate thiol alkylation. 
Yeast enolase (1 mg/mL) was initially denatured in argon purged Tris buffer (0.5 M, 
pH = 7.2) containing 5 mM EDTA and 8 M urea. Varying concentrations of TCEP or 
THPP (1-10 eq.) were added to aliquots of protein and incubated for 45 minutes at 
25 C. Maleimide-PEG2kDa (1 eq.) was subsequently added and the reaction was 





Figure 2.15: SDS-PAGE analysis of PEGylation (1 eq.) experiments on yeast enolase with 
varying TCEP/THPP concentrations (1-10 eq.). Lane 1: ladder, Lane 2: 
enolase, Lane 3: enolase + TCEP (1 eq.) + maleimide-PEG2kDa (10 eq.), Lane 
4: enolase + TCEP (1 eq.) + maleimide-PEG2kDa (1 eq.), Lane 5: enolase + 
TCEP (5 eq.) + maleimide-PEG2kDa (1 eq.), Lane 6: enolase + THPP (10 eq.) 
+ maleimide-PEG2kDa (1 eq.), Lane 7: enolase + THPP (1 eq.) + maleimide-
PEG2kDa (10 eq.), Lane 8: enolase + THPP (1 eq.) + maleimide-PEG2kDa (1 
eq.), Lane 9: enolase + THPP (5 eq.) + maleimide-PEG2kDa (1 eq.), Lane 10: 
enolase + THPP (10 eq.) + maleimide-PEG2kDa (1 eq.). The SDS-PAGE gel 
was stained with Coomassie solution and analysed utilising Image Studio 
Lite software. 
The phosphorus atom of TCEP and THPP competes with the cysteine thiol of yeast 
enolase for nucleophilic addition to maleimide-PEG2kDa, which results in very poor 
yields of PEGylated protein (Figure 2.15, Lanes 4-6 & 8-10). The electrophoresis 
results clearly demonstrates the need to consume or remove both TCEP and THPP 
prior to maleimide-based bioconjugation reactions. 
2.6.2) The Effect of Not Removing TCEP when Utilising Maleimide for Conjugate 
Vaccine Production 
There is an additional important implication regarding the reaction of TCEP with 
maleimide, particularly regarding the production of conjugate vaccines. The 
production of conjugate vaccines via thiol alkylation by methods utilising maleimide 
are well documented [131, 132]. The assembly of conjugate vaccines is generally 
achieved via coupling of a carrier protein to an antigen and may be achieved 
through two different strategies. The carrier protein may provide the nucleophilic 
thiol either via synthetic introduction or a naturally occurring cysteine residue, 
while the antigen may be functionalised with the electrophilic thiol alkylating 
reagent such as maleimide [133]. Conversely, it is also possible to functionalise the 
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carrier protein with maleimide while the antigen provides the nucleophilic thiol 
[134]. 
Regardless of the strategy employed, it is important that TCEP is completely 
removed prior to maleimide-dependant conjugation due to the potential for TCEP 
to covalently link to the maleimide functional group. If the maleimide is attached to 
either the antigen (Figure 2.16, A) or the carrier protein (Figure 2.16, B) there is a 
risk of forming heterogeneous products consisting of carrier protein, antigen and 
TCEP. The covalent attachment of TCEP to the bioconjugate presents an additional 
antigen to the host during vaccination and this may result in the production of non-
productive antibodies to the TCEP ligand attached to the bioconjugate. 
 
Figure 2.16: Illustration of the potential for TCEP addition to conjugate vaccine 
products. A) If the excess TCEP is not removed prior to the addition of a 
maleimide-functionalised antigen, the resulting bioconjugate could be 
composed of carrier protein, antigen and TCEP. B) If the excess TCEP is not 
removed prior to the addition of a maleimide-functionalised carrier 
protein, the resulting bioconjugate could be composed of carrier protein, 
antigen and TCEP. 
As such, the potential attachment of TCEP to maleimide functionalised ligands 
utilised for conjugate vaccine production was investigated. The antigenic 
polysaccharide (Pn6B) from the outer protective capsule of the pathogen 
Streptococcus pneumoniae was chosen as the ligand for maleimide 
functionalisation as it is a common antigen utilised in vaccine production to prevent 
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infection from S. pneumoniae [135]. The Pn6B is a 0.9-1.5 MDa carbohydrate and 
consists of a repeat unit of (→2-α-D-Galactopyranose-(1→3)-α-D-Glucopyranose-
(1→3)-α-L-rhamnopyranose-(1→4)-D-ribitol-5-phosphate→) (Figure 2.17). 
 
Figure 2.17: Repeat unit of the Pn6B polysaccharide, n1000. 
The maleimide-isocyanate linker N-(5-isocyanatopentyl)maleimide (2.23) was 
prepared for the functionalisation of Pn6B (2.24, Figure 2.18). 6-Maleimidohexanoic 
acid (0.25 g, 2.22) was dissolved in anhydrous THF (4 mL) containing triethylamine 
(0.3 mL). Diphenylphosphoryl azide (0.38 mL) was added and the reaction was 
stirred at room temperature for 2 hours. Anhydrous toluene (100 mL) was 
subsequently added and the solution was concentrated to a volume of 5 mL. The 
solution was heated at 70 C for 2 hours and then allowed to cool back to room 
temperature, followed by a silica gel chromatography purification step to produce 






Figure 2.18: Synthesis of N-(5-isocyanatopentyl)maleimide (2.23). 
Pn6B (10 mg) was added to 2 mL of water and stirred at room temperature until the 
carbohydrate dissolved. The viscous solution was then loaded onto an ion exchange 
column (tetrabutylammonium form) and incubated for 30 minutes before elution. 
The fractions containing carbohydrate as a tetrabutylammonium salt were pooled 
and subsequently lyophilised to yield a white solid (9.4 mg). The white solid was 
added to 4 mL of anhydrous DMSO and stirred at 30 °C under N2 overnight to 
dissolve the carbohydrate.  
An anhydrous DMSO solution (0.5 mL) containing 2.23 (3 mg) was added to a 
solution of Pn6B (9.4 mg) in anhydrous DMSO (4 mL) and allowed to stir for 2 hours 
at room temperature. The solution was transferred to a dialysis bag (12-14 kDa cut-
off) and dialysed against 5 litres of 0.1 M sodium phosphate buffer (pH = 7), 
followed by 5 litres of 0.01 M sodium phosphate buffer (pH = 7), 3) and finally 5 
litres of water. The solution within the dialysis bag was frozen and lyophilised to 
yield 6 mg of white solid (2.24, Figure 2.19). A portion of product (0.5 mg) was 
analysed by NMR spectroscopy to determine the maleimide/carbohydrate ratio. 
The amount of maleimide incorporated was estimated as being 2 % by comparing 
the integrals representing the maleimide alkene protons to the methyl protons of 








Figure 2.19: Maleimide functionalisation of Pn6B (2.24). 1) Dowex 50X4-200 (tBu4N+), 2) 
(2.23), DMSO, 3) dialysis a) 0.1 M sodium phosphate buffer, pH = 7, b) 0.01 
M sodium phosphate buffer, pH =7, c) water, d) lyophilisation. 
The maleimide-functionalised polysaccharide was dissolved in deuterium oxide for 
the acquisition of a 31P NMR spectrum. A characteristic peak for the phosphate 
functional group of the Pn6B repeat unit was identified at  -0.08 ppm in the 31P 
NMR spectrum. A sample of maleimide functionalised Pn6B polysaccharide was 
subsequently dissolved in water containing TCEP and incubated at room 
temperature for 1 hour. The polysaccharide was then extensively purified using gel 
filtration chromatography and subsequently lyophilised. The product was 
resuspended in deuterium oxide and analysed by 31P NMR spectroscopy. The peak 
representing the phosphate functional group within the repeat unit of Pn6B was 
still identifiable, along with the appearance of a new peak at  38.4 ppm, which is a 
characteristic chemical shift for the ylene product observed previously between 
maleimide and TCEP. This result provides clear evidence for the necessity of TCEP 
removal prior to addition of maleimide-functionalised ligands, especially in the 





Trialkylphosphines such as TCEP and THPP are effective disulfide reducing agents 
but are reactive with Michael acceptors such as maleimide and vinyl sulfone. TCEP 
and THPP have been found to react with maleimide to produce different products. 
TCEP reacts with maleimide to produce a stable ylene adduct that is resistant to 
nucleophilic attack by thiols. THPP reduces maleimide to succinimide which could 
significantly reduce yields during the bioconjugation process. TCEP reacts with vinyl 
sulfone to generate a speculated penta co-ordinate phosphorus product, while 
THPP reacts with vinyl sulfone to produce a complex mixture of products. These 
reactions may also lower yields during bioconjugate production and may also 
complicate purification protocols. It is clearly evident that both the reducing agents 
need to be completely removed before the alkylating reagents are added to the 
reaction. Towards this aim, a method for ‘in situ’ removal of phosphine reducing 




Chapter 3: A Novel Method for Thiol-Alkylation 
Reactions Involving in situ Reduction of 
Trialkylphosphines 
3.0) Introduction 
Our previous work demonstrated that both TCEP and THPP react with Michael 
acceptor thiol alkylating reagents such as maleimide and vinyl sulfone (Chapter 2), 
which clearly indicates the need for complete consumption or removal of TCEP or 
THPP prior to the bioconjugation reactions being performed. Currently, the 
consumption or removal of the TCEP or THPP is achieved using a number of 
methods. 
The use of an excess of alkylating reagent with respect to amount of TCEP or THPP 
present in the reaction ensures consumption of the reducing agent, while still 
enabling a successful alkylation reaction [108]. The addition of excess alkylating 
reagent offers a simple protocol to consume the disulfide reducing agent prior to 
thiol-alkylation reactions. The method does, however, require consumption of thiol-
alkylating ligands that may be expensive to synthesise or purchase, which would be 
the case for ADC production. The previous addition of excess alkylating reagent by 
other groups may be a reason why the reaction of TCEP (or THPP) with thiol-
alkylating reagents are often overlooked [123]. 
Another potential problem with not removing the reducing agent is the possibility 
of the trialkylphosphine forming a covalent adduct with a biomolecule derivatised 
with an alkylating functional group such as maleimide. The covalent adduct may 
compromise the bioconjugate’s structure or function. Chapter 2 demonstrated this 
pitfall within the context of conjugate vaccine production, where an adduct 




Excess reducing reagents may also be removed using purification techniques such 
as dialysis or gel filtration, however, the inclusion of a purification step to remove 
the reducing agent may affect the time and cost of production, especially when 
applied to a commercial scale. This purification step can contribute to a decrease in 
yields, as the freshly reduced disulfide of the biomolecule is potentially exposed to 
oxidising conditions. Exposure to oxygen is especially applicable to dialysis, which 
often requires an extensive incubation period for effective dialytic removal of the 
reducing agent. Gel filtration potentially offers a more rapid approach for reducing 
agent removal, therefore, minimising exposure of the thiols to oxidative conditions, 
however, gel filtration is not always effective in removing reducing agents such as 
TCEP. TCEP is reported to form high molecular weight oligomers, which co-elute 
with the proteins of interest during gel filtration [109]. 
Commercially available TCEP on solid support potentially offers a strategy for the 
effective reduction of disulfides, followed by rapid removal of the solid support by 
centrifugation or filtration prior to addition of thiol alkylating reagents. The 
potential to rapidly remove TCEP on solid support can minimise exposure of the 
reduced disulfides to oxidative conditions, therefore, promoting high yielding thiol 
alkylation reactions. There is, however, literature which claims a low recovery of 
peptides after utilising TCEP on solid support to reduce disulfides. The low peptide 
recovery is attributed to binding of the peptides to the solid support [136]. 
The methods mentioned above to remove excess disulfide reducing agents have 
been shown to possess some limitations. As such we sought to develop an 
alternative method to consume excess TCEP or THPP in situ, which does not 
interfere with thiol alkylation reactions. Here, the Staudinger reaction is explored as 
a potential protocol to oxidise excess TCEP or THPP prior to the addition of 
maleimide or vinyl sulfone ligands to alkylate thiols. 
The use of the Staudinger reaction could provide a protocol that eliminates dialysis 
or gel filtration to remove TCEP or THPP, therefore minimising the exposure of 
reduced disulfides to oxidative conditions. 
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TCEP has already been previously shown to react through a Staudinger mechanism 
with azides under aqueous conditions. [137, 138]. The Staudinger reaction was, 
therefore, utilised to develop a novel ‘one-pot’ protocol to oxidise excess TCEP or 
THPP followed by a thiol alkylation reaction. 
3.1) Addition of a Water Soluble Alkyl Azide to Oxidise Excess TCEP 
or THPP after the Reduction of Disulfides 
The Staudinger reaction was first reported by Staudinger, H. and Meyer J. in 1919, 
where a reaction between phenyl azide and triphenylphoshine was found to 
generate an iminophosphorane and nitrogen gas [60]. The iminophosphorane, 
under aqueous conditions, can be hydrolysed to generate phosphine oxide and an 
alkyl amine (Figure 3.1). 
 
Figure 3.1: Mechanism for the Staudinger reaction. A tri-substituted phosphine reacts 
with an alkyl azide to generate a phosphazide, which loses N2 to form an 
iminophosphorane intermediate. An aqueous work-up results in an alkyl 
amine and a trisubstituted phosphine oxide derivative. R = alkyl or aryl. 
We considered that the addition of a water soluble alkyl azide, following the 
reduction of disulfides by trialkylphosphine reducing agents (TCEP or THPP) should 
facilitate oxidation of the excess trialkylphosphine to trialkylphosphine oxide, 
generating nitrogen gas and an alkyl amine as products. The trialkylphosphine oxide 
should no longer react with alkylating reagents such as maleimide and vinyl sulfone. 
The alkyl amine product should also not react with alkylating reagents such as 
maleimide and vinyl sulfone providing the reactions are performed at pH  8.5. 
It was envisaged to test the ability of a water soluble alkyl azide to oxidise excess 
TCEP or THPP after a disulfide reduction step of cysteine derivatives, followed by 
the addition of a maleimide derivative to effect thiol alkylation. Derivatives of 
57 
 
cysteine were initially chosen for ease of purification, with the hope to quantify 
yields of the thiol alkylated products. 
Commercially available L-cysteine ethyl ester hydrochloride salt, which can exist as 
a dimer 3.1a, was dissolved in phosphate buffer at neutral pH, containing excess (3 
eq.) TCEP (2.6) to reduce any potential disulfides (Figure 3.2, A), generating the 
monomeric form of the amino acid 3.2a. The reaction was left for 30 minutes at 
room temperature. Initially, 1,14-diazido-3,6,9,12-tetraoxatetradecane (3.3) was 
not added to oxidise excess TCEP to TCEP oxide (3.4). N-ethyl maleimide (2.8) was 
added and the reaction incubated at room temperature for 30 minutes (Figure 3.2, 
C). Purification of the reaction by either silica gel or C-18 chromatography proved 
unsuccessful due to the polarity of reagents and products. The reaction was 
therefore analysed by HRMS. The negative ion mass spectrum revealed the 
presence of a number of compounds, including unreacted TCEP (2.6), TCEP oxide 
(3.4) and the ylene adduct between TCEP and N-ethyl maleimide (Chapter 2, 2.9). 
The positive ion mass spectrum revealed the presence of the intended product, 
ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate (3.7a). The HRMS data 
provided clear evidence of nucleophilic competition between TCEP (2.6) and 




Figure 3.2: Assessment of the ability of the water soluble alkyl azide 3.3 to oxidise 
excess reducing agents (TCEP or THPP) prior to thiol alkylation of L-cysteine 
derivatives 3.2a & 3.2b by N-ethyl maleimide (2.8). A) The oxidised amino 
acid 3.1 was reduced to monomers 3.2a or 3.2b by the addition of either 
TCEP or THPP. B) The alkyl azide 3.3 was added to oxidise excess TCEP or 
THPP. C) N-ethyl maleimide (2.8) was added to thiol alkylate 3.2a or 3.2b, 
generating 3.7a & 3.7b. 
The above reaction was repeated, this time, with the addition of 3 equivalents of 
alkyl azide 3.3 (Figure 3.2 B) to oxidise excess TCEP (2.6) to TCEP oxide (3.4) prior to 
the addition of N-ethyl maleimide (2.8, Figure 3.2 C). The reaction was 
subsequently investigated by HRMS and analysis of the negative ion mass spectrum 
confirmed the complete oxidation of TCEP (2.6) to TCEP oxide (3.4). There was also 
no detection of TCEP-maleimide ylene adduct 2.9. The mass spectrum confirmed 
the presence of intended product 3.7a, the mono-reduced azide 3.6 and unreacted 
azide 3.3. This experiment proved the potential of a water soluble azide to 
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completely oxidise TCEP (2.6) to TCEP oxide (3.4), resulting in a thiol alkylated 
amino acid 3.7a and no detection of a TCEP-maleimide adduct 2.9. 
The water soluble azide 3.3 was subsequently tested to potentially oxidise excess 
THPP (2.7) to THPP oxide (3.5) prior to maleimide alkylation of L-cysteine ethyl ester 
(3.2a). L-Cysteine ethyl ester hydrochloride salt (3.1) was dissolved in phosphate 
buffer at neutral pH containing excess (3 eq.) THPP (2.7) to reduce any potential 
disulfides and incubated at room temperature for 30 minutes (Figure 3.2, A). 
Initially the alkyl azide 3.3 was not added to oxidise excess THPP (2.7) to THPP oxide 
(3.5). N-Ethyl maleimide (2.8) was added and the reaction was incubated at room 
temperature for 30 minutes (Figure 3.2, C). Purification of the reaction by either 
silica gel or C-18 chromatography proved unsuccessful due to the polarity of 
reagents and products. The reaction was, therefore, analysed by HRMS. The 
positive ion mass spectrum revealed the presence of unreacted THPP (2.7) and 
THPP oxide (3.5). The unwanted reduction of N-ethyl maleimide to N-ethyl 
succinimide (2.15, Chapter 2) by THPP was also observed. The intended product 
3.7a was also observed in the HRMS. The experiment provides clear evidence of 
nucleophilic competition between THPP (2.7) and cysteine thiol of 3.2a for the 
alkene of N-maleimide (2.8). 
The reaction described was repeated, this time, with the addition of 3 equivalents 
of alkyl azide (3.3, Figure 3.2, B) to oxidise excess THPP (2.7) prior to the addition of 
N-ethyl maleimide (2.8, Figure 3.2 C). The reaction was subsequently analysed by 
HRMS. The positive ion mass spectrum confirmed the presence of THPP oxide (3.5), 
the intended product 3.7a and mono-reduced azide 3.6. No reduction of N-ethyl 
maleimide to N-ethyl succinimide (2.15) or excess THPP (2.7) was observed in the 
HRMS. The HRMS experiment proved the ability of a water soluble alkyl azide to 
completely oxidise THPP to THPP oxide, resulting in a thiol alkylated amino acid and 




We sought to quantify yields of a maleimide alkylated amino acid with and without 
the use of the alkyl azide 3.3 to oxidise excess TCEP or THPP in the reaction. N-
acetyl-L-cysteine methyl ester (3.1b, Figure 3.2) was therefore chosen as a 
substrate for thiol alkylation as it is more amenable to silica gel purification due to 
the derivatisation of both its amino and carboxylic acid functional groups. 
The experiments involved the dissolution of N-acetyl-L-cysteine methyl ester dimer 
(3.1b) in THF and Tris buffer (0.5 M, pH = 7.2), containing excess (5 eq.) TCEP (2.6) 
or THPP (2.7) and incubation for 30 minutes at room temperature. Initially, the 
excess reducing agents were not oxidised to phosphine oxides by the alkyl azide 3.3 
prior to addition of N-ethyl maleimide (2.8). N-Ethyl maleimide (2.8, 1.1 eq.) was 
added and the reactions were incubated at room temperature for 1 hour. The 
reactions were subsequently purified by silica gel chromatography to access the 
yields of methyl N-acetyl-S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate 
(3.7b) formation (Table 3.1, No. 1 & 2). Poor yields of 3.7b were observed for both 
reactions carried out in the absence of alkyl azide 3.3. The reaction where TCEP was 
utilised, and the excess was not oxidised by the addition of 3.3, resulted in a low 
yield of 3.7b of 27 %, following the addition of N-ethyl maleimide. A similarly low 
yield of 3.7b of 21 % was achieved following purification of the reaction where 
excess THPP was not oxidised by addition of 3.3 prior to the addition of N-ethyl 
maleimide. 
The reactions were subsequently repeated, but with the addition of excess (10 eq.) 
alkyl azide 3.3 to oxidise TCEP or THPP prior to the addition of N-ethyl maleimide 
(2.8). Purification of both the reactions and quantification of 3.7b was performed. 
Significant yield improvements were observed for both reactions, with a 74 % yield 
of 3.7b for the reaction utilising TCEP and a 69 % yield of 3.7b for the reaction 
utilising THPP (Table 3.1, No. 3 & 4). The experiments suggested that TCEP and 
THPP can be oxidised to trialkylphosphine oxides in situ through the addition of a 
water soluble alkyl azide 3.3. Maleimide can, subsequently, be added directly to the 
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Table 3.1: Summary of yields for 3.7b with and without trialkylphosphine (TCEP or 
THPP) oxidation by alkyl azide 3.3. 
3.2) Investigating the Potential Reaction of Maleimide with Alkyl 
Azide 3.3 
Although the addition of a water soluble azide to oxidise excess TCEP or THPP 
proved to be an effective method for effecting high yields of maleimide-alkylated 
products, it was also considered necessary to investigate the possibility of a 
reaction between maleimide and the alkyl azide 3.3, as it could potentially lead to 
reduced yields of conjugate. 
N-Ethyl maleimide (2.8, 5 mg) was incubated with equimolar alkyl azide 3.3 in 
deuterium oxide and monitored by 1H NMR spectroscopy. After 16 hours incubation 
at room temperature, the 1H NMR spectrum exhibited signs of product formation 
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by the appearance of doublets at  4.68 and 5.61 ppm with coupling constants of 
11 Hz. The appearance of these signals was an indication of a potential reaction 
between N-ethyl maleimide (2.8) and alkyl azide 3.3. 
The observation was further investigated by scaling up the reaction and monitored 
by thin layer chromatography (TLC). The alkyl azide 3.3 (50 mg) was dissolved in 
phosphate buffer (0.1 M, pH = 7, 2 mL) containing N-ethyl maleimide (2.8, 1.5 eq., 
32.6 mg) and left to stir at room temperature. The appearance of product was 
extremely slow and so the reaction was left to stir for 2.5 days. After 2.5 days a 
second product was detectable by TLC. Purification of the reaction by silica gel 
chromatography resulted in the isolation of triazoline derivatives 1-(14-azido-
3,6,9,12-tetraoxatetradec-1-yl)-5-ethyl-3a,6a-dihydropyrrolo[3,4-d][1,2,3]triazole-
4,6(1H,5H)-dione (3.8) in 42 % yield and 1,1'-(3,6,9,12-tetraoxatetradecane-1,14-
diyl)bis(5-ethyl-3a,6a-dihydropyrrolo[3,4-d][1,2,3]triazole-4,6(1H,5H)-dione) (3.9) in 
25 % yield (Figure 3.3). The formation of the two products 3.8 and 3.9 appears to 
occur via a [3+2] cycloaddition between the maleimide and azide functional groups. 
The cycloaddition reaction between an alkyl azide and a maleimide functional 
group is reported in the literature, although it was performed in an organic solvent 








Figure 3.3: Reaction of N-ethyl maleimide (2.8) with the alkyl azide 3.3 to generate 
triazoline derivatives 3.8 and 3.9. 
The low rate of triazoline formation is advantageous as it minimises potential 
interference with the reaction between the alkyl azide 3.3 and the 
trialkylphosphines TCEP and THPP prior to maleimide-based thiol alkylation 
reactions. The reaction between thiols and maleimide is extremely rapid hence 
thiols should out-compete the azide for addition to maleimide. This was confirmed 
by the absence of triazoline derivatives in the experiments performed in previous 
section 3.1, but required further validation through additional experiments. NMR 
and MS spectrometry experiments were designed to confirm that a thiol addition to 
maleimide would outcompete any possible triazoline formation through the 
reaction of the alkyl azide 3.3 with N-ethyl maleimide (2.8). 
Initially N-ethyl maleimide (2.8, 1 mM) was dissolved in deuterated phosphate 
buffer (0.5 M, pH = 7.2) and analysed by 1H NMR spectroscopy to verify the 
detection of the signature singlet at  7 ppm representing the alkene protons of 
the maleimide ring. The experiment was also performed to test the sensitivity of 
the NMR instrument to analyse the dilute solution. Analysis of the 1H NMR 
spectrum did confirm the presence of the singlet of the alkene protons at  6.75 
ppm. Reduced glutathione (2.21, 1 mM), a tripeptide containing a cysteine residue, 
was added to the solution of N-ethyl maleimide (2.8) and immediately analysed by 
1H NMR spectroscopy. The 1H NMR spectrum showed complete disappearance of 
the singlet representing the maleimide alkene protons, which was confirmation of a 
rapid reaction between N-ethyl maleimide (2.8) and glutathione (2.21). The thiol 
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alkylated peptide 3.10 was also confirmed by HRMS (Figure 3.4, m/z 433.1381 (M-
H+)). 
 
Figure 3.4: Reaction of glutathione (2.21) with N-ethyl maleimide (2.8) in a deuterated 
buffer to yield 3.10. 
An experiment was subsequently performed to prove the superior reaction rate of 
a thiol addition to maleimide over the [3+2] cycloaddition of the alkyl azide 3.3 to 
maleimide. Reduced glutathione (2.21, 1 eq.) was dissolved in deuterated 
phosphate buffer (0.5 M, pH = 7.2), containing alkyl azide 3.3 (50 eq.). N-Ethyl 
maleimide (2.8, 1 eq.) was subsequently added and the reaction was immediately 
analysed by 1H NMR spectroscopy. The 1H NMR spectrum showed complete 
disappearance of the singlet representing the maleimide alkene protons, which 
confirmed the consumption of N-ethyl maleimide. There was no evidence in the 1H 
NMR spectrum of a pair of doublets at   4.68 and  5.61 ppm with coupling 
constants of 11 Hz, which would have been a positive indication of triazoline 
formation. The above observations proved that reduced thiols react much more 
rapidly with maleimide than the water soluble alkyl azide, even when the alkyl azide 
is at a 50 fold excess to the thiol. The evidence was further validated by HRMS 
analysis. The identification of a maleimide derivatised peptide 3.10 (m/z 433.1375 
(M-H+)) and the absence of any peaks in the HRMS spectrum representing triazoline 





Figure 3.5: A) Glutathione (2.21) and alkyl azide 3.3 were initially dissolved in 
deuterated buffer. B) N-ethyl maleimide (2.8) was added to the solution 
and the reaction was subsequently analysed by NMR spectroscopy and MS. 
The thiol alkylated peptide 3.10 was confirmed by MS, while no reaction 
between N-ethyl maleimide (2.8) and alkyl azide 3.3 was observed by either 
NMR spectroscopy or MS. 
NMR experiments were subsequently performed to determine the rate of triazoline 
formation between maleimide derivatives and the alkyl azide 3.3. Either N-ethyl 
maleimide (2.8, 1 eq.) or maleimide-PEG2kDa (1 eq.) was dissolved in deuterated 
phosphate buffer (0.5 M, pH = 7.2) containing the alkyl azide 3.3 (100 eq.). The 
reactions were monitored by 1H NMR spectroscopy at room temperature (Graph 
3.1), through the consumption of maleimide (diminishing singlet representing the 
alkene protons of the maleimide ring) and the appearance of triazoline product 
(increasing appearance of doublets representing the bridgehead protons). A plot of 
the data revealed a 50 % consumption of N-ethyl maleimide (2.8) after 11.3 hours 
and 50 % consumption of maleimide-PEG2kDa after 10.7 hours (Graph 3.1). 
Analysis of the experiment indicated that triazoline formation is very slow, when 
comparing to a reaction between maleimide and thiols, which is too rapid to be 
analysed by NMR spectroscopy. The potential triazoline formation should not 
interfere with the rapid thiol alkylation reaction utilising maleimide chemistry. 
The accumulated NMR and MS data has indicated that triazoline formation does 
not interfere with bioconjugation between a thiol and a maleimide functional 
group, even with the water soluble alkyl azide present in a vast excess to the thiol 
functional group. The addition of a water soluble alkyl azide, therefore, offers a 
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simple solution to oxidising excess phosphine-based disulfide reducing agents prior 
to alkylation using maleimide chemistry. 
 
Graph 3.1: Consumption of maleimide derivatised ligands through triazoline formation 
with the alkyl azide 3.3. 
3.3) Reaction of a Vinyl Sulfone Functional Group with the Alkyl 
Azide 3.3 
As discussed earlier, vinyl sulfone derivatives are also utilised as Michael acceptors 
for the alkylation of thiol-containing molecules. As such, we next investigated the 
potential reaction of the alkyl azide 3.3 with a vinyl sulfone functional group, 
following the earlier observation that the Michael acceptor, N-ethyl maleimide (2.8) 
reacted with 3.3 to form triazoline derivatives 3.8 and 3.9. The possible reaction of 
3.3 with vinyl sulfone was explored because it was envisaged to potentially use 3.3 
as a reagent to oxidise excess TCEP or THPP prior to addition vinyl sulfone 
derivatives to alkylate thiols. 
The alkyl azide 3.3 (110 mg) was dissolved in THF (2 mL) and water (8 mL), 
containing phenyl vinyl sulfone (2.18, 2 eq., 128 mg) and stirred at room 
temperature (Figure 3.6). The appearance of a product (TLC analysis) was extremely 
slow and so the reaction was allowed to stir for 4 days. Purification of the reaction 
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by silica gel chromatography resulted in the isolation of the triazoline derivative 1-
(14-azido-3,6,9,12-tetraoxatetradecan-1-yl)-4-(benzenesulfonyl)-4,5-dihydro-1H-
1,2,3-triazole (3.11) in 59 % yield (Figure 3.7). However, unlike the analogous 
reaction with N-ethyl maleimide, here no di-triazoline derivative was isolated. 
 
Figure 3.6: Reaction of phenyl vinyl sulfone (2.18) with the alkyl azide 3.3 to generate 
the triazoline derivative 3.11. 
The [3+2] cycloaddition reaction of phenyl vinyl sulfone (2.18) with the alkyl azide 
3.3 appeared to be much slower than that of N-ethyl maleimide with the alkyl azide 
3.3. The slower rate implied that utilisation of the alkyl azide 3.3 for 
trialkylphosphine oxidation should also be compatible to vinyl sulfone-based 
chemistry, with little chance of triazoline formation occurring, given the rate 
difference. 
To demonstrate this, glutathione (2.21, 1 eq.) was incubated with the alkyl azide 3.3 
(50 eq.) in deuterated phosphate buffer (0.5 M, pH = 7.2), followed by the addition 
of phenyl vinyl sulfone (2.18, 1 eq.). The reaction was monitored by 1H NMR 
spectroscopy and HRMS. Analysis of the 1H NMR spectra revealed the absence of 
peaks representing the vinyl protons, which indicated that phenyl vinyl sulfone had 
undergone a reaction, possibly to glutathione, which was confirmed by HRMS (3.12, 
Figure 3.7). There was no evidence of triazoline formation in the 1H NMR spectrum 
or HRMS spectrum. The alkyl azide 3.3, therefore, can be added to a conjugation 
reaction to oxidise excess TCEP or THPP when utilising vinyl sulfone derivatised 




Figure 3.7: Reaction of phenyl vinyl sulfone (2.18) with glutathione (2.21) to generate 
the thiol alkylated peptide 3.12. 
3.4) Addition of the Water Soluble Alkyl Azide 3.3 to Oxidise Excess 
TCEP or THPP in Bioconjugation Reactions 
The addition of a water soluble alkyl azide could prove a useful technique to 
achieve the goal of trialkyphosphine oxidation in bioconjugation reactions, without 
resorting to traditional purification techniques such as dialysis or gel filtration. 
3.4.1) TCEP and THPP Oxidation by the Alkyl Azide 3.3 in Bioconjugation 
Reactions 
The incubation time of 3.3 (100 eq.) necessary to oxidise excess TCEP or THPP (10 
eq.) prior to addition of maleimide derivatised ligands was explored. 
Initially, 31P NMR spectroscopy was utilised to follow the reaction of TCEP (10 eq.) 
with 3.3 (100 eq.) in Tris buffer (0.5 M, pH = 7.2) by monitoring the disappearance 
of the peak representing the phosphorus atom of trialkylphosphine and the 
appearance of the peak representing the phosphorus of trialkylphosphine oxide. 31P 
NMR spectroscopy proved ineffective in accurately monitoring the reaction due to 
the poor signal-to-noise ratio of the phosphorus peak of the trialkylphosphine. 
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HRMS proved an excellent alternative method to monitor the oxidation of 
trialkylphosphine to trialkylphosphine oxide. TCEP or THPP (10 mM) was incubated 
with 3.3 (100 mM) in Tris buffer (0.5 M, pH = 7.2) at 37 °C. After 30 minutes the 
reactions were analysed by HRMS and indicated the complete oxidation of both 
TCEP and THPP to the corresponding trialkylphosphine oxide products. Incubation 
of 3.3 (10 eq.) with either TCEP or THPP for 30 minutes at 37 C was sufficient to 
oxidise both the reducing agents. 
3.4.2) Use of Alkyl Azide 3.3 to Oxidise Excess TCEP or THPP to Ensure High 
Protein-Maleimide-Fluorescein Conjugate Yields 
Protein labelling by maleimide derivatised fluorescent probes has previously been 
shown by SDS-electrophoresis to significantly decreases as the TCEP concentration 
increases relative to the fluorescent probe [8] and similar results are presented in 
Chapter 2, Figure 2.15. Yeast enolase was utilised as a model protein for both 
investigations. It was, therefore, envisaged to utilise yeast enolase and maleimide-
fluorescein in experiments where either excess TCEP or THPP would be oxidised by 
the addition of alkyl azide 3.3 prior to the addition of maleimide-fluorescein to 
alkylate yeast enolase. 
Varying amounts of TCEP (1-10 eq.) were added to aliquots of yeast enolase and 
incubated for 45 minutes at 25 C. Commercially available maleimide-fluorescein (1 
eq.) was subsequently added and the reactions were incubated at 37 C for 18 
hours (Figure 3.8, lanes 1-3). In parallel experiments the alkyl azide 3.3 (100 eq.) 
was added to aliquots of yeast enolase containing varying amounts of TCEP (1-10 
eq.). The samples were incubated for 1 hour at 37 C prior to addition of 
maleimide-fluorescein (1 eq.) followed by incubation at 37 C for 18 hours (Figure 




Figure 3.8: SDS-PAGE analysis of reactions between maleimide-fluorescein (1 eq.) and 
yeast enolase in the presence of varying TCEP amounts (1-10 eq.), in the 
presence or absence of the alkyl azide 3.3 (100 eq.). Lane 1: enolase + TCEP 
(1 eq.) + maleimide-fluorescein (1 eq.), Lane 2: enolase + TCEP (5 eq.) + 
maleimide-fluorescein (1 eq.), Lane 3: enolase + TCEP (10 eq.) + maleimide-
fluorescein (1 eq.), Lane 4: enolase + TCEP (1 eq.) + 3.3 (100 eq.) + 
maleimide-fluorescein (1 eq.), Lane 5: enolase + TCEP (5 eq.) + 3.3 (100 eq.) 
+ maleimide-fluorescein (1 eq.), Lane 6: enolase + TCEP (10 eq.) + 3.3 (100 
eq.) + maleimide-fluorescein (1 eq.). The SDS-PAGE gel was analysed 
utilising Image Studio Lite software. 
The SDS gel shows that there is a progressive decrease in the amount of fluorescent 
bioconjugate as the concentration of TCEP increases relative to the concentration 
of maleimide-fluorescein as a result of the reaction between TCEP and the 
maleimide functionalised fluorescent probe (Figure 3.8, Lanes 1-3). In contrast, the 
addition of alkyl azide 3.3 results in consistent levels of conjugation (Figure 3.8, 
Lanes 4-6). The effectiveness of 3.3 in oxidising TCEP is illustrated in Graph 3.2 by 
quantification of the fluorescent bands representing the enolase-fluorescein 
conjugate. Quantification of the fluorescent bands was achieved by utilising a Licor 
ODYSSEY® CLx scanner and Image Studio Lite software, which is capable of 
determining the intensity of the selected bands on the gel. Graph 3.2 illustrates a 
consistent level of fluorescent protein conjugate by the addition of alkyl azide 3.3, 
regardless of the initial TCEP concentration relative to the concentration of 
maleimide-fluorescein added. The addition of 3.3 is, therefore, an effective strategy 




Graph 3.2: Enolase-fluorescein conjugate production with and without the addition of 
the alkyl azide 3.3 to oxidise TCEP. 
The addition of alkyl azide 3.3 to oxidise THPP was investigated using maleimide-
fluorescein as the ligand to attach to the thiol-containing yeast enolase protein. 
Varying concentrations of THPP (1-10 eq.) were added to aliquots of yeast enolase 
and incubated for 45 minutes at 25 C. Maleimide-fluorescein (1 eq.) was 
subsequently added and the reactions were incubated at 37 C for 18 hours (Figure 
3.9, lanes 1-3). In parallel experiments 3.3 (100 eq.) was added to aliquots of 
enolase containing varying amounts of THPP (1-10 eq.). The samples were 
incubated for 1 hour at 37 C prior to addition of maleimide-fluorescein (1 eq.) 
































Figure 3.9: SDS-PAGE analysis of reactions between maleimide-fluorescein (1 eq.) and 
yeast enolase in the presence of varying THPP amounts (1-10 eq.), in the 
presence or absence of the alkyl azide 3.3 (100 eq.). Lane 1: enolase + THPP 
(1 eq.) + maleimide-fluorescein (1 eq.), Lane 2: enolase + THPP (5 eq.) + 
maleimide-fluorescein (1 eq.), Lane 3: enolase + THPP (10 eq.) + maleimide-
fluorescein (1 eq.), Lane 4: enolase + THPP (1 eq.) + 3.3 (100 eq.) + 
maleimide-fluorescein (1 eq.), Lane 5: enolase + THPP (5 eq.) + 3.3 (100 eq.) 
+ maleimide-fluorescein (1 eq.), Lane 6: enolase + THPP (10 eq.) + 3.3 (100 
eq.) + maleimide-fluorescein (1 eq.). The SDS-PAGE gel was analysed 
utilising Image Studio Lite software. 
The SDS gel shows that there is a progressive decrease in the amount of fluorescent 
conjugate as the concentration of THPP increases relative to the concentration of 
maleimide-fluorescein as a result of the reaction between THPP and the maleimide 
functionalised probe (Figure 3.9, Lanes 1-3). In contrast, the addition of the alkyl 
azide 3.3 results in consistent levels of conjugation (Figure 3.9, Lanes 4-6). The 
effectiveness of 3.3 in oxidising THPP is illustrated in Graph 3.3, showing a 
consistent level of fluorescent protein conjugate, regardless of the initial THPP 
concentration relative to concentration of the maleimide-fluorescein added. The 
addition of 3.3 is, therefore, an effective strategy to oxidise THPP prior to addition 




Graph 3.3: Enolase-fluorescein conjugate production with and without the addition of 
the alkyl azide 3.3 to oxidise excess THPP. 
Here we have shown that the presence of TCEP or THPP in solution with maleimide 
functionalised ligands reduces the yields of conjugate production. The addition of a 
water alkyl azide oxidises these disulfide reducing agents, which no longer react 
with maleimide, enabling consistent conjugation to the denatured protein.  
The addition of alkyl azide 3.3 to oxidise TCEP or THPP prior to thiol alkylation of a 
folded protein was subsequently investigated. The experiments were pursued to 
illustrate the usefulness of the method for trilakylphosphine oxidation in non-
denaturing conditions, and the potential of the method to facilitate the production 
of high yielding, folded protein conjugates. 
Experiments were performed on the folded protein, Staphylococcus aureus binder 
of immunoglobulins (Sbi3,4-Cys). Sbi3,4-Cys is a 15 kDa protein with a single C-terminal 
cysteine residue. The thiol of the cysteine residue is solvent-exposed, therefore, 
denaturing conditions are not required to effect bioconjugations via thiol-
alkylation. Pre-reduction of the protein is, however, necessary to reduce the 
disulfide bonds that can form dimers of the protein. 
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Varying amounts of TCEP (1-10 eq.) were added to aliquots of Sbi3,4-Cys and 
incubated for 45 minutes at 25 C. Maleimide-fluorescein (1 eq.) was subsequently 
added and the reactions were incubated at 37 C for 18 hours (Figure 3.10, lanes 1-
3). In parallel experiments 3.3 (100 eq.) was added to aliquots of Sbi3,4-Cys containing 
varying amounts of TCEP (1-10 eq.). The samples were incubated for 1 hour at 37 C 
prior to addition of maleimide-fluorescein (1 eq.) followed by incubation at 37 C 
for 18 hours (Figure 3.10, lanes 4-6). 
 
Figure 3.10: SDS-PAGE analysis of reactions between maleimide-fluorescein (1 eq.) and 
Sbi in the presence of varying TCEP amounts (1-10 eq.) and in the presence 
or absence of the alkyl azide 3.3 (100 eq.). Lane 1: Sbi + TCEP (1 eq.) + 
maleimide-fluorescein (1 eq.), Lane 2: Sbi + TCEP (5 eq.) + maleimide-
fluorescein (1 eq.), Lane 3: Sbi + TCEP (10 eq.) + maleimide-fluorescein (1 
eq.), Lane 4: Sbi + TCEP (1 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.), Lane 5: Sbi + TCEP (5 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.), Lane 6: Sbi + TCEP (10 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.). The SDS-PAGE gel was analysed utilising Image Studio Lite software. 
There is a progressive decrease of fluorescent conjugate as the concentration of 
TCEP increases relative to the amount of maleimide-fluorescein (Figure 3.10, Lanes 
1-3). The addition of 3.3, however, results in consistent yields of fluorescent protein 
conjugate (Figure 3.10, Lanes 4-6). Graph 3.4 illustrates a consistent level of 
fluorescent protein conjugate production by the addition of alkyl azide 3.3, 
regardless of the initial TCEP concentration relative to the concentration of 
maleimide-fluorescein. There is, however a progressive loss of fluorescent 
conjugate without the addition of 3.3 and as the TCEP concentration increase 
relative to the maleimide-fluorescein concentration. The addition of 3.3 is, 
therefore, an effective strategy to oxidise TCEP prior to addition of thiol reactive 





Graph 3.4: Sbi-fluorescein conjugate production with and without the addition of the 
alkyl azide 3.3 to oxidise TCEP. 
The addition of alkyl azide 3.3 to oxidise THPP was subsequently investigated, using 
maleimide-fluorescein as the ligand to attach to the folded thiol-containing protein 
Sbi3,4-Cys. Varying concentrations of THPP (1-10 eq.) were added to aliquots of 
protein and incubated for 45 minutes at 25 C. Maleimide-fluorescein (1 eq.) was 
subsequently added and the reaction was incubated at 37 C for 18 hours (Figure 
3.11, lanes 1-3). In parallel experiments 3.3 (100 eq.) was added to aliquots of Sbi3,4-
Cys containing varying amounts of THPP (1-10 eq.). The samples were incubated for 
1 hour at 37 C prior to addition of maleimide-fluorescein (1 eq.), followed by 







Figure 3.11: SDS-PAGE analysis of reactions between maleimide-fluorescein (1 eq.) and 
Sbi in the presence of varying THPP amounts (1-10 eq.) and in the presence 
or absence of the alkyl azide 3.3 (100 eq.). Lane 1: Sbi + THPP (1 eq.) + 
maleimide-fluorescein (1 eq.), Lane 2: Sbi + THPP (5 eq.) + maleimide-
fluorescein (1 eq.), Lane 3: Sbi + THPP (10 eq.) + maleimide-fluorescein (1 
eq.), Lane 4: Sbi + THPP (1 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.), Lane 5: Sbi + THPP (5 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.), Lane 6: Sbi + THPP (10 eq.) + 3.3 (100 eq.) + maleimide-fluorescein (1 
eq.). The SDS-PAGE gel was analysed utilising Image Studio Lite software. 
There is decrease of fluorescent conjugate as the amount of THPP increases relative 
to the amount of maleimide-fluorescein (Figure 3.11, Lanes 1-3). There is, however, 
consistent conjugate production following the oxidation of THPP by the addition of 
3.3 (Figure 3.11, Lanes 4-6). The effectiveness of excess THPP oxidation by addition 
of 3.3 is illustrated in Graph 3.5. The Graph 3.5 illustrates a consistent level of 
fluorescent protein conjugate production by the addition of alkyl azide 3.3, 
regardless of the initial THPP concentration relative to the concentration of 
maleimide-fluorescein. There is, however a progressive loss of fluorescent 
conjugate without the addition of 3.3 and as the THPP concentration increases 
relative to the maleimide-fluorescein concentration. The addition of 3.3 is, 
therefore, an effective strategy to oxidise THPP prior to addition of thiol reactive 





Graph 3.5: Sbi-fluorescein conjugate production with and without the addition of the 
alkyl azide 3.3 to oxidise THPP. 
The utilisation of a low molecular weight thiol-reactive fluorescent probe 
(maleimide-fluorescein) to functionalise unfolded and folded proteins has so far 
been useful in analysing trends in functionalisation when in the presence or 
absence of excess TCEP or THPP. 
The experiments, however, have not been useful in quantifying yields of conjugate 
production as there is insufficient molecular weight gain of the fluorescent 
conjugate relative to the native protein to visualise both proteins bands by SDS-
PAGE. The experiments were, therefore, repeated using maleimide-PEG2kDa to 
thiol alkylate the proteins. PEGylation of the proteins would result in a sufficient 
molecular weight gain relative to the native proteins to be resolved by SDS-PAGE. 
PEGylation experiments should allow quantification of conjugation reactions where 
excess TCEP or THPP is present in the conjugation reactions compared to the 




3.4.3) Addition of the Alkyl Azide 3.3 to Oxidise TCEP/THPP to Ensure High Yeast 
Enolase-Maleimide-PEG2kDa Conjugate Yields 
Quantification of PEGylation experiments by SDS-PAGE were initially performed on 
yeast enolase, a denatured protein. Yeast enolase was denatured in argon purged 
Tris buffer (0.5 M, pH = 7.2) containing 5 mM EDTA and 8 M urea. Varying amounts 
of TCEP (1-10 eq.) were added to aliquots of protein and incubated for 45 minutes 
at 25 C. Maleimide-PEG2kDa (1 eq.) was subsequently added and the reactions 
were incubated at 37 C for 18 hours (Figure 3.12, lanes 3-5). In parallel 
experiments 3.3 (100 mM) was added to aliquots of yeast enolase containing 
varying amounts of TCEP (1-10 eq.). The samples were incubated for 1 hour at 37 C 
prior to addition of maleimide-PEG2kDa (1 eq.), followed by incubation at 37 C for 












Figure 3.12: SDS-PAGE analysis of reactions between maleimide-PEG2kDa (1 eq.) and 
yeast enolase in the presence of varying TCEP amounts (1-10 eq.) and in the 
presence or absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: 
enolase, Lane 3: enolase + TCEP (1 eq.) + maleimide-PEG2kDa (1 eq.), Lane 
4: enolase + TCEP (5 eq.) + maleimide-PEG2kDa (1 eq.), Lane 5: enolase + 
TCEP (10 eq.) + maleimide-PEG2kDa (1 eq.), Lane 6: enolase + TCEP (1 eq.) + 
3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.), Lane 7: enolase + TCEP (5 eq.) + 
3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.), Lane 8: enolase + TCEP (10 eq.) 
+ 3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.). The SDS-PAGE gel was stained 
with Coomassie solution and analysed utilising Image Studio Lite software. 
There is a significant and progressive decrease in protein conjugation as the amount 
of TCEP increases relative to the amount of maleimide-PEG2kDa (Figure 3.12, Lanes 
3-5). The addition of the alkyl azide 3.3 (Figure 3.12, Lanes 6-8) was successful in 
oxidising excess TCEP to facilitate high conjugate yields. The experiment has proved 
that the addition of 3.3 is an effective strategy to quench TCEP, resulting in high 
yields (Table 3.2) of PEGylated proteins, without necessity for intermediate 
purification protocols. 
The ability of the alkyl azide 3.3 to quench the alternative reducing agent (THPP) 
and effect high PEGylated yeast enolase yields was subsequently investigated. Yeast 
enolase was denatured in argon purged Tris buffer (0.5 M, pH = 7.2), containing 5 
mM EDTA and 8 M urea. Varying amounts of THPP (1-10 eq.) were added to 
aliquots of protein and incubated for 45 minutes at 25 C. Maleimide-PEG2kDa (1 
eq.) was subsequently added and the reactions were incubated at 37 C for 18 
hours (Figure 3.13, lanes 3-5). In parallel experiments the alkyl azide 3.3 (100 eq.) 
was added to aliquots of enolase containing varying amounts of THPP (1-10 eq.). 
The samples were incubated for 1 hour at 37 C prior to addition of maleimide-
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PEG2kDa (1 eq.) followed by incubation at 37 C for 18 hours (Figure 3.13, lanes 6-
8). 
 
Figure 3.13: SDS-PAGE analysis of reaction between maleimide-PEG2kDa (1 eq.) and 
yeast enolase in the presence of varying THPP amounts (1-10 eq.) and in 
the presence or absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, 
Lane 2: enolase, Lane 3: enolase + THPP (1 eq.) + maleimide-PEG2kDa (1 
eq.), Lane 4: enolase + THPP (5 eq.) + maleimide-PEG2kDa (1 eq.), Lane 5: 
enolase + THPP (10 eq.) + maleimide-PEG2kDa (1 eq.), Lane 6: enolase + 
THPP (1 eq.) + 3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.), Lane 7: enolase + 
THPP (5 eq.) + 3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.), Lane 8: enolase + 
THPP (10 eq.) + 3.3 (100 eq.) + maleimide-PEG2kDa (1 eq.). The SDS-PAGE 
gel was stained with Coomassie solution and analysed utilising Image 
Studio Lite software. 
There is a significant and progressive decrease in protein conjugation as the amount 
of THPP increases relative to the amount of maleimide-PEG2kDa (Figure 3.13, Lanes 
3-5). The addition of an alkyl azide (Figure 3.13, Lanes 6-8) was successful in 
oxidiing excess THPP, facilitating high conjugate yields. The addition of 3.3 is an 
effective strategy to quench THPP and produce PEGylated proteins in high yields. 
Quantification of PEGylated yeast enolase yields in the presence or absence of 
excess TCEP or THPP was achieved utilising Image Studio Lite version 4.0 software. 
The results are presented in Table 3.2. The presence of TCEP in the conjugation 
reactions significantly lowered PEGylated protein yields from 42 % when present in 
equimolar amounts relative to maleimide-PEG2kDa to as low as 11 % when the 
TCEP was in a tenfold excess relative to the maleimide-PEG2kDa. However, fairly 
consistent yields of 76-85 % of PEGylated protein were achieved when TCEP was 
oxidised by alkyl azide 3.3 prior to addition of maleimide-PEG2kDa. A similar trend 
was observed with the experiments utilising THPP. The presence of THPP produced 
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low PEGylated protein yields, from 37 % when present in equimolar amounts 
relative to maleimide-PEG2kDa to 3 % when the THPP was in a tenfold excess 
relative to the maleimide-PEG2kDa. Fairly consistent yields of 68-76 % of PEGylated 
protein were achieved when THPP was oxidised by alkyl azide 3.3 prior to addition 
of maleimide-PEG2kDa. Table 3.2 also illustrates the superior reactivity of THPP 
compared to TCEP. When there is no addition of alkyl azide 3.3 to oxidise either 
TCEP or THPP, there are consistently lower conjugate yields when utilising THPP 
compared to TCEP. The trishydroxypropyl substituents of THPP are less electron 
withdrawing than the 2-carboxyethyl substituents of TCEP. The phosphorus atom of 
THPP is, therefore, more nucleophilic than the phosphorus atom of TCEP and reacts 
more rapidly with maleimide-PEG2kDa than TCEP, resulting in comparably lower 
conjugate yields. The addition of 3.3 to oxidise TCEP or THPP, however, offers an 
excellent strategy to ensure consistent and high yields of conjugation when utilising 








Table 3.2: Yields of yeast enolase PEGylation by maleimide-PEG2kDa when in the 
presence or absence of reducing agents (TCEP or THPP), with and without 
the addition of the alkyl azide 3.3. 
3.4.4) Addition of an Alkyl Azide to Oxidise TCEP/THPP to Ensure High Sbi3,4-Cys-
Maleimide-PEG2kDa Conjugate Yields 
Quantification of PEGylation yields on the folded protein Sbi3,4-Cys was subsequently 
pursued, in a similar fashion to that achieved for the PEGylation of the unfolded 
yeast enolase experiments in section 3.4.3. 
Sbi3,4-Cys was suspended in argon purged Tris buffer (0.5 M, pH = 7.2), containing 5 
mM EDTA. Varying amounts of TCEP (1-10 eq.) were added to aliquots of the 
protein and incubated for 45 minutes at 25 C. Maleimide-PEG2kDa (1 eq.) was 
subsequently added and the reaction was incubated at 37 C for 18 hours (Figure 
3.14, lanes 3-5). In parallel experiments 3.3 (100 eq.) was added to aliquots of Sbi3,4-
Cys containing varying amounts of TCEP (1-10 eq.). The samples were incubated for 1 
hour at 37 C prior to addition of maleimide-PEG2kDa (1 eq.), followed by 




Figure 3.14:  SDS-PAGE analysis of reactions between maleimide-PEG2kDa (1 eq.) and 
Sbi in the presence of varying TCEP amounts (1-10 eq.) and in the presence 
or absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: Sbi, Lane 
3: Sbi + TCEP (1 eq.) + maleimide-PEG2kDa (1 eq.), Lane 4: Sbi + TCEP (5 eq.) 
+ maleimide-PEG2kDa (1 eq.), Lane 5: Sbi + TCEP (10 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 6: Sbi + TCEP (1 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 7: Sbi + TCEP (5 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 8: Sbi + TCEP (10 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.). The SDS-PAGE gel was stained with Coomassie solution 
and analysed utilising Image Studio Lite software. 
There is a decrease of PEGylated protein as the amount of TCEP increases relative 
to the amount of maleimide-PEG2kDa (Figure 3.14, Lanes 3-5). There is, however, 
production of consistent amounts of PEGylated protein following the oxidation of 
excess TCEP (Figure 3.14, Lanes 6-8) by the addition of the alkyl azide 3.3. 
The ability of the alkyl azide 3.3 to quench THPP and effect high bioconjugations 
yields between the folded protein (Sbi3,4-Cys) and maleimide-derivatised ligands was 
also investigated. 
Sbi3,4-Cys was suspended in argon purged Tris buffer (0.5 M, pH = 7.2), containing 5 
mM EDTA. Varying amounts of THPP (1-10 eq.) were added to aliquots of the 
protein and incubated for 45 minutes at 25 C. Maleimide-PEG2kDa (1 eq.) was 
subsequently added and the reaction was incubated at 37 C for 18 hours (Figure 
3.15, lanes 3-5). In parallel experiments 3.3 (100 eq.) were added to aliquots of 
Sbi3,4-Cys containing varying amounts of THPP (1-10 eq.). The samples were 
incubated for 1 hour at 37 C prior to addition of maleimide-PEG2kDa (1 eq.) 




Figure 3.15: SDS-PAGE analysis of reactions between maleimide-PEG2kDa (1 eq.) and 
Sbi in the presence of varying THPP amounts (1-10 eq.) and in the presence 
or absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: Sbi, Lane 
3: Sbi + THPP (1 eq.) + maleimide-PEG2kDa (1 eq.), Lane 4: Sbi + THPP (5 
eq.) + maleimide-PEG2kDa (1 eq.), Lane 5: Sbi + THPP (10 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 6: Sbi + THPP (1 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 7: Sbi + THPP (5 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.), Lane 8: Sbi + THPP (10 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.). The SDS-PAGE gel was stained with Coomassie solution 
and analysed utilising Image Studio Lite software. 
There is a decrease in bioconjugate yields as the amount of THPP increases relative 
to the amount of maleimide-PEG2kDa (Figure 3.15, Lanes 3-5). There is, however, 
production of consistent yields of PEGylated protein following the oxidation of 
excess THPP (Figure 3.15, Lanes 6-8) by the addition of 3.3. 
Quantification of PEGylated Sbi3,4-Cys yields in the presence or absence of excess 
TCEP or THPP are presented in Table 3.3. The presence of TCEP significantly 
lowered PEGylated protein yields to 36 % and 27 % when present in fivefold or 
tenfold excess relative to the maleimide-PEG2kDa respectively. However, fairly 
consistent yields of 70 % of PEGylated protein were achieved when TCEP was 
oxidised by alkyl azide 3.3 prior to addition of maleimide-PEG2kDa. A similar trend 
was observed with the experiments utilising THPP. The presence of THPP 
significantly lowered PEGylated protein yields to 19 % and 10 % when present in 
fivefold or tenfold excess relative to the maleimide-PEG2kDa respectively. Fairly 
consistent yields of 67-70 % of PEGylated protein were achieved when THPP was 




Table 3.3: Yields of Sbi3,4-Cys PEGylation by maleimide-PEG2kDa when in the presence 
or absence of reducing agents (TCEP or THPP), with and without the 
addition of alkyl azide 3.3. 
3.5) Conclusion 
TCEP and THPP are disulfide reducing agents that react with Michael acceptor thiol 
alkylating reagents such as maleimide and vinyl sulfone. They, therefore, need to be 
removed prior to performing the bioconjugation reaction between the Michael 
acceptor derivatised reagent and a thiol-containing biomolecule. The addition of a 
water soluble alkyl azide is able to oxidise excess TCEP or THPP to the 
corresponding phosphine oxides. The phosphine oxide products are not reactive 
with the alkylating reagents, which allows for a ‘one-pot’ protocol for performing 
bioconjugations using thiol-alkylation chemistry. The method was initially validated 
during functioanlisation of cysteine amino acid derivatives and was subsequently 
utilised during the functionslisation of both folded and unfolded folded proteins. 
The method proved successful in oxidising excess reducing agents to facilitate high 





Chapter 4: 4-Vinyl Pyridine Derivatives as 
Reagents for Thiol-Alkylation 
4.0) Introduction 
4-Vinyl pyridine (4-VP) has been utilised as a reagent for thiol-alkylation, which has 
been reported to be 300 times faster compared to alkylation of amines at pH 
greater than 7 [18]. Previously 4-VP has primarily been used for the alkylation of 
cysteine-containing peptides and proteins for mass spectrometric analysis [81, 140]. 
4-VP has not been extensively explored as a reagent for bioconjugation chemistry, 
predominantly as a consequence of the success of maleimide-derivatised products. 
As such, we sought to investigate the application of 4-VP in bioconjugation 
reactions by synthesising a variety of 4-VP derivatives as potential linkers for the 
attachment of ligands to thiol-containing peptides and proteins. 
Thiol-alkylation by 4-VP proceeds via conjugate addition of the thiolate at the 
terminal carbon of the vinyl functional group, resulting in a thio-ether bond (Figure 
4.1), which is stable towards hydrolysis [141]. The use of 4-VP for thiol alkylation 
also offers the advantage of utilising UV analysis for the detection and monitoring 
of thiol-alkylated products. However, the conjugate addition of 4-VP to thiols is 
reported to be much slower (x103) in rate when compared to maleimide-derived 
conjugate additions [18]. As such, reaction conditions for thiol alkylation of 
peptides and proteins by 4-VP would require optimisation, largely to minimise 





Figure 4.1: General scheme for thiol-alkylation using a 4-VP linker. R1 = peptide or 
protein, R2 = alkyl or aryl ligand. 
The development of 4-VP derivatives as potential linkers for thiol alkylation requires 
functionalisation of the pyridine ring (Figure 4.1), with functional groups such as 
hydroxyls, amines or carboxylic acids for the attachment of ligands through ester or 
amide bond formation. The investigation, therefore, aimed to develop suitable 4-VP 
derivatives for the attachment of ligands, followed by rapid and specific thiol 
alkylation of peptides and proteins. There were, however, a number of factors that 
required prior consideration. 
The pKa of the nitrogen atom of the pyridine ring is a key determinant of reactivity 
for 4-VP derivatives. Protonation of the nitrogen atom increases the electrophilicity 
of the vinyl group, which promotes nucleophilic attack at the terminal carbon of the 
vinyl group by a thiolate. The substituents on the pyridine ring, which are required 
for the attachment of ligands to the aromatic ring will affect the pKa of the ring 
nitrogen, ultimately influencing the rate of thiol alkylation. The pKa of the thiol 
functional group attached to the peptide or protein is also an important factor. It is 
the deprotonated thiol, the thiolate anion, which acts as a nucleophile towards the 
vinyl group to generate a thioether bond. Hence, the pH of the reaction will also 
influence the rate of alkylation. Additional reaction variables also need to be 
considered. Reactions should ideally be performed in an oxygen depleted and metal 
ion free environment to minimise oxidation of thiols, which might render the thiol 
unreactive towards the vinyl group. As such, we first sought to investigate the 
impact of the above mentioned factors on the ability of the 4-VP derivatives to 
react with thiols. 
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4.1) pKa Prediction of the Nitrogen Atom for Selected 4-VP 
Derivatives 
The experimentally determined pKa of 4-VP is 5.62 [142]. Ideally, reactions should 
be performed at a pH lower than the pKa to promote protonation of nitrogen atom 
of the pyridine ring to increase the reactivity of 4-VP. However, this would also 
promote protonation of the sulfur atom to generate a thiol functional group instead 
of a nucleophilic thiolate. Additionally, performing conjugations under acidic 
conditions may also be unsuitable for the stability of some proteins. Hence, our 
initial aim was to develop 4-VP linkers where the pyridine nitrogen atom exhibits a 
pKa closer to neutral pH. Raising the nitrogen’s pKa closer towards that of a general 
thiol was predicted to result in increased reaction rates at neutral pH, since optimal 
conjugation rates should occur at a pH which is the average of the 4-VP derivative 
and the thiol pKa values [141]. 
The inductive effects of functional groups on the pyridine ring can raise or lower the 
pKa value of the pyridine ring nitrogen. When considering raising the pKa of the 
nitrogen atom of a derivatised 4-VP reagent from a value of around 5.6 to a value 
closer to 7, the effect of substituents in the ortho position of the aromatic ring on 
the nitrogen’s pKa were investigated. The pKa of four selected 4-VP derivatives as 
potential linker precursors, 4.1-4.4, were calculated using REAXYS software and 
are illustrated in Figure 4.2 [143]. The 4-VP derivatives were chosen where the 
substituent at C-2 of the aromatic ring could be chemically transformed to generate 
functional groups such as hydroxyls or carboxylic acids for the subsequent 




Figure 4.2: Predictions of the pKa of 4-VP derivatives 4.1-4.4 using REAXYS software. 
The accuracy of the pKa predictions by the REAXYS software was initially tested by 
comparing the predicted pKa of 4-VP to the experimentally derived pKa of 4-VP. 
The REAXYS software predicted a pKa of 5.46 for 4-VP, which is a close 
approximation to the reported literature value of 5.62 [142]. The software was 
subsequently utilised to predict the pKa values of 4-VP derivatives 4.1-4.4. The pKa 
of compound 4.1 was predicted to be 4.15. Hence, alkylation at the ortho position 
of the nitrogen is predicted to result in a considerable decrease in pKa relative to 4-
VP. This decrease in pKa is attributed to the inductive effect of the electronegative 
oxygen atom of the methyl acetate substituent. The pKa of compound 4.2 was 
predicted to be 5.36, which is a significant increase in pKa compared to 4.1, though 
still not as high as the parent 4-VP itself. The electron donating effect of the methyl 
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group at C-6 of the pyridine ring of 4.2 improves the availability of the nitrogen 
atoms lone pair for protonation. The close proximity of the electronegative sulfur 
atom of the methyl (methylsulfanyl)acetate substituent to the ring nitrogen may, 
however, decrease the pKa of the ring nitrogen. The 4-VP derivative 4.3 has a 
predicted pKa of 5.64, a marginal increase in pKa compared to derivative 4.2. The 2 
carbon atom separation between the electron withdrawing ester functionality and 
the pyridine ring increases the basicity of the ring nitrogen in addition to the 
electron donating effect of the methyl group at C-6 of the pyridine ring. The 4-VP 
derivative 4.4, however, has a predicted pKa of 6.67, a significant increase over the 
pKa of derivative 4.3. The three carbon-atom separation between the electron 
withdrawing oxygen atom of the ethyl 3-propoxypropanoate substituent and the 
pyridine ring further increases the basicity of the ring nitrogen, in addition to the 
electron donating effect of the methyl group at C-6 of the pyridine ring. The 4-VP 
derivatives 4.1-4.4 were deemed valuable synthetic targets for comparing their 
potential as thiol alkylation reagents. 
4.2) Synthesis of 4-VP Derivatives 4.1-4.4 
The chemical synthesis of the 4-VP derivative (4-ethenylpyridin-2-yl)methyl acetate 
(4.1) was achieved in four steps in an overall yield of 34 % (Figure 4.3). The 
synthesis of 4.1 began with the bromination of commercially available 2-methyl-4-
nitropyridine 1-oxide (4.5), which generated 4-bromo-2-methylpyridine 1-oxide 
(4.6) in 59 % yield [144, 145]. The oxygen atom of 4.6 was acylated utilising 
trifluoracetic anhydride, which underwent base catalysed rearrangement to (4-
bromopyridin-2-yl)methyl trifluoroacetate as an intermediate. The basic conditions 
employed subsequently hydrolysed the acetate group to produce (4-bromopyridin-
2-yl)methanol (4.7) in 77 % yield [144, 145]. The hydroxyl functional group was 
reacylated utilising acetic anhydride in pyridine, which yielded (4-bromopyridin-2-
yl)methyl acetate (4.8) in 92 % yield. The vinyl functional group was introduced 
through a palladium catalysed cross coupling reaction (Stille reaction), which 





Figure 4.3: Synthesis of 4.1  a) AcBr, AcOH, 120 °C, b) 1) TFAA, 2) NaOH, c) Ac2O, 
pyridine, d) Bu3SnC2H3, tetrakis(triphenylphosphine)Pd(0), toluene, 85 °C. 
The chemical synthesis of the 4-VP derivative methyl {[(4-ethenyl-6-methylpyridin-
2-yl)methyl]sulfanyl}acetate (4.2) was achieved in five steps in an overall yield of 27 
% (Figure 4.4). The synthesis of 4.2 started with the bromination of commercially 
available 2,6-dimethylpyridine 1-oxide (4.9), which generated 4-bromo-2,6-
dimethylpyridine 1-oxide (4.10) in 72 % yield [144, 145]. The oxygen atom of 4.10 
was acylated utilising trifluoracetic anhydride, which underwent base catalysed 
rearrangement to (4-bromo-6-methylpyridin-2-yl)methyl trifluoroacetate as an 
intermediate. The basic conditions employed subsequently hydrolysed the acetate 
group to produce (4-bromo-6-methylpyridin-2-yl)methanol (4.11) in 64 % yield 
[144, 145]. Tosylation of the hydroxyl functional group of 4.11, resulted in (4-
bromo-6-methylpyridin-2-yl)methyl 4-methylbenzenesulfonate (4.12) in 94 % yield, 
which was subsequently treated with methyl thioglycolate, resulting in methyl 2-
(((4-bromo-6-methylpyridin-2-yl)methyl)thio)acetate (4.13) in 72 % yield [147]. The 
vinyl functional group was introduced in a palladium catalysed cross coupling 
reaction (Stille reaction), which yielded the target compound 4.2 in 86 % yield 





Figure 4.4: Synthesis of 4.2  a) Br2, AcOH, 85 °C, b) 1) TFAA, 2) NaOH, c) TsCl, NaOH, d) 
methyl thioglycolate, e) Bu3SnC2H3, tetrakis(triphenylphosphine)Pd(0), 
toluene, 85 °C. 
The chemical synthesis of the 4-VP derivative methyl 3-(4-ethenyl-6-methylpyridin-
2-yl)propanoate (4.3) was achieved in five steps in an overall yield of 14 % (Figure 
4.5). The synthesis of 4.3 began with the oxidation of commercially available 3-(6-
methylpyridin-2-yl)propan-1-ol (4.14), generating 3-(6-methylpyridin-2-yl)propanoic 
acid (4.15), which was subsequently esterified, to give methyl 3-(6-methylpyridin-2-
yl)propanoate (4.16) in 55 % yield [148]. The nitrogen atom of 4.16 was then 
oxidised using m-CPBA, to give 2-(3-methoxy-3-oxopropyl)-6-methylpyridine 1-
oxide (4.17) in 67 % yield [149]. Compound 4.17 was subsequently brominated to 
give 4-bromo-2-(3-methoxy-3-oxopropyl)-6-methylpyridine 1-oxide (4.18) in 52 % 
yield [144, 145]. The nitrogen atom of 4.18 was reduced using phosphorus 
tribromide, to give methyl 3-(4-bromo-6-methylpyridin-2-yl)propanoate (4.19) in 87 
% yield [150]. The 4-vinyl functional group was introduced through a palladium 
catalysed cross coupling reaction (Stille reaction) which yielded the target 




Figure 4.5: Synthesis of 4.3  a) RuCl3, NaIO4, b) H2SO4, MeOH, reflux, c) m-CPBA, CH2Cl2, 
d) Br2, AcOH, 85 °C, e) PBr3, toluene, f) Bu3SnC2H3, 
tetrakis(triphenylphosphine)Pd(0), toluene, 85 °C. 
The chemical synthesis of the 4-VP derivative ethyl 3-[3-(4-ethenyl-6-methylpyridin-
2-yl)propoxy]propanoate (4.4) was achieved in seven steps in an overall yield of 9 % 
(Figure 4.6). The synthesis of 4.4 started with the acylation of commercially 
available 3-(6-methylpyridin-2-yl)propan-1-ol (4.14), generating 3-(6-methylpyridin-
2-yl)propyl acetate (4.20) in 95 % yield. The nitrogen atom of 4.20 was oxidised 
using m-CPBA, to give 2-(3-acetoxypropyl)-6-methylpyridine 1-oxide (4.21) in 79 % 
yield, which was subsequently brominated to give 2-(3-acetoxypropyl)-4-bromo-6-
methylpyridine 1-oxide (4.22) in 56 % yield [144, 145, 149]. The nitrogen atom of 
4.22 was reduced using phosphorus tribromide to give 3-(4-bromo-6-methylpyridin-
2-yl)propyl acetate (4.23) in 85 % yield [150]. The intermediate 4.23 was 
deacetylated using sodium methoxide in methanol to give 3-(4-bromo-6-
methylpyridin-2-yl)propan-1-ol (4.24) in 94 % yield. Michael addition of 4.24 to 
ethyl acrylate, resulted in 3-(3-(4-bromo-6-methylpyridin-2-yl)propoxy)propanoate 
(4.25) in 34 % yield [151]. The vinyl functional group was then introduced using a 
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palladium catalysed cross coupling reaction (Stille reaction) to yield the target 
compound 4.4 in 75 % yield (Figure 4.6) [146]. 
 
Figure 4.6: Synthesis of 4.4  a) Ac2O, pyridine, b) m-CPBA, CH2Cl2, c) Br2, AcOH, 85 °C, d) 
PBr3, toluene, e) NaOMe, MeOH, f) (Bu)4NOH, ethyl acrylate, g) Bu3SnC2H3, 
tetrakis(triphenylphosphine)Pd(0), toluene, 85 °C. 
4.3) Experimental Determination of the pKa of the Pyridine Ring for 
Compounds 4.1-4.4 
Following the successful synthesis of 4-VP derivatives 4.1-4.4, the pKa values for 
each of the respective ring nitrogen atoms were experimentally determined. 
The 4-VP derivatives 4.1-4.4 were titrated against a dilute sodium hydroxide (NaOH) 
solution, followed by titration against a dilute hydrochloric acid (HCl) solution, with 
the continual monitoring of the pH of the solution. The pKa values of the 4-VP 
derivatives 4.1-4.4 were determined by the intersection of the two titration curves. 
Intersections occurred at inflection points of individual titration curves. The results 




Figure 4.7: Titration curves to determine the pKa values for derivatives 4.1-4.4. 
Derivatives 4.1-4.4 were titrated against acid (HCl) and base (NaOH). The 
pKa values were determined by the intersection points of the acid/base 
titration curves. 
The REAXYS software proved to be a reasonably accurate method for predicting 
the pKa values of 4-VP derivatives 4.1-4.4 when compared to the values that were 
experimentally determined (Table 4.1). The titration experiments confirmed the 
effectiveness of the introduction of the electron donating methyl group at C-6 of 
the pyridine ring in raising the pKa of the ring nitrogen. The increased length of the 
alkyl chain of 4.4 compared to 4.3 to separate electron withdrawing groups from 
the pyridine ring imparted only a small increase in the pKa value to 4.4 relative to 
4.3. The titration experiments have predicted that 4.3 and 4.4 should exhibit similar 








4.1 4.15 4.27 
4.2 5.36 5.12 
4.3 5.64 5.99 
4.4 6.67 6.05 
Table 4.1: A comparison between predicted (REAXYS) and experimentally determined 
pKa values for 4-VP derivatives 4.1-4.4. 
4.4) Investigation of the Reactions between the 4-VP Derivatives 
4.1-4.4 and the Thiol-Containing Peptide Glutathione 
We next sought to investigate the reaction of 4-VP derivatives 4.1-4.4 with the thiol 
containing peptide glutathione (2.21) to determine the impact of pKa on reaction 
rate. Each of the derivatives 4.1-4.4 were reacted in a THF/phosphate buffer 
solution (0.1 M, pH = 7) with glutathione (0.9 eq.), followed by purification of the 
reaction mixtures by reverse phase (C-18) chromatography and characterisation of 
the products by NMR spectroscopy. All four 4-VP derivatives were found to undergo 
a reaction with glutathione, successfully alkylating the thiol of the peptide. The 




Figure 4.8: Reaction of 4-VP derivatives 4.1-4.4 with reduced glutathione (2.21) to 
yield thiol-alkylated products 4.26-4.29. 
Following the successful synthesis of alkylated glutathione derivatives 4.26-4.29, we 
next sought to investigate the rate of formation of 4.26-4.29 as a function of pH. 
These experiments were performed to determine the pH optimum for performing 
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thiol alkylation conjugations for each of the 4-VP derivatives 4.1-4.4. The rates of 
alkylation of glutathione were determined using NMR spectroscopy (Figure 4.9). 
The 4-VP derivatives 4.1-4.4 were individually incubated with glutathione (2.21) in 
deuterated dimethyl sulfoxide (DMSO-d6, 10 %) and deuterated aqueous sodium 
phosphate (0.1 M, pH = 7) within a NMR tube and vortexed vigorously before being 
continuously monitored by NMR spectroscopy over 90 minutes at 25 °C. The 
reactions were monitored through consumption of the 4-VP derivatives 
(represented by the gradual decrease of the vinyl proton peaks and shift of the H-3 
and H-5 aromatic proton peaks) and the appearance of thiol alkylated peptide 
(represented by the increase in product peaks of H-3’ and H-5’ aromatic proton 

















Figure 4.9: An example of using NMR to monitor the time-course of thiol-alkylation of 
glutathione by a 4-VP derivative. 
The relative rates of thiol-alkylation of glutathione by 4-VP derivatives 4.1-4.4 at pH 
= 7 were plotted from which a time for 50 % consumption (t1/2) of 4-VP could be 
































Figure 4.10: Relative rates, pKa values and half-life of thiol-alkylation of glutathione 
(2.21) by 4-VP derivatives 4.1-4.4 at pH = 7. NMR spectroscopy was utilised 
to monitor the reaction of 4-VP derivatives 4.1-4.4 with 2.21. The graphical 
data was utilised to obtain a time at which 50 % of the alkylating reagent 
was consumed. 
Linker 4.1 proved to be the least reactive (t1/2 = 15.8 mins.) of the four alkylating 
reagents utilised to functionalise glutathione at pH = 7. The ring nitrogen of 4.1 is 
mostly unprotonated at pH = 7 due to its low pKa value (pKa = 4.27), which 
decreases the electrophilic potential of the vinyl group and leads to a relatively slow 
thiol alkylation reaction. Linker 4.2 was almost 3 times more reactive (t1/2 = 5.5 
mins.) than derivative 4.1, consistent with the higher pKa of the ring nitrogen (pKa = 
5.12). The 4-VP linkers 4.3 & 4.4 displayed similar reactivity and proved to be the 
most reactive linkers at pH = 7. The 4-VP linkers 4.3 & 4.4 possess pKa values that 
are closest to the pH of the reaction and, therefore, exhibited superior thiol-
alkylation kinetics (t1/2 = 2.8 mins. & 2.1 mins. respectively) compared to 4-VP 
derivatives 4.1 & 4.2. Similar pKa’s reflected in similar rates further supported the 
suggestion that the pKa of the pyridine ring is an important factor influencing 
reactivity with regards to thiol alkylation. 
The pH of the reactions were subsequently varied (pH = 6 & pH = 8) for the reaction 
between 4.3 or 4.4 and reduced glutathione (2.21) to determine the relative rate 
changes of thiol-alkylation as a function of reaction pH. The reactions were 
monitored by NMR spectroscopy, similar to that performed previously, to yield 




Figure 4.11: Relative rates and half-life of thiol-alkylation of glutathione (2.21) by 4-VP 
derivatives 4.3 & 4.4 as a function of the pH of the reaction. NMR 
spectroscopy was utilised to monitor the reaction of 4-VP derivatives 4.3 & 
4.4 with 2.21. The graphical data was utilised to obtain a time at which 50 
% of the alkylating reagent was consumed (t1/2). 
An insignificant rate change for thiol alkylation was observed for both linkers 4.3 
and 4.4 when raising the pH from pH = 7 to pH = 8 (Figure 4.11). The alkaline pH 
favours deprotonation of the thiol to form a nucleophilic thiolate, which may 
compensate for a decreased concentration of protonated 4-VP species. An 
approximate ten-fold drop in the rate of alkylation was, however, observed for both 
linkers 4.3 and 4.4 when decreasing the pH from pH = 7 to pH = 6. The reduction in 
pH may favour the protonated form of the 4-VP derivatives, but this does not seem 
to be the significant factor with regards to the rate of the reaction. The 
concentration of the thiolate seems to be the critical determinant.  
The most effective pH range for thiol-alkylation of thiols by 4.3 and 4.4 is between 
pH = 7 and pH = 8, a compromise between the pKa of the nitrogen of the pyridine 
ring of the 4-VP derivatives and the pKa of the thiol of glutathione. 
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4.5) Specificity of 4-VP Derivatives 4.2 and 4.3 for Thiol Alkylation 
The specificity of a selection of 4-VP derivatives for alkylation of thiol nucleophiles 
over amine nucleophiles as a function of pH was investigated.  
The specificity of 4-VP 4.2 towards thiol alkylation over amine alkylation was tested 
at pH = 7 and pH = 8 (Figure 4.12). N-acetyl-L-cysteine (3.9) and benzyl amine (4.30, 
1 eq.) were dissolved in argon purged 10 % THF in aqueous sodium phosphate (0.9 
mL, 0.1 M, pH = 7). A solution of 4-VP (4.2, 1 eq.) in THF (0.1 mL) was added and the 
reaction was rapidly stirred at room temperature for three hours. The reaction was 
initially investigated by mass spectrometry. The thiol-alkylated product 4.31 was 
detected in the mass spectrum, however, no alkylation of benzyl amine by the 4-VP 
derivative 4.2 was observed. Purification of the reaction by silica gel 
chromatography confirmed the observations by mass spectrometry. The thiol 
alkylated amino acid 4.31 was isolated in 76 % yield while no amine-alkylated 
product was isolated. 
The above reaction was repeated at pH = 8 and initially investigated by mass 
spectrometry. The thiol alkylated product 4.31 was again observed, however no 
amine alkylated product was detected. Purification of the reaction by silica gel 
chromatography yielded the thiol alkylated product 4.31 in 79 % yield, while no 






Figure 4.12: 4-VP derivative 4.2 reacts specifically with the thiol derivative 3.9 instead of 
the amine derivative 4.30 at both pH = 7 and pH = 8. 
The specificity of 4-VP derivative 4.3 towards thiol alkylation over amine alkylation 
was also tested at pH = 7 and pH = 8 (Figure 4.13). N-acetyl-L-cysteine (3.9) and 
benzyl amine (4.30, 1 eq.) were dissolved in argon purged 10 % THF in aqueous 
sodium phosphate (0.9 mL, 0.1 M, pH = 7). A solution of 4-VP (4.3, 1 eq.) in THF (0.1 
mL) was added and the reaction was rapidly stirred at room temperature for three 
hours and subsequently investigated by mass spectrometry. The thiol-alkylated 
product 4.32 was observed in the mass spectrum, however, no alkylation of benzyl 
amine was observed. Purification of the reaction by silica gel chromatography 
yielded the thiol alkylated product 4.32 in 75 % yield, while no amine alkylated 
product was isolated. 
The above reaction was repeated at pH = 8 and initially investigated by mass 
spectrometry. The thiol alkylated product 4.32 was again observed, however no 
amine alkylated product was detected. Purification of the reaction by silica gel 
chromatography yielded the thiol alkylated product 4.32 in 81 % yield, while no 




Figure 4.13: 4-VP derivative 4.3 reacts specifically with the thiol derivative 3.9 instead of 
the amine derivative 4.30 at both pH = 7 and pH = 8. 
The above experiments have indicated that a selection of 4-VP derivatives for 
bioconjugation purposes are reagents that can be specific for thiol alkylation. The 
specificity for thiol alkylation at an alkaline pH offers a significant advantage over -
halo-carbonyl and maleimide linkers, which have been reported to react with thiols 
and amines at pH  7 [18]. 
4.6) Reaction of TCEP (2.6) and THPP (2.7) with 4-VP (4.33) 
4-VP is a Michael-like acceptor similar to maleimide and vinyl sulfone and, 
therefore, may exhibit similar reaction trends with TCEP (2.6) and THPP (2.7) to 
those observed for maleimide and vinyl sulfone in Chapter 2. It has been reported 
that tributylphosphine is compatible with 4-VP but there is no evidence for the 
potential reaction of TCEP or THPP with 4-VP derivatives [152]. TCEP or THPP could 
potentially be used as disulfide reducing agents of peptides or proteins prior to the 
addition of 4-VP derivatives to effect thiol alkylation. As such, an assessment of a 
potential reaction between TCEP or THPP and 4-VP was deemed necessary. 
4-VP (4.33, 20 mg) was first incubated with TCEP (2.6, 49 mg) in THF (2 mL) and 
aqueous sodium phosphate (0.1 M, pH = 7, 8 mL) for three hours at room 
temperature. Purification of the reaction by C-18 chromatography yielded a 4-VP-
TCEP adduct in 64 % yield that could not be distinguished by NMR spectroscopy as 
either 4.34 or 4.35 (Figure 4.14). However, the isolation of an adduct between 4-VP 
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and TCEP demonstrated that the reducing agent should be removed before 
addition of 4-VP derivatised ligands into bioconjugation reactions. 
 
Figure 4.14: Reaction of 4-VP (4.33) with TCEP (2.6). 
4-VP (4.33, 15.0 mg) was subsequently incubated with THPP (2.7, 26.7 mg) in THF (2 
mL) and aqueous sodium phosphate (0.1 M, pH = 7, 8 mL) for three hours at room 
temperature. Purification of the reaction by C-18 chromatography yielded a 4-VP-
THPP adduct in 61 % yield that could not be distinguished by NMR spectroscopy as 
either 4.36 or 4.37 (Figure 4.15). Again, the isolation of an adduct between 4-VP 
and THPP, similar to TCEP, suggested that the reducing agent should be removed 








Figure 4.15: Reaction of 4-VP (4.33) with THPP (2.7). 
4.7) Investigating a Possible Reaction of 4-VP with Alkyl Azide 3.3 
It was envisaged to utilise the water soluble alkyl azide 3.3 (discussed in Chapter 3) 
to oxidise excess TCEP or THPP after reduction of disulfides and before the addition 
of 4-VP derivatised ligands for alkylation of thiols. A [3+2] cycloaddition reaction of 
alkyl azide 3.3 was characterised with both Michael acceptors N-ethyl maleimide 
(2.8) and phenyl vinyl sulfone (2.18). 4-VP is also a Michael acceptor and so the 
possible reaction between 3.3 and 4-VP (4.33) was investigated. 
4-VP (4.33) was dissolved in THF (1.5 mL) and aqueous sodium phosphate (0.25 M, 
pH = 7, 1.5 mL) containing alkyl azide 3.3 (1 eq.). The reaction was rapidly stirred at 
room temperature and monitored by TLC and HRMS. After 2 days no evidence of 
triazoline formation was evident by either TLC or HRMS. This investigation indicated 
that the addition of 3.3 for excess phosphine oxidation can be used in a reaction 
containing thiol alkylating reagents based on 4-VP. 
A selection of 4-VP derivatives were subsequently functionalised with ligands such 
as carbohydrates and PEG to investigate bioconjugation reactions with thiol-
containing peptides and proteins. 
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4.8) A 4-VP Derivatised Carbohydrate for the Conjugation of 
Carbohydrates to Peptides and Proteins 
A 4-VP-carbohydrate derivative was explored as a novel method for the site-specific 
addition of glycans to thiol-containing peptides and proteins. The 4-VP acceptor 
4.39 was synthesised in 68 % yield for subsequent glycosylation to a carbohydrate 
containing donor (Figure 4.16). The acceptor 4.39 was based on the 4-VP derivative 
4.4 due to its favourable reactivity at neutral pH. 
 
Figure 4.16: Synthesis of the 4-VP derivative 4.39. a) Bu3SnC2H3, 
tetrakis(triphenylphosphine)Pd(0), toluene, 85 °C, b) NaOMe, MeOH. 
Lactose, a disaccharide consisting of β-D-galactopyranosyl-(1→4)-D-glucose (4.40) 
was chosen as a model carbohydrate for attachment to the 4-VP linker 4.39. 
Lactose is a cheap and commercially available starting material. It was readily 
available in our laboratory, which was the main reason for its choice as the 
carbohydrate ligand. The lactose donor 4.43 was synthesised using standard 
protection/deprotection strategies employed in synthetic carbohydrate chemistry 
in an overall 51 % yield (Figure 4.17). The final 4-VP-lactose derivative 4.45 was 
generated through a glycosylation step between the 4-VP acceptor 4.39 and the 
lactosyl donor 4.43 followed by a deacetylation reaction of 4.44 in an overall yield 




Figure 4.17: Synthesis of the 4-VP-lactose derivative 4.45. a) Ac2O, pyridine, b) 
NH2NH2AcOH, MeOH/CH2Cl2, c) CCl3CN, DBU, CH2Cl2, d) 4.39, TMSOTf, 
DCM, e) NaOMe, MeOH. 
The reaction of the 4-VP-lactose derivative 4.45 with a thiol-containing peptide was 
initially performed on glutathione (2.21). The 4-VP-lactose derivative (4.45, 10 mg) 
was dissolved a solution of THF (1 mL) and aqueous sodium phosphate (0.1 M, pH = 
7, 3 mL). Glutathione (2.21, 5.5 mg) was added and the reaction was left to stir for 
three hours at room temperature. Purification of the reaction by reverse phase 
chromatography resulted in the isolation of the thiol alkylated peptide 4.46 in 65 % 
yield, which was characterised by NMR spectroscopy (Figure 4.18). The 
characterisation of product 4.46 confirmed the ability of utilising a 4-VP linker to 




Figure 4.18: Thiol alkylation of glutathione (2.21) using the 4-VP-lactose derivative 4.45. 
The 4-VP-lactose derivative 4.45 was subsequently utilised for the glycosylation of a 
longer peptide sequence possessing a single cysteine residue. The final 20 amino 
acid sequence at the carboxy terminal end from the protein, Staphylococcus aureus 
binder of immunoglobulins (Sbi3,4-Cys), which was in utilised in Chapter 3, was 
outsourced for synthesis to Thermo Fisher Scientific (4.47). The synthesised peptide 
consists of the following amino acid sequence: 
 
The glycosylation of the 20 amino acid peptide by via thiol-alkylation of the C-
terminal cysteine residue was monitored by high performance liquid 
chromatography (HPLC). The reaction of the peptide (0.37 mM) with 4.45 (1.1 mM) 
was performed in aqueous sodium phosphate (0.1 M, pH = 7). The native peptide 
sequence eluted at 12.8 minutes, while the glycosylated peptide eluted at 12.2 
minutes under the conditions developed on the HPLC instrument. The adequate 
resolution of the reactant and product peaks permitted the monitoring of the 
glycosylation reaction over a time course. A plot of the glycosylation reaction was 
performed through analysis of the integrals associated with the diminishing 
reactant peak and increasing product peak over the time course (Graph 4.1). HPLC 
analysis revealed that 50 % of glycosylated peptide product was achieved after 3.3 
hours. The product eluting at 12.2 minutes was subsequently collected and 
analysed by mass spectrometry. The product was identified by MS (m/z 2773.43), 
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which was expected for the glycosylated product (expected for C123H202N29O41S1 
(M+H+) = 2773.43). 
 
Graph 4.1: Thiol alkylation of a cysteine-containing peptide utilising the 4-VP-lactose 
derivative 4.45. 
The potential of the 4-VP-lactose derivative 4.45 to alkylate a protein was 
subsequently investigated using the full Sbi3,4-Cys protein and analysed by mass 
spectrometry. Sbi3,4-Cys (1 mg/mL) was incubated with TCEP (5 mM) for 1 hour then 
desalted using a PD-10 column. Mass spectrometry analysis of the unfunctionalised 
Sbi3,4-Cys revealed a mass of m/z 14832.29 for the protein. Reaction of the Sbi3,4-Cys 
protein(33 M) with the 4-VP-lactose derivative 4.45 (0.5 mM) was performed in 
aqueous sodium phosphate (0.1 M, pH = 7) for 6 hours, desalted using a PD-10 
column and analysed by mass spectrometry. A peak of m/z 15334.16 was identified 
which was expected for the glycosylated protein (M+H+). 
In summary, a 4-VP linker has been successfully utilised to attach a carbohydrate to 
peptides and a protein via thiol alkylation. A selection of 4-VP linkers were 
subsequently derivatised with polyethylene glycol (PEG) to demonstrate that 4-VP 
can be functionalised with a variety of ligands, followed by alkylation experiments 


































4.9) 4-VP Derivatised PEG’s as Reagents for Protein PEGylation 
4-VP derivatives 4.2 and 4.3 were chosen as linkers for the functionalisation of 
commercially available methoxy-PEG-amine-2kDa, due to the availability of suitable 
intermediates for their synthesis and their favourable rates of alkylation of a 
peptide at neutral pH (Figure 4.10). The synthesis of both the 4-VP-PEG derivatives 
4.48 and 4.49 are illustrated in Figure 4.19. 
 
Figure 4.19: Synthesis of 4-VP-PEG derivatives 4.48 and 4.49. 
The ability of 4-VP-PEG derivatives 4.48 and 4.49 to alkylate a thiol containing 
protein was tested on yeast enolase, a 47 kDa protein with a single cysteine 
residue, which was previously utilised in Chapter 3. The effect of excess TCEP or 
THPP present in reactions with 4-VP-PEG derivatives on PEGylation yields was also 
investigated. Further, the addition of the water soluble alkyl azide 3.3 was pursued 
as a method to oxidise excess TCEP or THPP prior to addition of 4.48 or 4.49 for 
thiol alkylation of the protein. The reactions between yeast enolase and 4-VP 
derivatives 4.48 and 4.49 were analysed by SDS-PAGE. 
Yeast enolase was denatured in argon purged Tris buffer (0.5 M, pH = 7.2), 
containing 5 mM EDTA and 8 M urea. Varying amounts of TCEP (1-10 eq.) were 
added to aliquots of protein and incubated for 45 minutes at 25 C. The 4-VP-
PEG2kDa 4.48 (1 eq.) was subsequently added and the reaction was incubated at 37 
C for 18 hours (Figure 20, lanes 3-5). In parallel experiments, the alkyl azide 3.3 
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(100 eq.) was added to aliquots of yeast enolase containing varying amounts of 
TCEP (1-10 eq.). The samples were incubated for 1 hour at 37 C prior to addition of 
4-VP-PEG2kDa 4.48 (1 eq.), followed by incubation at 37 C for 18 hours (Figure 
4.20, lanes 6-8). 
 
Figure 4.20: SDS-PAGE of reactions between 4.48 (1 eq.) and yeast enolase in the 
presence of varying TCEP amounts (1-10 eq.) and in the presence or 
absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: enolase, 
Lane 3: enolase + TCEP (1 eq.) + 4.48 (1 eq.), Lane 4: enolase + TCEP (5 eq.) 
+ 4.48 (1 eq.), Lane 5: enolase + TCEP (10 eq.) + 4.48 (1 eq.), Lane 6: 
enolase + TCEP (1 eq.) + 3.3 (100 eq.) + 4.48 (1 eq.), Lane 7: enolase + TCEP 
(5 eq.) + 3.3 (100 eq.) + 4.48 (1 eq.), Lane 8: enolase + TCEP (10 eq.) 3.3 
(100 eq.) + 4.48 (1 eq.). The SDS-PAGE gel was stained with Coomassie 
solution and analysed utilising Image Studio Lite software. 
The presence of TCEP in the conjugation reactions with 4-VP-PEG2kDa 4.48 results 
in extremely low yields (calculated using Image Studio Lite version 4.0) of PEGylated 
protein (Figure 20, Lanes 3-5). Much lower yields (0-11 %, Table 4.2) were obtained 
when comparing to similar experiments utilising maleimide-PEG2kDa to PEGylate 
yeast enolase (11-42 %, Chapter 3, Table 3.2 and included in Table 4.2) in the 
presence of TCEP. The 4-VP-PEG2kDa derivative 4.48 appears to be less reactive 
than maleimide-PEG2kDa with regards to thiol alkylation and reacts with the TCEP 
present in the reaction, resulting in low PEGylation yields. The addition of the alkyl 
azide 3.3 (Figure 4.20, Lanes 6-8) was successful in oxidising TCEP, which resulted in 
higher yields of PEGylated yeast enolase when utilising 4-VP-PEG2kDa derivative 
4.48 (62-79 %, Table 4.2). Similar yields (76-85 %, Chapter 3, Table 3.2 and included 
in Table 4.2) were obtained in experiments utilising maleimide-PEG2kDa, illustrating 
that 4-VP derivatives can produce conjugate yields comparable to established 
reagents, such as maleimide derivatives. 
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The addition of the alkyl azide 3.3 to oxidise excess TCEP present in solution 
improved PEGylation of yeast enolase by 4.48. High Pegylation yields were achieved 
without the necessity for intermediate purification protocols. 
The effect of the reducing agent THPP (2.7) on PEGylation of a protein by 4-VP-
PEG2kDa derivative 4.48 was subsequently investigated. The ability of the alkyl 
azide 3.3 to oxidise THPP prior to PEGylation by 4-VP-PEG2kDa derivative 4.48 was 
also explored. Yeast enolase was denatured in argon purged Tris buffer (0.5 M, pH = 
7.2), containing 5 mM EDTA and 8 M urea. Varying amounts of THPP (1-10 eq.) 
were added to aliquots of protein and incubated for 45 minutes at 25 C. 4-VP-
PEG2kDa 4.48 (1 eq.) was subsequently added and the reactions were incubated at 
37 C for 18 hours (Figure 4.21, lanes 3-5). In parallel experiments the alkyl azide 
3.3 (100 eq.) was added to aliquots of enolase containing varying amounts of THPP 
(1-10 eq.). The samples were incubated for 1 hour at 37 C prior to addition of 4-VP-
PEG2kDa 4.48 (1 eq.) followed by incubation at 37 C for 18 hours (Figure 4.21, 
lanes 6-8). 
 
Figure 4.21: SDS-PAGE of reactions between 4.48 (1 eq.) and yeast enolase in the 
presence of varying THPP amounts (1-10 eq.) and in the presence or 
absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: enolase, 
Lane 3: enolase + THPP (1 eq.) + 4.48 (1 eq.), Lane 4: enolase + THPP (5 eq.) 
+ 4.48 (1 eq.), Lane 5: enolase + THPP (10 eq.) + 4.48 (1 eq.), Lane 6: 
enolase + THPP (1 eq.) + 3.3 (100 eq.) + 4.48 (1 eq.), Lane 7: enolase + THPP 
(5 eq.) + 3.3 (100 eq.) + 4.48 (1 eq.), Lane 8: enolase + THPP (10 eq.) + 3.3 
(100 eq.) + 4.48 (1 eq.). The SDS-PAGE gel was stained with Coomassie 
solution and analysed utilising Image Studio Lite software. 
The presence of THPP with 4-VP-PEG derivative 4.48 in the reactions results in low 
yields of PEGylated protein (Figure 21, Lanes 3-5). The yields (0-38 %) are, however, 
comparable (Table 4.2) with similar experiments utilising maleimide-PEG2kDa to 
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PEGylate yeast enolase (3-37 %) in the presence of THPP (Chapter 3, Table 3.2 and 
included in Table 4.2). It appears that THPP is a very nucleophilic phosphine 
derivative and reacts rapidly with both maleimide and 4-VP derivatives before the 
low concentration of thiolates are alkylated. 
The addition of the alkyl azide 3.3 (Figure 4.21, Lanes 6-8) was successful in 
oxidising excess THPP, which resulted in higher yields (56-57 %) of PEGylated yeast 
enolase (Table 4.2) when utilising 4-VP-PEG2kDa derivative 4.48. The yields are 
lower than the yields (68-76 %) achieved in similar experiments utilising maleimide-
PEG2kDa (Chapter 3, Table 3.2 and included in Table 4.2). The slower rates of thiol 
alkylation exhibited by 4-VP derivatives compared to maleimide derivatives may 
result in the oxidation of the thiols before alkylation is effected by the 4-VP 
derivatives. 
The addition of the alkyl azide 3.3 proved to be an effective strategy to oxidise 
THPP present in solution, which allows PEGylation of yeast enolase by 4.48 in 
consistently yields, without necessity for intermediate purification protocols. 
 
Table 4.2: Comparison of PEGylated yeast enolase yields achieved by 4-VP-PEG2kDa 
derivative 4.48 and maleimide-PEG2kDa, with and without the use of the 
alkyl azide 3.3 to oxidise reducing agents TCEP (2.6) or THPP (2.7). 
The PEGylation yields of yeast enolase when utilising 4-VP-PEG2kDa derivative 4.49 
in the presence or absence of TCEP or THPP was subsequently explored. Yeast 
enolase was denatured in argon purged Tris buffer (0.5 M, pH = 7.2) containing 5 
mM EDTA and 8 M urea. Varying amounts of TCEP (1-10 eq.) were added to aliquots 
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of protein and incubated for 45 minutes at 25 C. The 4-VP-PEG2kDa derivative 4.49 
(1 eq.) was subsequently added and the reactions were incubated at 37 C for 18 
hours (Figure 22, lanes 3-5). In parallel experiments the alkyl azide 3.3 (100 eq.) was 
added to aliquots of yeast enolase containing varying amounts of TCEP (1-10 eq.). 
The samples were incubated for 1 hour at 37 C prior to addition of 4-VP-PEG2kDa 
derivative 4.49 (1 eq.), followed by incubation at 37 C for 18 hours (Figure 4.22, 
lanes 6-8). 
 
Figure 4.22: SDS-PAGE analysis of reactions between 4.49 (1 eq.) and yeast enolase in 
the presence of varying TCEP amounts (1-10 eq.) and in the presence or 
absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: enolase, 
Lane 3: enolase + TCEP (1 eq.) + 4.49 (1 eq.), Lane 4: enolase + TCEP (5 eq.) 
+ 4.49 (1 eq.), Lane 5: enolase + TCEP (10 eq.) + 4.49 (1 eq.), Lane 6: 
enolase + TCEP (1 eq.) + 3.3 (100 eq.) + 4.49 (1 eq.), Lane 7: enolase + TCEP 
(5 eq.) + 3.3 (100 eq.) + 4.49 (1 eq.), Lane 8: enolase + TCEP (10 eq.) + 3.3 
(100 eq.) + 4.49 (1 eq.). The SDS-PAGE gel was stained with Coomassie 
solution and analysed utilising Image Studio Lite software. 
The presence of TCEP with 4-VP-PEG2kDa derivative 4.49 in the reactions resulted 
in extremely low yields of PEGylated protein (Figure 22, Lanes 3-5). Much lower 
yields (0-4 %, Table 4.3) were obtained when comparing to similar experiments 
utilising maleimide-PEG2kDa to PEGylate yeast enolase (11-42 %, Chapter 3, Table 
3.2 and included in Table 4.3) in the presence of TCEP. The 4-VP-PEG2kDa 
derivative 4.49 appears to be less reactive than maleimide-PEG2kDa with regards to 
thiol alkylation and reacts with the excess TCEP present in the reaction, resulting in 




The addition of the alkyl azide 3.3 (Figure 4.22, Lanes 6-8) was successful in 
oxidising TCEP, which resulted in higher yields (79-86 %) of PEGylated yeast enolase 
(Table 4.3) when utilising the 4-VP-PEG2kDa derivative 4.49. The yields are similar 
to the yields (76-85 %, Chapter 3, Table 3.2 and included in Table 4.3) achieved in 
similar experiments utilising maleimide-PEG2kDa. The addition of alkyl azide 3.3 is 
an effective strategy to oxidise TCEP and produce PEGylated protein in a high yield, 
without necessity for intermediate purification protocols. 
The addition of the alkyl azide 3.3 to oxidise the alternative reducing agent THPP to 
facilitate high bioconjugation yields between yeast enolase and 4-VP-PEG2kDa 
derivative 4.49 was next investigated. Yeast enolase was first denatured in argon 
purged Tris buffer (0.5 M, pH = 7.2) containing 5 mM EDTA and 8 M urea. Varying 
amounts of THPP (1-10 eq.) were then added to aliquots of protein and incubated 
for 45 minutes at 25 C. The 4-VP-PEG2kDa derivative 4.49 (1 eq.) was subsequently 
added and the reactions were incubated at 37 C for 18 hours (Figure 4.23, lanes 3-
5). In parallel experiments the alkyl azide 3.3 (100 eq.) was added to aliquots of 
enolase containing varying amounts of THPP (1-10 eq.). The samples were 
incubated for 1 hour at 37 C prior to addition of 4-VP-PEG2kDa derivative 4.49 (1 








Figure 4.23: SDS-PAGE analysis of reactions between 4.49 (1 eq.) and yeast enolase in 
the presence of varying THPP amounts (1-10 eq.) and in the presence or 
absence of the alkyl azide 3.3 (100 eq.). Lane 1: ladder, Lane 2: enolase, 
Lane 3: enolase + THPP (1 eq.) + 4.49 (1 eq.), Lane 4: enolase + THPP (5 eq.) 
+ 4.49 (1 eq.), Lane 5: enolase + THPP (10 eq.) + 4.49 (1 eq.), Lane 6: 
enolase + THPP (1 eq.) + 3.3 (100 eq.) + 4.49 (1 eq.), Lane 7: enolase + THPP 
(5 eq.) + 3.3 (100 eq.) + 4.49 (1 eq.), Lane 8: enolase + THPP (10 eq.) + 3.3 
(100 eq.) + 4.49 (1 eq.). The SDS-PAGE gel was stained with Coomassie 
solution and analysed utilising Image Studio Lite software. 
The presence of THPP with 4-VP-PEG derivative 4.49 in the reactions resulted in 
extremely low yields of PEGylated protein (Figure 21, Lanes 3-5). Lower yields (0-11 
%, Table 4.3) were obtained when comparing similar experiments utilising 
maleimide-PEG2kDa to PEGylate yeast enolase (3-37 %) in the presence of THPP 
(Chapter 3, Table 3.2 and included in Table 4.3). The maleimide derivatives are 
more reactive than 4-VP derivatives with regards to thiol alkylation and are, 
therefore, less affected by the presence of excess reducing agent in solution. 
The addition of the alkyl azide 3.3 (Figure 4.23, Lanes 6-8) was successful in 
oxidising excess THPP, which resulted in higher yields (63-65 %) of PEGylated yeast 
enolase (Table 4.3) when utilising 4-VP-PEG2kDa derivative 4.49. The yields are 
similar to the yields of 68-76 % (Chapter 3, Table 3.2 and included in Table 4.3) 
achieved in similar experiments utilising maleimide-PEG2kDa, illustrating that 4-VP 
derivatives can produce conjugation yields similar to well established chemistry 
such as maleimide. 
The addition of the alkyl azide 3.3 (Figure 4.23, Lanes 6-8) was successful in 
oxidising THPP, which resulted high yields of PEGylated yeast enolase, without 




Table 4.3: Comparison of PEGylated yeast enolase yields achieved by 4-VP-PEG2kDa 
derivative 4.49 and maleimide-PEG2kDa, with and without the use of the 
alkyl azide 3.3 to oxidise reducing agents TCEP (2.6) or THPP (2.7). 
4.10) Time Dependant PEGylation of Yeast Enolase by Maleimide-
PEG2kDa versus 4-VP-PEG2kDa Derivatives 4.48 and 4.49 
The yields of PEGylated yeast enolase achieved when using a commercial 
maleimide-PEG2kDa reagent versus 4-VP-PEG2kDa derivatives 4.48 and 4.49 over a 
24 hour incubation period were investigated. The experiments were performed to 
determine the time required to achieve maximum conjugate yields when utilising 4-
VP thiol alkylating reagents in comparison to the use of maleimide reagents. The 
thiol-containing protein yeast enolase was reduced utilising TCEP, followed by the 
use of the alkyl azide 3.3 to oxidise excess reducing agent prior to the addition of 
the PEGylation reagents. 
Yeast enolase was denatured in argon purged Tris buffer (0.5 M, pH = 7.2) 
containing 5 mM EDTA and 8 M urea at 85 C for 15 minutes. The solution was 
allowed to cool to room temperature before aliquoting solutions of yeast enolase 
(100 L) for the experiments. TCEP (5 eq.) was added to aliquots of protein in 
solution and incubated for 45 minutes at 25 C. The alkyl azide 3.3 (100 eq.) was 
added and the solutions were incubated for 1 hour at 37 C. Maleimide-PEG2kDa or 
4-VP-PEG2kDa derivatives 4.48 or 4.49 (1 eq.) were subsequently added to the 
reactions and incubated at 37 C for a total of 24 hours. Aliquots were taken from 
each of the reactions at time points, 1 hour, 4 hours and 24 hours and analysed by 
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SDS-PAGE (Figure 4.24) and yields quantified utilising Image Studio Lite version 4.0 
software (Table 4.4). 
 
Figure 4.24: SDS-PAGE of time dependant PEGylation of yeast enolase by maleimide-
PEG2kDa, 4-VP-PEG2kDa 4.48 and 4-VP-PEG2kDa 4.49. Lane 1: ladder, Lane 
2: enolase, Lane 3: enolase + TCEP (5 eq.) + 3.3 (100 eq.) + maleimide-
PEG2kDa (1 eq.), t = 1 hr., Lane 4: enolase + TCEP (5 eq.) + 3.3 (100 eq.) + 
maleimide-PEG2kDa (1 eq.), t = 4 hrs., Lane 5: enolase + TCEP (5 eq.) + 3.3 
(100 eq.) + maleimide-PEG2kDa (1 eq.), t = 24 hrs., Lane 6: enolase + TCEP 
(5 eq.) + 3.3 (100 eq.) + 4.48 (1 eq.), t = 1 hr., Lane 7: enolase + TCEP (5 eq.) 
+ 3.3 (100 eq.) + 4.48 (1 eq.), t = 4 hrs., Lane 8: enolase + TCEP (5 eq.) + 3.3, 
(100 eq.) + 4.48 (1 eq.), t = 24 hrs., Lane 9: enolase + TCEP (5 eq.) + 3.3 (100 
eq.) + 4.49 (1 eq.), t = 1 hr., Lane 10: enolase + TCEP (5 eq.) + 3.3 (100 eq.) + 
4.49 (1 eq.), t = 4 hrs. Lane 11: enolase + TCEP (5 eq.) + 3.3 (100 eq.) + 4.49 
(1 eq.), t = 24 hrs. The SDS-PAGE gel was stained with Coomassie solution 
and analysed utilising Image Studio Lite software. 
The PEGylation of yeast enolase by maleimide-PEG2kDa was rapid, with a yield of 
78 % achieved within the first hour of incubation (Table 4.4). A small increase in 
yield of 84 % was achieved by the fourth hour of the reaction (Table 4.4). High 
yields of PEGylated protein can, therefore, be achieved in 1-4 hours when utilising 
maleimide-functionalised PEG. In comparison, the 4-VP-PEG derivatives were less 
reactive than the maleimide-PEG derivative, with the 4-VP-PEG2kDA derivative 4.48 
proving to be the least reactive of the three PEG derivatives utilised. A low 
conjugate yield of 4 % was observed in the first hour of incubation, which improved 
to 45 % by the fourth hour of the reaction (Table 4.4). An excellent yield of 88 % 
was, however, achieved after 24 hours of incubation (Table 4.4). The 4-VP-PEG2kDa 
derivative 4.49 proved to be more reactive than 4-VP-PEG2kDa derivative 4.48. A 
PEGylated protein yield of 21 % (Table 4.4) was observed after 1 hour of incubation, 
which increased significantly to 80 % (Table 4.4) after 4 hours of incubation. The 
yield marginally increased to 81 % after 24 hours of incubation (Table 4.4). High 
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yields of PEGylated protein can, therefore, be achieved within 4 hours when 
utilising 4-VP-PEG2kDa derivative 4.49. The 4-VP-PEG2kDa derivative 4.49 is more 
reactive than 4-VP-PEG2kDa derivative 4.48 likely due to the higher pKa value of the 
nitrogen atom of the pyridine ring (Table 4.1). These experiments have illustrated 
that 4-VP-PEG derivatives can be utilised to produce PEGylated proteins in high 
yields, which are comparable to yields obtained with maleimide-PEG. Furthermore, 
the 4-VP-PEG2kDa derivative 4.49 can produce comparable alkylation yields to 
maleimide-PEG2kDa after 4 hours. 
 
Table 4.4: Yields of PEGylated yeast enolase achieved by maleimide-PEG2kDa, 4-VP-
PEG2kDa derivative 4.48 and 4-VP-PEG2kDa derivative 4.49 after 1, 4 and 









A variety of 4-VP linkers for bioconjugation via thiol alkylation were successfully 
synthesised. Methyl substitution at C-6 of the pyridine ring and extending the alkyl 
chain of the linker attached at C-2 of the pyridine ring was successful in raising the 
pKa of the pyridine ring to pKa  6. The increased pKa resulted in more favourable 
thiol alkylation rates at both pH = 7 and pH = 8, generally a pH that is a compromise 
between the pKa of the nitrogen of the pyridine ring of the 4-VP derivatives and the 
pKa of the thiol acceptor. The 4-VP derivatives also demonstrated specificity for 
thiol alkylation over amine alkylation at both pH = 7 and pH = 8. A selection of 4-VP 
derivatives were functionalised with carbohydrate and PEG ligands and utilised for 
thiol alkylation of peptides and proteins. Water soluble trialkylphosphines such as 
TCEP and THPP were demonstrated to react with 4-VP and, therefore, require 
either removal or complete consumption prior to addition of 4-VP derivatised 
ligands to a conjugation reaction. A protocol developed in Chapter 3 utilising a 
water soluble alkyl azide to oxidise TCEP or THPP in situ was effective in ensuring 
high PEGylated protein yields when 4-VP derivatised PEG’s were incubated with 
thiol-containing proteins. A 4-VP-PEG derivative was also successful in producing 




Chapter 5: Development of a Novel Method for 
Thiol Alkylation of S-Nitrosated (SNO) Proteins 
5.0) Aim of Investigation 
The thiol functional group of cysteine is mostly recognised as a key residue for 
structural or catalytic functions in proteins. The thiol functional group of cysteine is, 
however, also involved in the additional function of signal transduction in biological 
systems. The covalent attachment of nitric oxide (NO), a biological secondary 
messenger, to the sulfur atom of cysteine, generates a S-nitroso (SNO) peptide or 
protein. This nitrosation of thiols is a transient post translational modification, 
which is implicated in a variety of biological processes, such as cellular trafficking, 
muscle contractility and apoptosis [153]. The specific modification of a cysteine 
thiol to a SNO functional group may offer a site for the specific attachment of 
ligands to proteins for the production of bioconjugates. This method of attachment 
of ligands to cysteine containing proteins may provide an alternative method for 
the production of homogenous bioconjugates. A simple method of ligand 
conjugation to a SNO bond was therefore sought. 
5.1) Background 
Nitric oxide (NO) was first discovered by Jason Priestly in 1772, referring to it as 
nitrous air [154]. It is a reactive, colourless gas that exists as a neutral radical. 
During the 1980’s NO was recognised as a powerful biomessenger, with diverse 
physiological functions [155]. The increased research into the biology of NO-
dependant signalling won it the prize as molecule of the year in 1992. In 1998 the 
research into nitric oxide’s involvement in the cardiovascular and nervous system 
won R.F. Furchgott, L. J. Ignaro and F. Murad the Nobel prize in Physiology and 
Medicine [156]. It is now recognised as a fundamental molecule in the processes of 
vascular dilation, neuronal signalling and immunology [157, 158]. 
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The primary source of biological NO is the oxidation of the guanidino nitrogen of L-
arginine to L-citrulline and nitric oxide by the enzyme nitric oxide synthase (NOS) 
[154]. There are 3 major isoforms of NOS: neuronal NOS (nNOS), inducible NOS 
(iNOS) and endothelial NOS (eNOS). The expression of these enzymes is not as 
limited as their names might imply and can be found in many different cell types 
[159]. 
Nitric oxide is a highly diffusible molecule and can elicit effects a distance from its 
initial production. NO is able to rapidly diffuse through cellular membranes, an 
advantageous property of a biological messenger. It is, however, a radical, and is a 
fairly reactive and short lived species, especially in an aqueous environment, with a 
half-life of 0.5-1 s in blood [160]. The reactivity of NO can be a beneficial quality as a 
short-lived messenger, since high, uncontrolled concentrations can cause cellular 
damage such as DNA deamination [154]. Cellular mechanisms have evolved for the 
necessary production of the ubiquitously required biomessenger and also the 
trafficking of this reactive molecule as a stable entity, such as S-nitrosation of 
peptides and proteins. 
The classical NO signalling pathway involves the ability of NO to act as an allosteric 
modulator of guanylyl cyclase (sGC) activity. The sGC enzyme is a heterodimeric 
protein that catalyses the formation of the biomessenger cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate (GTP). The molecule cGMP is 
a cyclic nucleotide that binds to phosphodiesterases (PDE), ion-gated channels and 
cGMP-dependant kinases (cGK) regulating functions such as smooth muscle 
relaxation and neurotransmission [159]. The allosteric binding of NO to sGC leads to 
a 100-400 fold increase in activity [161]. 
The non-classical NO signalling pathway is through NO-induced post translational 
modification of proteins. The nitrosation of a cysteine thiol (RSNO) is a method for 
the storage or stable delivery of the reactive NO moiety to biological targets. It can 
also influence the activity of the nitrosated biomolecule similar to post translational 
modifications such as phosphorylation [162]. A variety of RSNO’s have been 
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identified from low molecular weight S-nitrosocysteine (CysNO) and S-
nitrosoglutathione (GSNO) to high molecular weight S-nitrosoalbumin (SNO-alb), 
with reported endogenous levels ranging from 28 nM to 7 M [160]. 
NO does not react directly with thiols or thiolates under biological conditions but 
requires either oxidation of the thiol to the thiyl radical or the prior oxidation of NO 
to generate NO+ donors. NO can react with oxygen (O2) or superoxide (O2) to 
produce reactive nitrogen species such as dinitrogen trioxide (N2O3), which is a NO+ 
donor for the nitrosation of cysteine residues [163, 164]. RSNO’s can also be 
formed through transition metal catalysed pathways. NO has a high affinity for 
heme centres, a common moiety of biological proteins such as haemoglobin (Figure 
5.1). The metal atoms of the heme group can catalyse nitrosothiol formation via 
transient oxidation of NO to NO+ [165]. Translocation of the NO+ group from one 
sulfur atom to another in a transnitrosation reaction is another method of RSNO 
formation and is implicated as an important post-translation modification 
mechanism involved in cellular signalling [162]. The post-translational modification 
of cysteine by nitric oxide may alter the activity of the protein and lead to 
downstream effects on the biological signalling processes. This transient 
modification of proteins, therefore, needs to be highly specific to affect the 
necessary biological outcome. There are a number of factors that ensures 




Figure 5.1: The diverse physiological effects of nitric oxide. Taken from [166]. 
Proteomic analysis of SNO-proteins has suggested that the specificity of nitrosation 
may be governed by the recurrence of an acid-base motif within 8 Å of the target 
cysteine thiol for nitrosation. The acidic aspartic acid (Asp) and glutamic acid (Glu) 
residues and basic arginine (Arg), histidine (His) and lysine (Lys) residues are 
suggested to aid the nitrosation of cysteine. Arginine (Arg), histidine (His) or lysine 
(Lys) residues are suggested to aid in the deprotonation of the cysteine thiol to 
generate a nucleophilic thiolate to facilitate transnitrosation (Figure 5.2) [167]. The 
coordination of metal ions to specific cysteine thiols is also thought to decrease the 
thiol pKa and facilitate transnitrosation reactions. Allostery is thought to play an 
important part in causing structural changes in the protein that influences the 
availability and reactivity of the cysteine thiol for nitrosation [167]. 
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Compartmentalisation of cysteine residues in hydrophobic regions of a protein is 
also thought to favour a nitrosation reaction. The hydrophobic regions provide a 
suitable environment to concentrate the lipophilic nitric oxide and molecular 
oxygen to form N2O3, which is a NO+-donor for SNO formation [167]. 
 
Figure 5.2: Acid-base catalysis for protein transnitrosation. Deprotonation of a 
cysteine thiol by arginine (Arg) promotes its nucleophilicity for a 
transnitrosation reaction with a RSNO, which is further facilitated by 
proton donation to the RSNO donor by aspartic acid (Asp). R = alkyl. 
Adapted from [167]. 
5.2) Direct SNO-Protein Detection 
The generally low abundance of SNO-proteins requires sensitive detection methods 
that are also specific for SNO-proteins. The SNO bond is fairly labile, which can 
make identification difficult when laborious protocols are utilised. The SNO bond is 
also susceptible to decomposition by light and the presence of transition metals. A 
number of techniques have been developed for the identification of SNO proteins 
and the characterisation of the NO modified site.  
5.2.1) Detection of SNO-Proteins by X-Ray Crystallography 
X-ray crystallography is a powerful tool for the analysis of nitrosated proteins. X-ray 
crystallography has the potential to identify the site of nitrosation as well as the 
structural changes that the modification induces. There are, however, a few 
drawbacks to this technique. The protein needs to have been previously identified 
as a nitrosated species, isolated from the sample matrix and be susceptible to 
crystallisation conditions. The SNO bond also needs to be stable during the 
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crystallisation process. A number of SNO-proteins have now been successfully 
crystallised, including S-nitrosated hemeproteins and thioredoxin [168, 169]. 
5.2.2) Detection of SNO-Proteins by Mass Spectrometry 
Mass spectrometry provides the potential to analyse either intact or protease 
digested SNO proteins. A mass shift of 29 atomic mass units in nitrosated samples 
relative to non-nitrosated samples can suggest the presence of nitric oxide. Modern 
mass spectrometric methods allow sequencing of peptide fragments which can 
prove useful in determining the nitrosation sites. SNO proteins are not, however, 
compatible with all ionisation methods, proving unstable to matrix assisted laser 
desorption ionisation mass spectrometry (MALDI-MS) [170]. The protease digestion 
protocols may also prove deleterious to the labile SNO linkage, although this may 
depend on individual sample characteristics. 
5.2.3) Detection of SNO-Proteins by SNO-Specific Antibodies 
Immunoglobulins recognising the SNO motif were first recognised in MS patients 
and soon developed into research tools such as ELISA and immunohistochemistry-
based analysis of SNO proteins [171, 172]. There are some limitations to this 
technique. The SNO linkage must be stable during the course of the assay, SNO 
antibodies may only be raised at solvent accessible SNO sites and antibodies may 
show low specificity for SNO-cysteine versus cysteine, which may lead to false 
positive detection [173]. 
5.3) Indirect SNO-Protein Detection 
5.3.1) Biotin Switch Technique (BST) 
The BST method was first described by Jaffrey et al as a method for identifying the 
SNO sites in proteins [174]. Many variations of the method have since been 
developed such as SNO-resin assisted capture (SNO-RAC) and SNO-site 
identification (SNO-SID), which are summarised in Figure 5.3. The BST method and 
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its variations generally rely on 4 steps, including (1) free thiol capping, (2) reduction 
of the SNO site to a thiol functional group, (3) biotin labelling of the resultant free 
thiol and (4) detection of the biotin labelled thiol [175]. SNO-SID is a modification of 
the BST method, where biotinylated protein samples are trypsinised. The 
biotinylated peptides are captured on avidin or streptavidin beads, eluted and 
analysed by mass spectrometry [173]. 
 
Figure 5.3: Biotin-based protocols for the enrichment of SNO-peptides and proteins. 
Adapted from [173]. 
The BST technique of SNO identification is very versatile and has been applied to 
purified protein, cultured cells and plasma [176, 177] but there are some pitfalls 
associated with each of the 4 steps of the BST protocol, which are summarised 
below. 
5.3.1.1) Thiol Capping Utilised in the BST Protocol 
The first step for the BST method and its variations involves capping of the free 
thiols present in the protein. Thiol capping is performed to prevent the 
identification of false positives since S-nitrosation is generally a cysteine-specific 
modification. The free thiols are generally capped with methyl methanethiosulfate 
(MMTS) to generate mixed disulfides. A disulfide is a relatively labile bond and may 
not survive the subsequent chemical steps. The capping reagent can be replaced by 
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N-ethyl maleimide (NEM) or iodoacetamide (IAM) to generate more stable thio-
ether bonds. A disadvantage of the capping step is the lability of the SNO linkage. If 
the SNO bond is hydrolysed, it could lead to the capping of the target cysteine 
residue, leading to a failure of identifying the SNO site. Residual capping reagent is 
removed before the next step in the protocol, usually by protein precipitation or 
spin column filtration. 
5.3.1.2) Reduction of the SNO Linkage in the BST Protocol 
The second step in the BST protocol requires the selective reduction of any SNO 
bonds in the protein to the thiol functional group for the subsequent labelling of 
the cysteine thiol using a biotin-functionalised molecule. The initial protocol relied 
on ascorbate for reduction of the SNO linkage but this has raised some potential 
pitfalls. The ascorbate dependant reduction of SNO exhibits slow kinetics [178]. 
Trace metals such as Cu() are attributed to the SNO reduction, with ascorbate 
serving to reduce Cu() back to Cu(). The addition of Cu() to the ascorbate 
solution has been shown to improve the reduction of the SNO bond and improve 
yields of subsequent biotinylated samples [179]. Ascorbate has also been shown to 
reduce disulfides [180]. This may lead to the identification of false positives when 
the MMTS capping reagent is utilised in the first step of the BST protocol [181]. 
5.3.1.3) Labelling of the Thiol Following SNO Reduction in the BST Protocol 
Immediately after SNO reduction, the free thiol is labelled with a biotin-
functionalised tag. The original tag utilised was biotin-(N-[6-(Biotinamido)hexyl]-3'-
(2'-pyridyldithio)propionamide, Bt-HPDP, 5.1), resulting in a mixed disulfide linkage 
between the protein and biotin molecule. The lability of a disulfide bond may lead 
to loss of biotinylated product during the subsequent purification steps. The 
presence of ascorbate in the solution from the previous step may reduce the 
protein-biotin disulfide bond, which could also cause a decrease of biotinylated 
product. Biotin functionalised with thiol-alkylating functional groups such as 
maleimide or iodoacetamide offer a solution to the above mentioned problems. 
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Maleimide and iodoacetamide, however, can also react with amines present on the 
protein such as lysine and histidine to produce artefacts into the experiment. 
 
5.3.1.4) Detection of Biotinylated Thiols in the BST Protocol 
Isolation of the biotinylated proteins is achieved by affinity purification using avidin 
or streptavidin beads. A variety of methods are utilised to characterise the isolated 
products including Western blot analysis and mass spectrometry [182]. 
The variety of potential pitfalls associated with the BST protocol has prompted the 
development of alternative strategies for the functionalisation and isolation of SNO-
proteins. 
5.3.2) Phosphine-Based Detection of S-Nitrosothiols 
Xian and colleagues have developed a method for the detection of RSNO’s using 
phosphine ester derivatives. The first generation of phosphine ester derivatives 
were capable of specifically reacting with a SNO functional groups to generate 
stable sulfenamide derivatives (Figure 5.4, No. 5.3) [183]. The concept was further 
developed and modified for the detection and isolation of SNO-proteins by affinity 
capture methods. Biotin-conjugate phosphine thioester derivatives were 
synthesised and reacted with a SNO-protein. A SNO-protein reacts with a phosphine 
thioester derivative 5.4 to initially generate an azaylide intermediate 5.5. An 
intramolecular acyl transfer results in protein sulfenamide 5.6 and biotin-thiolate 
5.7 intermediates, which further react to generate a phosphine oxide by-product 
5.8 and a protein-biotin disulfide derivative 5.9 [184]. 
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Although the reductive ligation method offers a simple alternative to the BST 
protocol for the direct detection of S-nitroso proteins, there are still a few pitfalls 
associated with the protocol. The reductive ligation method does not include a 
thiol-blocking step which may result in competition between thiolate-proteins in 
the sample matrix and the biotin-thiolate in the reaction mechanism for disulfide 
formation and could lower yields of protein-biotin production. The protein-biotin 
disulfide bond is prone to scission which may lower also lower yields. The protein-
biotin disulfide may also undergo disulfide exchange with other protein thiols 
present in the sample matrix, leading to identification of false positives. 
 
Figure 5.4: Reductive ligation protocols for S-nitrosothiol-protein detection. A) A S-
nitrosothiol is reacted with a phosphine ester derivative 5.2 to yield a 
sulfenamide derivative 5.3. B). A SNO-protein reacts with a phosphine 
thioester derivative 5.4 to generate a phosphine oxide products 5.8 and a 
protein-biotin disulfide derivative 5.9. 
5.4) A Novel Direct Method for SNO-Protein Functionalisation and 
Detection 
The potential pitfalls highlighted in the BST and phosphine reductive ligation 
methods highlighted above prompted an investigation into developing an 
alternative method for SNO functionalisation and detection. A more simple, direct 
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and robust method of SNO functionalisation was sought whereby the SNO bond 
could be specifically targeted over cysteine thiols. A reaction specific for the SNO 
bond could potentially negate the thiol capping and SNO reduction steps in the BST 
method and also avoid yield loss and false positives arising from the use of mixed 
disulfide chemistry. 
5.4.1) Characterisation the Cavero Reaction between a Sterically Hindered SNO 
Derivative and an Alkene 
Cavero et al have reported a free radical addition of a tritylthionitrite (5.10) to 
alkenes in organic solvents to form -alkylthio or -arylthio oximes, however, no 
product characterisation was reported for the published reactions (Figure 5.5) 
[185]. 
 
Figure 5.5: General scheme reported by Cavero et al. describing the reaction between 
tritylthionitrite (5.10) and an alkene to give either α-alkylthio or α-arylthio 
oxime products. Adapted from [185]. 
Here the Cavero method was repeated utilising 4-VP (4.33) and tritylthionitrite 
(5.10) in isopropyl alcohol (IPA) and toluene to characterise the reported oxime 
product to determine the potential of 4-VP to directly functionalise S-nitrosated 
ligands (Figure 5.6). Purification of the reaction resulted in the successful isolation 
of (E,Z)-N-[1-(pyridine-4-yl)-2-[(triphenylmethyl)sufanyl]ethylidene]hydroxylamine 
(5.11). The isolation and characterisation of 5.11 verified the reaction reported by 





Figure 5.6: Reaction of 4-VP (4.33) with tritylthionitrite (5.10) to generate the oxime 
derivative 5.11. 
However, as discussed previously (Chapter 4), 4-VP is also utilised as a Michael 
acceptor for thiol alkylation of peptides and proteins. The Michael addition of 4-VP 
with thiols will be problematic when considering its use for specific SNO 
functionalisation. The use of 4-VP to functionalise a SNO bond would require a pre-
capping step of any free thiols that may be present in the protein, similar to that 
performed in the BST protocol. The Michael addition between 4-VP and a thiol was 
confirmed by the isolation of 4-[2-(tritylsulfanyl)ethyl]pyridine (5.13) after the 






Figure 5.7: Reaction of 4-VP (4.33) with triphenylmethanethiol (5.12) to yield the 
Michael addition product 5.13. 
5.4.2) Characterisation of the Reaction of an Amino Acid-SNO with 4-VP 
Despite the potential pitfall (Michael addition) of utilising 4-VP in a SNO 
functionalisation protocol, the reaction of 4-VP with the SNO-amino acid, methyl N-
acetyl-S-nitroso-L-cysteinate (5.14) was investigated (Figure 5.8). This reaction was 
performed to investigate the reaction of 4-VP with a more biologically relevant 
SNO-ligand (SNO-amino acid) compared to the SNO-derivative 5.10. The reaction of 
4.33 with 5.14 was also performed to compare the potential yield of the oxime 
derivative 5.15 to that of the Michael addition product 5.16 and to identify any 
other possible by-products. Purification of the reaction between 4.33 and 5.14 
yielded a number of different products. The oxime product methyl N-acetyl-S-
[(2E,Z)-2-hydroxyimino-2-(pyridin-4-yl)ethyl]-L-cysteinate (5.15) was successfully 
isolated in a 43 % yield. The second major side product isolated was dimethyl N,N'-
diacetyl-L-cystinate (5.17) in a 52 % yield as well as minor amounts of 4,4'-but-1-
ene-2,4-diyldipyridine (5.18) in 3 % yield. The Michael addition product methyl N-
acetyl-S-[2-(pyridin-4-yl)ethyl]-L-cysteinate (5.16) was detected by mass 




Figure 5.8: Reaction of 4-VP (4.33) with the SNO-amino acid derivative 5.14. 
Although 4-VP (4.33) was capable of functionalising 5.14 in a moderate yield to 
generate the desired oxime 5.15, a number of unwanted side reactions had 
occurred. The most important side reaction identified was the Michael addition of 
4-VP (4.33) to form 5.16. The identification of 5.16 confirmed the pitfall of 
potentially utilising 4-VP for specific SNO-protein functionalisation, without a prior 
thiol capping step. A protocol was, therefore sought, whereby a pre-capping step 
would not be required, by utilising chemistry that could differentiate between a 
SNO and a thiol functional group. As such, the allyl functional group was 
investigated as an alternative method to specifically functionalise SNO-proteins. 
5.5) Investigation of the Potential Reaction of an Allyl Functional 
Group with a SNO Linkage 
5.5.1) Reaction of the Allyl Functional Group in an Organic Solvent with a 
Hindered SNO Derivative 
A method was sought that could simplify the protocol for potentially functionalising 
and isolating SNO-proteins. The allyl functional group was investigated as an 
alternative to 4-VP for the covalent addition to a SNO bond. The allyl functional 
group may potentially react with the SNO bond through a radical mechanism, but 
not act as a Michael acceptor with thiol functional groups as previously seen in the 
reaction of 4-VP with a free thiol. A specific reaction between an allyl functional 
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group and a SNO bond may offer the potential to use an allyl derivative to directly 
functionalise SNO-proteins in the presence of free thiols. 
N-allylacetamide (5.20) was synthesised from allylamine (5.19) and subsequently 
reacted with tritylthionitrite (5.10) utilising the conditions described by Cavero 
[185]. Mass spectrometric analysis of the reaction successfully identified N-[(2E,Z)-
2-(hydroxyimino)-3-(tritylsulfanyl)propyl]acetamide (5.21), however, isolation of 
this product by silica gel chromatography was not possible, indicating a poor 
yielding reaction (Figure 5.9). This result indicated that the reaction of an allyl 
functionalised ligand with and SNO-protein may not useful as a technique for 
production of bioconjugates but may be more suitable as an analytical tool for the 
detection of SNO-proteins. The investigation was directed towards developing an 
allyl functionalised ligand for the detection of SNO-proteins by affinity capture 
techniques and mass spectrometry. 
 
Figure 5.9: Synthesis of N-allylacetamide (5.20) followed by reaction with 





5.5.2) Reaction of D-Allyl Biotin with a SNO-Peptide in an Aqueous/Organic 
Solvent Mixture 
The moderate success of the reaction between N-allylacetamide (5.20) and 
tritylthionitrite (5.10) to generate the oxime product 5.21 prompted the synthesis 
of a D-allyl biotin (5.23) from D-biotin (5.22, Figure 5.10) for detection of SNO 
proteins by affinity capture techniques. Compound 5.23 has the potential to react 
with SNO-peptides and proteins via the allyl functional group and enable sample 
enrichment for detection by Western blotting. 
D-Allyl biotin (5.23) was reacted with the SNO-peptide S-nitrosoglutathione (5.24) in 
a buffer/DMSO solvent combination to facilitate dissolution of the reagents and 
also mimic conditions that may be employed in reactions of 5.23 with SNO-
proteins. Incubation of 5.23 with 5.24 at 50 C was successful in generating the 
oxime derivative 5.25 (Figure 5.10). The oxime 5.25 could not be isolated by 
chromatography, but encouragingly was detected by mass spectrometry. The 
advantage of a simple method to directly detect SNO linkages without laborious 
sample preparation required in the BST method may outweigh the disadvantage of 
low yields and could find use in some applications. This may be applicable to 
developing a sensitive detection assay where product yields may not be a major 
issue. The allyl-biotin derivative 5.23 should ensure sample enrichment by affinity 
chromatography to provide sufficient signal for detection by techniques such as 




Figure 5.10: Synthesis of D-allyl biotin (5.23) from D-biotin (5.22) followed by reaction 
of 5.23 with S-nitrosoglutathione (5.24) to yield the biotin derivative 5.25, 
which was confirmed by mass spectrometry. 
5.5.3) Reaction of Allyl-Biotin Compounds with a SNO Protein 
The moderate success of D-allyl biotin (5.23) to functionalise the SNO peptide S-
nitrosoglutathione (5.24) prompted an investigation into utilising 5.23 to 
functionalise a S-nitrosated protein. The D-Biotin-allyl derivatives 5.26 and 5.27 
were also synthesised to potentially functionalise a SNO-protein (Figure 5.11). The 
allyl-biotin derivatives 5.26 and 5.27 possess longer alkyl chains than derivative 5.23 
to investigate the impact of steric bulk that may be present around the S-nitrosated 
cysteine in the protein, which may prevent access of the allyl functional group to 
the reaction site. The saturated D-biotin derivative 5.28 was also synthesised as a 




Figure 5.11: Structures of D-allyl-biotin derivatives 5.26 & 5.27 for the functionalisation 
of SNO-proteins and the negative control biotin derivative 5.28 for Western 
blot experiments. 
The commercially available protein bovine serum albumin (BSA) was considered to 
be an appropriate model protein for S-nitrosation experiments as it contains 12 
disulfide bridges as well as one free surface cysteine residue (Cys58). It has 
previously been shown that human serum albumin acts as a carrier of NO in vivo so 
the bovine equivalent was postulated as a cheap and suitable model protein [186]. 
Samples of BSA (30 µg/mL, Tris buffer, pH = 7) were nitrosated using the NO 
releasing reagent diethylamine (DEA) NONOate and subsequently treated with 450 
μM of either allylamide derivatives 5.23, 5.26 or 5.27 or the propylamide control 
5.28 for 15 minutes at 60 °C. In parallel experiments, control samples of native 
(non-nitrosated) BSA were also treated under identical conditions. Protein samples 
were then resolved using SDS-PAGE and the presence of biotin was detected by 
Western blot analysis using a Horseradish peroxidase (HRP)-NeutrAvidin conjugate 
which possesses a high affinity for biotinylated derivatives (Figure 5.12). 
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The incorporation of biotin onto nitrosated (DEA-NONOate treated) BSA was clearly 
observed through Western blotting (Figure 5.12, lanes 1, 3 & 5), however, no biotin 
could be detected in the control samples of BSA which had not been nitrosated 
(Figure 5.12, lanes 2, 4 & 6). No incorporation of biotin was observed on either the 
nitrosated (Figure 5.12, lane 7) or non-nitrosated (Figure 5.12, lane 8) samples of 
BSA when utilising the negative control 5.28, demonstrating that the allyl functional 
group is essential for conjugation to occur. 
 
Figure 5.12: Labelling of BSA (30 µg/mL) with biotinylated compounds 5.23, 5.26, 5.27 
(450 μM) for 15 minutes at 60°C in the presence (+) or absence (-) of pre-
treatment with the NO donor DEA NONOate (1 mM, 20 min), then 
visualised by Western Blot analysis [187]. 
5.5.4) MS Analysis of Biotinylated BSA to Confirm Site of Nitrosation 
A peptide mapping experiment was performed to confirm that the observed 
functionalisation of S-nitrosated BSA was through the reaction of the allylamide 
with a S-nitrosothiol group [188]. Compound 5.27 (450 μM) was treated with S-
nitrosated BSA (2 mg/mL, pH 7) for 1 hour at 37°C. The protein was subsequently 
subjected to pepsin digestion (4 hours, pH = 2) and the biotinylated peptides were 
isolated using CaptAvidin™ resin. The purified protein digest was then analysed by 
in-line ESI-LC/MS, which identified the presence of a single species with exact 
masses of 998.2881 Da (M+H+) and 1020.2826 (M+Na+). The masses of the species 
detected correspond to an adduct of compound 5.27 covalently bound to the thiol 
containing peptide fragment QQCP (5.29), where the observed cysteine residue in 
this peptide corresponds to the surface cysteine of BSA, Cys58 (Figure 5.13). The 
observed mass of this species indicates that the biotinylated adduct exists in the 
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ketone form, rather than the oxime, likely owing to the strongly acidic conditions 
employed during LC and MS analysis. 
 











Biotinylated allylamides have been demonstrated to act as agents for the 
functionalsation and detection of S-nitrosothiols through a single chemical step 
under aqueous conditions. The biotinylated allylamide compounds proved to be 
effective for the visualisation of a S-nitrosated protein (BSA) using Western blot 
analysis, which was further characterised by proteolytic analysis of biotinylated 
BSA. An LC isolated peptide fragment identified the surface cysteine, Cys58, as the 
site of nitrosation. The biotinylated allylamides described were capable of 
functionalising a S-nitrosated protein (BSA), suggesting that these compounds may 
prove to be important tools in the future for the investigation of protein S-




Chapter 6: Experimental 
Chemical reagents were purchased from Sigma-Aldrich unless specifically stated. 
Anhydrous solvents were purchased from Sigma-Aldrich. All other solvents were 
purchased from Fisher Scientific. Thin layer chromatography (TLC) was carried out 
on Merck aluminium backed TLC plates silica gel 60 F254 (0.25 mm thickness), 
viewed using UV light of wavelength 254 nm or stained with potassium 
permanganate solution. Silica gel chromatography was performed on silica gel 60 Å 
(200-400 mesh) from Sigma-Aldrich. Reverse phase chromatography was 
performed using a VersaFlash hand held column (23 x 110 mm) from Supelco. 
Melting points were obtained using a Thermo Fisher IA9000 digital melting point 
apparatus. 1H, 13C and 31P and 19F NMR spectra were recorded using Bruker 
Advance III (400 and 500 MHz) spectrometers. Deuterated solvents were purchased 
from Cambridge Isotope Laboratories. The NMR chemical shifts δ are recorded in 
parts per million (ppm) with reference to tetramethylsilane for 1H and 13C and 
phosphoric acid for 31P NMR spectroscopy. High resolution mass spectrometry was 
performed using a BrukerMicrOTOF electrospray ionisation mass spectrometer. 
Infrared spectra were recorder on a PerkinElmer Spectrum 65 FT-IR spectrometer. 
HPLC was performed on a Dionex Ultimate 3000 instrument equipped with a 
variable wavelength detector. SDS-PAGE was performed utilising an Invitrogen xCell 
SureLock cell and a Biorad PowePac HV. SDS gels were scanned utilising a Licor 










N-Ethyl maleimide (2.8, 10.0 mg, 0.080 mmol) and TCEP (2.6, 0.9 eq., 20.6 mg, 
0.0719 mmol) were dissolved in a mixture of THF (1 mL) and argon purged aqueous 
sodium phosphate (0.1 M, pH = 7.0, 9 mL) and stirred under argon at room 
temperature for 1 hour. The solution was then concentrated in vacuo to 3 mL and 
the residual liquid then loaded onto a C-18 column for purification (100 % H2O  
20 % MeCN/H2O) to yield 2.9 as a white sticky solid (19.7 mg, 73 %).  1H NMR, D2O, 
400 MHz:    3.49 (q, 2H, NCH2, J = 7.2 Hz), 3.26-3.09 (m, 2H, CCH2CO), 2.84-2.73 (m, 
12H, 3 x CH2CH2CO), 1.05 (t, 3H, CH3, J = 7.2 Hz).  13C NMR, D2O, 125 MHz:    175.97 
(d, CH2CON, J = 8.8 Hz), 174.16 (d, 3C, 3 x CH2CO2H, J = 11.9 Hz), 172.95 (CCO, J = 3.0 
Hz), 35.05 (NCH2), 33.51 (m, CH2CCO), 29.39 (CCH2CO), 25.82 (d, 3C, 3 x 
CH2CH2CO2H, J = 3.5 Hz), 14.34 (d, 3C, PCH2, J = 49.9 Hz), 11.54 (CH3).  31P NMR, D2O, 
162 MHz:    39.2.  HRMS: Expected for C15H21N1O8P1 (M-H+) = m/z 374.1005. 
Found: m/z 374.1029.  Infrared (KBr): 3442, 1700 cm-1.  HPLC: column: Phenomenex 
Luna-C18 (250 x 4.60 mm), gradient elution: (0.7 mL/min), 100 % water containing 
0.1 % TFA  100 % MeCN over 16 minutes, retention time, 12.81 mins., purity: 93 







N2-(tert-Butoxycarbonyl)-L-lysine (2.24, 190.4 mg, 0.771 mmol) was dissolved in 
anhydrous DMF (5 mL). Triethylamine (1 eq., 108 µL, 0.771 mmol) and 3-
maleimidopropionic acid N-hydroxysuccinimide ester (1.2 eq., 246.9 mg, 0.928 
mmol) were added and the reaction was stirred at room temperature while under 
nitrogen gas for 18 hours. The solution was concentrated and purified by silica gel 
chromatography (5 % MeOH/DCM  20 % MeOH/DCM) to yield N2-(tert-
butoxycarbonyl)-N6-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl]-L-lysine 
(2.25) as a white sticky solid (261.1 mg, 85 %).  1H NMR, CD3OD, 400 MHz:    6.83 
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(s, 2H, COCHCHCO), 3.98 (m, 1H, NHCHCO2H), 3.77 (t, 2H, NCH2, J = 7.0 Hz), 3.12 (m, 
2H, NHCH2CH2), 2.45 (t, 2H, COCH2CH2, J = 7.0 Hz), 1.84-1.60 (m, 2H, CHCH2CH2), 
1.55-1.37 (m, 13H, CHCH2CH2CH2CH2, 3 x CH3).  13C NMR, CD3OD, 100 MHz:    
179.14 (CHCO2H), 172.86 (NHCOCH2), 172.13 (2 x COCH), 158.03 (NHCO2C), 135.50 
(2 x COCH), 80.28 (OCCH3), 56.08 (NHCHCO2H), 40.22 (NHCH2CH2), 35.81 
(NHCOCH2CH2), 35.48 (NCH2CH2), 33.08 (CHCH2CH2), 29.91 (NHCH2CH2CH2), 28.78 
(CCH3), 24.26 (CHCH2CH2CH2).  HRMS: Expected for C18H26N3O7 (M-H+) = m/z 
396.1776. Found: m/z 396.1809.  Infrared (KBr): 3370, 1713, 1649 cm-1.  HPLC: 
column: Waters Symmetry Shield-RP8 (100 x 4.60 mm), gradient elution:  (1.0 
mL/min) 90 % water/MeCN containing 0.1 % TFA  90 % MeCN/H2O over 13 
minutes, retention time, 6.15 mins., purity: 97%. Detection at 225 nm. 
The Boc-protected derivative 2.25 (80.0 mg, 0.201 mmol) was suspended in THF (1 
mL) and cooled to 0 C. TFA (4 mL) was slowly added to the solution which was left 
to warm to room temperature and then stirred for a further 5 hours. The solution 
was concentrated and the residue was redissolved in 2 mL of water. The solution 
was neutralised with K2CO3 and subsequently purified by C-18 chromatography 
(100 % H2O  20 % MeOH/H2O) to yield 2.11 as a transparent solid (42.5 mg, 71 
%).  1H NMR, D2O, 400 MHz:    3.79 (t, 2H, NCH2CH2, J = 7.0 Hz), 3.72 (t, 1H, 
NHCHCO2H, J = 5.9 Hz), 3.12 (t, 2H, NHCH2CH2, J = 6.9 Hz), 2.48 (t, 2H, COCH2CH2, J = 
6.4 Hz), 1.85 (m, 2H, CHCH2CH2), 1.45 (m, 2H, NHCH2CH2CH2), 1.33 (m, 2H, 
CHCH2CH2).  13C NMR, D2O, 100 MHz:    174.67 (CHCO2H), 173.37 (NHCOCH2), 
172.57 (2 x NCOCH), 134.45 (2 x NCOCH), 54.62 (NHCHCO2H), 38.96 (NHCH2CH2), 
34.76 (COCH2CH2), 34.53 (NCH2CH2), 30.02 (CHCH2CH2), 27.88 (NHCH2CH2CH2), 
21.76 (CHCH2CH2CH2).  HRMS: Expected for C13H18N3O5 (M-H+) = m/z 296.1252. 
Found: m/z 296.1229.  Infrared (KBr): 3325, 1714, 1630 cm-1.  HPLC: column:  
Phenomenex Luna-NH2 (250 x 4.60 mm), gradient elution:  (1.0 mL/min) 10 % 
MeCN in water containing 0.1 % TFA  100 % MeCN over 20 minutes, retention 







Compound 2.11 (15.4 mg, 0.0518 mmol) and TCEP (2.6, 0.9 eq., 13.4 mg, 0.0466 
mmol) was dissolved in 2 mL of argon purged aqueous sodium phosphate (0.1 M, 
pH = 7). The reaction was stirred, under argon, and at room temperature for 1 hour. 
The reaction was the subsequently purified by C-18 chromatography (100 % water). 
The product was lyophilised to give 2.12 as an amorphous white solid (18.0 mg, 70 
%).  1H NMR, D2O, 400 MHz:    3.80 (t, 2H, NCH2CH2, J = 6.6 Hz), 3.76 (t, 1H, 
NH2CHCO2H, J = 6.3 Hz), 3.34-3.21 (m, 2H, CCH2CO), 3.14 (t, 2H, NHCH2CH2, J = 6.9 
Hz), 2.79-2.74 (m, 12H, 3 x CH2CH2CO), 2.51 (t, 2H, NHCOCH2, J = 6.6 Hz), 1.90-1.83 
(m, 2H, CHCH2CH2), 1.55-1.47 (m, 2H, NHCH2CH2CH2), 1.45-1.33 (m, 2H, 
CHCH2CH2CH2).  13C NMR, D2O, 100 MHz:    175.6 (d, NCOCH2, J = 8.7 Hz), 175.5 (d, 
3 x CH2CO2H, J = 11.8 Hz), 174.5 (CHCO2H), 172.8 (NHCOCH2), 172.7 (d, NCOC, J = 
3.4 Hz), 54.4 (NH2CHCO2H), 39.0 (NHCH2CH2), 36.4 (NCH CH2), 34.0 (m, COCCH2), 
33.2 (COCH2CH2), 29.9 (CHCH2CH2), 29.5 (COCH2C), 27.8 (NHCH2CH2CH2), 26.9 (d, 3 x 
CH2CH2CO2H, J = 3.8 Hz), 21.7 (CHCH2CH2CH2), 15.0 (d, PCH2CH2, J = 49.5 Hz). 31P 
NMR, D2O, 162 MHz:    38.9.  HRMS: Expected for C22H33N3O11P1 (M-H+) = m/z 
546.1858. Found: m/z 546.1864.  Infrared (KBr):  3456, 1708, 1642 cm-1.  HPLC: 
column:  Phenomenex Luna-C18 (250 x 4.60 mm), gradient elution:  (0.7 mL/min) 
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100 % water containing 0.1 % TFA  100 % MeCN over 16 minutes, retention time, 
11.68 mins, purity,  87%). Detection at 225 nm. 
Synthesis of 3,3',3''-[(1-ethyl-2,5-dioxopyrrolidin-3-ylidene, 4-deutero)-
5-phosphanetriyl]tripropanoic acid (2.14). 
 
N-Ethyl maleimide (2.8, 10.0 mg, 0.0800 mmol) and TCEP (2.6, 0.9 eq., 20.6 mg, 
0.0719 mmol) was dissolved in THF (1 mL) and argon purged deuterated aqueous 
sodium phosphate (0.1 M, pH = 7.0, 9 mL) and stirred under argon at room 
temperature for 1 hour. The reaction was concentrated in vacuo to 3 mL and then 
loaded onto a C-18 column for purification (100 % H2O  20 % MeCN/H2O) to yield 
2.14 as a pale yellow sticky solid (21.4 mg, 79 %).  1H NMR, D2O, 400 MHz:    3.54 
(q, 2H, NCH2CH3, J = 7.3 Hz), 3.26-3.14 (m, 1H, CCHDCO), 2.89-2.77 (m, 12H, 3 x 
CH2CH2CO2H), 1.10 (t, 3H, CH2CH3, J = 7.3 Hz).  13C NMR, D2O, 125 MHz:    176.0 (d, 
NCOCHD, J = 8.8 Hz), 174.2 (d, CH2CO2H, J = 11.8 Hz), 173.0 (d, NCOC, J = 3.5 Hz), 
35.0 (NCH2CH3), 33.6 (m, COCCHD), 29.2 (m, COCHDC), 25.8 (d, 3 x CH2CH2CO2H, J = 
4.0 Hz), 14.4 (d, 3 x CH2CH2CO2H, J = 49.8 Hz), 11.5 (CH2CH3).  31P NMR, D2O, 162 
MHz:   39.2.  HRMS:  Expected for C15H22D1N1O8P1 (M+H+) = m/z 377.1219.  Found: 
m/z 377.1222.  Infrared (KBr): 3439, 1705 cm-1.  HPLC:  column:  Phenomenex Luna-
C18 (250 x 4.60 mm), gradient elution (0.7 mL/min), water containing 0.1 % TFA  
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100 % MeCN over 16 minutes, retention time, 12.73 mins, purity, 91 %. Detection 
at 225 nm. 
Synthesis of N-ethyl succinimide (2.15). 
 
A solution of THPP (2.7, 0.9 eq., 29.9 mg, 0.144 mmol) was prepared in THF (1 mL) 
and argon purged aqueous sodium phosphate (0.1 M, pH = 7.0, 9 ml). N-Ethyl 
maleimide (2.8, 20.0 mg, 0.160 mmol) was added slowly to the rapidly stirring 
solution of THPP. The reaction was left to stir for 30 minutes at room temperature. 
A further 0.1 eq. of THPP was added and left to stir for an additional 30 minutes. 
The reaction was diluted with 25 mL of diethyl ether and extracted with water (30 
mL). The aqueous layer was extracted with diethyl ether (2 x 30 mL). The organic 
extraction layers were combined and dried using MgSO4. The mixture was filtered 
and the organic solution was concentrated (550 mbar, 25 °C). The crude was 
purified by silica gel chromatography (CH2Cl2  2 % acetone/CH2Cl2) to yield 2.15 
as a clear oil (12.4 mg, 61 %). Spectral data was consistent with that reported in the 
literature [189].  1H NMR, CDCl3, 400 MHz:    3.46 (q, 2H, NCH2CH3, J = 7.2 Hz), 2.61 
(s, 4H, 2 x COCH), 1.07 (t, 3H, CH2CH3, J = 7.2 Hz).  13C NMR, CDCl3, 100 MHz:   
177.0 (2 x NCOCH), 33.5 (NCH2CH3), 28.0 (2 x COCH), 12.8 (CH2CH3).  HRMS:  




Synthesis of N6-[3-(2,5-dioxopyrrolidin-1-yl)propanoyl]-L-lysine (2.16). 
 
Compound 2.11 (10.0 mg, 0.0336 mmol) and THPP (2.7, 0.9 eq., 6.30 mg, 0.0303 
mmol) was dissolved in 1 mL of argon purged aqueous sodium phosphate (0.1 M, 
pH = 7). The reaction was stirred, under argon, and at room temperature for 1 hour. 
The reaction was the subsequently purified by C-18 chromatography (100 % water 
 20 % MeCN/water). The product was lyophilised to give 2.16 as a white 
amorphous solid (5.35 mg, 59 %). 1H NMR, D2O, 400 MHz:    3.77-3.69 (m, 3H, 
NCH2CH2 & NH2CHCO2H), 3.14 (t, 2H, NHCH2CH2, J = 6.8 Hz), 2.77 (s, 4H, 
COCH2CH2CO), 2.46 (t, 2H, NHCOCH2CH2, J = 6.8 Hz), 1.91-1.83 (m, 2H, CHCH2CH2), 
1.55-1.43 (m, 2H, NHCH2CH2CH2), 1.41-1.33 (m, 2H, CHCH2CH2CH2).  13C NMR, D2O, 
100 MHz:    181.11 (2 x NCOCH), 174.72 (CHCO2H), 173.22 (NHCOCH2), 54.65 
(NH2CHCO2H), 38.99 (NHCH2CH2), 35.47 (NCH2CH2CO), 33.79 (COCH2CH2), 30.02 
(CHCH2CH2), 27.98 (2 x COCH), 27.84 (NHCH2CH2CH2), 21.73 (CHCH2CH2CH2).  
Expected for C13H20N3O5 (M-H+) = m/z 298.1408. Found: m/z 298.1412.  Infrared 
(KBr): 3447, 1696 cm-1.  HPLC: column:  Phenomenex Luna-NH2 (250 x 4.60 mm), 
gradient elution:  (1.0 mL/min) 10 % MeCN in water containing 0.1 % TFA  100 % 





Synthesis of 1-ethyl-3-dideutero-(4R,S)-deutero-pyrrolidine-2,5-dione 
(2.17). 
 
A solution of THPP (2.7, 0.9 eq., 29.9 mg, 0.144 mmol) was prepared in THF (1 mL) 
and purged deuterated aqueous sodium phosphate (0.1 M, pH = 7.0, 9 ml). N-Ethyl 
maleimide (2.8, 20.0 mg, 0.160 mmol) was added slowly to the rapidly stirring 
solution of THPP. The reaction was left to stir for 30 minutes at room temperature. 
A further 0.1 eq. of THPP was added and left to stir for an additional 30 minutes. 
The reaction was diluted with 25 mL of diethyl ether and extracted with water (30 
mL). The aqueous layer was extracted with diethyl ether (2 x 30 mL). The organic 
extraction layers were combined and dried using MgSO4. The mixture was filtered 
and the organic solution was concentrated (550 mbar, 25 °C). The crude was 
purified by silica gel chromatography (CH2Cl2  2 % acetone/CH2Cl2) to yield 2.17 
as a clear oil (10.8 mg, yield: 52 %). 1H NMR, CDCl3, 400 MHz:    3.50 (q, 2H, 
NCH2CH3, J = 7.2 Hz), 2.62 (br. s, 1H, COCHDCD2), 1.10 (t, 3H, CH2CH3, J = 7.2 Hz).  
13C NMR, CDCl3, 100 MHz:    177.1 (2 x NCO), 33.5 (NCH2CH3), 27.7 (m, 
COCHDCD2CO), 12.9 (CH2CH3).  ESI-HRMS: Expected for C6H6D3N1O2 (M+Na+) = m/z 
153.0714.  Found: m/z 153.0704.  Infrared (thin film): 1695 cm-1.  HPLC: column:  
Phenomenex Luna-NH2 (250 x 4.60 mm), gradient elution:  (1.0 mL/min) 10 % 
MeCN in water containing 0.1 % TFA  100 % MeCN over 20 minutes, retention 
time, 2.90 mins, purity 99 %. Detection at 225 nm. 
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Synthesis of 3,3'-{5-oxo-2-[2-(phenylsulfonyl)ethyl]-1,2 5-
oxaphospholane-2,2-diyl}dipropanoic acid (2.20). 
 
Phenyl vinyl sulfone (2.18, 10.0 mg, 0.0594 mmol) and TCEP (2.6, 0.9 eq., 15.3 mg, 
0.0535 mmol) was dissolved in THF (2 mL) and argon purged aqueous sodium 
phosphate (0.1 M, pH = 7.0, 8 ml) and stirred under argon at room temperature for 
1 hour. The reaction was concentrated in vacuo to 3 mL and then loaded onto a C-
18 column for purification (100 % H2O  40 % MeCN/H2O) to yield 2.20 as a white 
solid (18.8 mg, 84 %).    1H NMR, D2O, 400 MHz:  7.95-7.67 (m, 5H, Ar-H), 3.72 (m, 
2H, SCH2CH2), 2.74-2.66 (m, 2H, SCH2CH2), 2.63-2.54 (m, 12H, 3 x CH2CH2CO).  13C 
NMR, D2O, 100 MHz:    175.3 (d, 3 x CH2 CO2H, J = 12.7 Hz), 135.45 (ipso -C & para 
Ar-C), 130.0 & 128.09 (4C, ortho & meta Ar-C), 47.2 (SCH2CH2), 26.5 (d, 3 x 
CH2CH2CO2, J = 3.8 Hz), 14.6 (d, 3 x CH2CH2CO2, J = 50.1 Hz), 13.5 (d, PCH2CH2, J = 
49.3 Hz).  31P NMR, D2O, 162 MHz:    37.7.  HRMS:  Expected for C17H22O8P1S1 (M-
H+) = m/z 417.0778.  Found: m/z 417.0797.  Melting point: 115 C.  Infrared (KBr):  
3427, 2925, 1721, 1419, 1153 cm-1.  HPLC: column:  Phenomenex Luna-C18 (250 x 
4.60 mm), gradient elution:  (0.7 mL/min) 10 % MeCN in water containing 0.1 % TFA 
 100 % MeCN over 20 minutes, retention time, 12.43 mins., purity, 97 %. 
Detection at 280 nm. 
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Reaction of THPP with vinyl sulfone: a thiol-alkylating functional group. 
 
Phenyl vinyl sulfone (2.18, 10.0 mg, 0.0594 mmol) and THPP (2.7, 0.9 eq., 11.1 mg, 
0.0535 mmol) was dissolved in THF (2 mL) and argon purged aqueous sodium 
phosphate (0.1 M, pH = 7.0, 8 mL) and stirred under argon at room temperature for 
1 hour. The reaction was concentrated in vacuo to 3 mL and then loaded onto a C-
18 column for purification (100 % H2O  80 % MeCN/H2O). No product could be 
isolated for characterisation. 
Reaction of the TCEP-maleimide adduct 2.9 with thiols. 
At pH = 4. N-Ethyl maleimide (2.8, 3.9 mg, 0.032 mmol) was dissolved in argon 
purged deuterated aqueous citric acid/sodium phosphate (0.5 mL, 0.1 M, pH = 4). 
TCEP (2.6, 1 eq., 9.05 mg, 0.032 mmol) was added and the reaction was incubated 
at room temperature for 1 hour. The TCEP-maleimide adduct 2.9 was evident by 31P 
NMR ( 38.9). Reduced glutathione (2.21, 1.5 eq., 14.6 mg, 0.047 mmol) was added 
and the reaction was left at room temperature overnight. The reaction was 
monitored by 31P NMR. The  38.90 ppm signal for 2.9 was still evident, with no 
appearance of new peaks in the spectrum. 
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At pH = 7. N-Ethyl maleimide (2.8, 8.0 mg, 0.064 mmol) was dissolved in argon 
purged aqueous sodium phosphate (1.0 mL, 0.1 M, pH = 7.0). TCEP (2.6, 1 eq., 18.3 
mg, 0.064 mmol) was added and the reaction was incubated at room temperature 
for 1 hour. Reduced glutathione (2.21, 1.2 eq., 23.6 mg, 0.077 mmol) was added 
and the reaction was stirred at room temperature overnight. The reaction was 
monitored by HRMS. No glutathione-maleimide product was evident. The TCEP-
maleimide adduct 2.9 (m/z 374.1040 (M-H+)) was still visible as well as unreacted 
glutathione (m/z 306.0787 (M-H+)). 
At pH = 8. N-Ethyl maleimide (2.8, 4.0 mg, 0.032 mmol) was dissolved in argon 
purged, deuterated aqueous sodium phosphate (0.5 mL, 0.1 M, pH = 8.0). TCEP 
(2.6, 1 eq., 9.2 mg, 0.032 mmol) was added and the reaction was incubated at room 
temperature for 1 hour. Reduced glutathione (2.21, 1.5 eq., 14.7 mg, 0.048 mmol) 
was added and the reaction was left at room temperature overnight. The reaction 
was monitored by 31P NMR. No change of the   38.90 ppm signal for 2.9 was 
evident. 
The effect of not removing TCEP or THPP prior to maleimide PEGylation 
of a model protein. 
Yeast enolase (1 mg/mL, Sigma Aldrich) was denatured in argon purged buffer (0.5 
M Tris, pH = 7.2, 5 mM EDTA) containing 8 M urea at 85 C for 15 minutes. The 
solution was allowed to cool to room temperature before aliquoting out 100 L 
samples for the experiments. Varying concentrations of TCEP or THPP (1-10 mM) 
were added to aliquots of protein solution (11 M) and incubated for 45 minutes at 
25 C. Maleimide-PEG2kDa (1 mM) was subsequently added and the reaction was 
incubated at 37 C for 18 hours. Samples (15 L) were taken from each of the 
reactions and added to Laemmli sample buffer (15 L). Aliquots (9 L) of these 
solutions were loaded into a precast gradient gel (4-12 % Bis-Tris, Invitrogen) along 
with a protein ladder (EZ-Run, Fisher Scientific) and resolved by SDS Page 
electrophoresis [MOPS running buffer (Invitrogen), 180 V, 60 mins]. The precast 
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gels were stained by Coomassie solution and destained using a 
water/ethanol/acetic acid (16:3:1) solution. 
Synthesis of N-(5-isocyanatopentyl)maleimide (2.23). 
 
6-Maleimidohexanoic acid (2.22, 0.25 g, 1.18 mmol) was dissolved in anhydrous 
THF (4 mL) containing triethylamine (0.3 mL). Diphenylphosphoryl azide (0.38 mL, 
1.76 mmol) was added and the reaction was stirred at room temperature for 2 
hours. Anhydrous toluene (100 mL) was subsequently added and the solution was 
concentrated to a volume of 5 mL. The solution was heated at 70 C for 2 hours and 
then allowed to cool back to room temperature. The solution was loaded directly 
onto a silica gel column for purification: 100 % petroleum ether  30 % 
EtOAc/petroleum ether to yield 2.23 as a transparent oil (125.7 mg, 51 %). Spectral 
data was consistent with that reported in the literature [190].  1H NMR CDCl3, 400 
MHz:    6.69 (s, 2H, COCHCHCO), 3.52 (t, 2H, NCH2CH2, J = 7.2 Hz), 3.29 (t, 2H, 
CH2CH2NCO, J = 6.7 Hz), 1.66-1.58 (m, 4H, NCH2CH2 & CH2CH2CH2NCO), 1.42-1.37 
(m, 2H, CH2CH2CH2NCO).  13C NMR CDCl3, 100 MHz:    170.78 (2 x COCH), 134.05 (2 
x COCH), 121.89 (CH2NCO), 42.69 (CH2NCO), 37.44 (NCH2CH2), 30.57 & 27.82 
(CHCONCH2CH2 & OCNCH2CH2CH2), 23.62 (OCNCH2CH2CH2).  ESI-MS: Expected for 
C10H12N2Na1O3 (M+Na+) = m/z 231.0740. Found m/z 231.0739. Infrared (thin film):  






Synthesis of Pn6B-maleimide (2.24). 
 
Pn6B (10 mg, LGC Standards) was added to 2 mL of water and stirred at room 
temperature until the carbohydrate until dissolved. The viscous solution was then 
loaded onto an ion exchange column (Dowex 50W x 4, 200 mesh, 
tetrabutylammonium form) and incubated for 30 minutes before allowing elution. 
The fractions containing carbohydrate were pooled and subsequently freeze dried 
to yield a white solid. The solid was added to 4 mL of anhydrous DMSO and stirred 
at 30 °C under N2 overnight to dissolve the carbohydrate. An anhydrous DMSO 
solution (0.5 mL) of 2.23 (3 mg) was added to the carbohydrate solution and 
allowed to stir for 2 hours at room temperature. The solution was transferred to a 
dialysis bag (12-14 KDa cut-off) and dialysed against 5 litres of 0.1 M aqueous 
sodium phosphate (pH = 7), followed by 5 litres of 0.01 M aqueous sodium 
phosphate (pH = 7), and finally 5 litres of water. The solution within the dialysis bag 
was frozen and lyophilised to yield 6 mg of white solid (2.24). A portion of product 





1H NMR spectrum of Pn6B-maleimide (2.24). 
 
31P NMR spectrum of Pn6B-maleimide. 
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Synthesis of Pn6B-maleimide-TCEP adduct. 
Control: Maleimide functionalised Pn6B (1.0 mg) was dissolved in D2O (0.45 mL) 
and analysed by 31P NMR spectroscopy. 31P NMR, D2O, 162 MHz:    -0.08. 
Experiment: Maleimide functionalised Pn6B (1.0 mg) was dissolved in water (1 mL) 
containing TCEP (2.0 mg). The reaction was incubated at room temperature for 1 
hour then purified using a PD-10 desalting column. The fractions containing 
carbohydrate were pooled and lyophilised. The lyophilised powder was redissolved 
in D2O and analysed by 31P NMR spectroscopy. 31P NMR, D2O, 162 MHz:    -0.08 & 
38.4. 
 






Synthesis of 1,14-diazido-3,6,9,12-tetraoxatetradecane (3.3). 
 
Penta(ethylene glycol)di-p-toluenesulfonate (3.16, 2.0 g, 3.66 mmol) was dissolved 
in anhydrous DMF (15 mL). Sodium azide (4 eq., 0.95 g, 14.6 mmol) was added and 
the reaction was stirred at 80 C, under argon for 6 hours. The reaction was allowed 
to cool to room temperature and then filtered. The organic solution was 
concentrated and then resuspended in ethyl acetate (200 mL). The solution was 
washed with saturated NaHCO3 solution (100 mL) and then saturated brine solution 
(50 mL). The organic layer was dried over MgSO4, filtered and concentrated to yield 
the crude material. This was purified by silica gel chromatography: 10 % EtOAc/Pet. 
ether  60 % EtOAc/Pet. Ether) to give 3.3 as a colourless oil (0.89 g, 84 %). 
Experimental data was consistent with that reported in the literature [191].  1H 
NMR, CDCl3, 400 MHz:    3.67-3.64 (m, 16H, 4 x CH2OCH2), 3.37 (t, 4H, 2 x N3CH2, J 
= 5.0 Hz).  13C NMR, CDCl3, 100 MHz:    70.61, 70.59, 70.53, 69.94 (N3CH2CH2), 
50.59 (N3CH2CH2).  ESI-HRMS: Expected for C10H21N6O4 (M+H+) = m/z 289.1619.  









Synthesis of ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate 
(3.7a) after TCEP reduction. No addition of alkyl azide 3.3. 
 
L-Cysteine ethyl ester hydrochloride salt (3.2, 10.0 mg, 0.0539 mmol) was dissolved 
in deoxygenated aqueous sodium phosphate (1 M, pH = 7.0, 1 mL) and stirred 
under argon at room temperature. TCEP (3 eq., 46.3 mg, 0.162 mmol) was added to 
the stirring solution and left to stir for 30 minutes. N-Ethyl maleimide (2.8, 1.2 eq., 
8.1 mg, 0.0646 mmol) was subsequently added and the reaction was stirred for 30 





Mass spectra of synthesis of ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-
cysteinate (3.7a). 
Synthesis of ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate 
(3.7a) after TCEP reduction. Addition of alkyl azide 3.3. 
 
L-Cysteine ethyl ester hydrochloride salt (3.2, 10.0 mg, 0.0539 mmol) was dissolved 
in deoxygenated aqueous sodium phosphate (1 M, pH = 7.0, 1 mL) and stirred 
under argon at room temperature. TCEP (3 eq., 46.3 mg, 0.162 mmol) was added to 
the stirring solution and left to stir for 30 minutes. The alkyl azide 3.3 (3 eq., 46.6 
M+H+ (3.7a) M-H+ (2.6) 
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mg, 0.162 mmol) was added and the reaction was stirred rapidly for 30 minutes. N-
Ethyl maleimide (2.8, 1.2 eq., 8.09 mg, 0.0646 mmol) was subsequently added and 
the reaction was stirred for 30 minutes. The reaction was analysed by HRMS. 
 















Synthesis of ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate 
(3.7a) after THPP reduction. No addition of alkyl azide 3.3. 
 
L-Cysteine ethyl ester hydrochloride salt (10.0 mg, 0.0539 mmol) was dissolved in 
deoxygenated aqueous sodium phosphate (1 M, pH = 7.0, 1 mL) and stirred under 
argon at room temperature. THPP (3 eq., 33.7 mg, 0.162 mmol) was added to the 
stirring solution and left to stir for 30 minutes. N-Ethyl maleimide (2.8, 1.2 eq., 8.09 
mg, 0.0646 mmol) was subsequently added and the reaction was stirred for 30 

















Synthesis of ethyl S-[(3R,S)-1-ethyl-2,5-dioxopyrrolidin-3-yl]-L-cysteinate 
(3.7a) after THPP reduction. Addition of alkyl azide 3.3. 
 
L-Cysteine ethyl ester hydrochloride salt (10.0 mg, 0.0539 mmol) was dissolved in 
deoxygenated aqueous sodium phosphate (1 M, pH = 7.0, 1 mL) and stirred under 
argon at room temperature. THPP (3 eq., 33.6 mg, 0.162 mmol) was added to the 
stirring solution and left to stir for 30 minutes. The alkyl azide 3.3 (3 eq., 46.6 mg, 
0.162 mmol) was added and the reaction was stirred rapidly for 30 minutes. N-Ethyl 
maleimide (2.8, 1.2 eq., 8.1 mg, 0.0646 mmol) was subsequently added and the 



















cysteinate (3.7b) after TCEP reduction. No addition of alkyl azide 3.3. 
 
N-Acetyl-L-cysteine methyl ester (20.0 mg, 0.113 mmol) was dissolved in 
deoxygenated THF (2 mL) and Tris buffer (500 mM, pH = 7.2, 8 mL) and stirred 
under argon at room temperature. TCEP (5 eq., 161.8 mg, 0.564 mmol) was added 
to the stirring solution and left to stir for 30 minutes. N-Ethyl maleimide (2.8, 1.1 
eq., 15.5 mg, 0.124 mmol) was subsequently added and the reaction was stirred for 
1 hour. The reaction was extracted with diethyl ether (2 x 30 mL). The organic layer 
was dried (MgSO4), filtered and concentrated. The residue was purified by silica gel 
chromatography: 10 % EtOAc/petroleum ether  70 % EtOAc/petroleum ether to 
yield (3.7b) as a white solid (9.8 mg, 27 %).  1H NMR, CDCl3, 400 MHz:  
Diastereomeric mixture:    7.03 (br. d, 1H, NH, J = 7.8 Hz), 6.57 (br. d, 1H, NH, J = 
7.7 Hz), 4.89 (m, 2H, 2 x NHCHCO2), 3.88 (dd, 1H, COCHCH2CO, J = 3.9 & 9.1 Hz), 
3.75-3.72 (m, 7H, COCHCH2CO, 2 x OCH3), 3.57-3.42 (m, 6H, 2 x NCH2CH3, 2 x 
CHCHHS), 3.16-3.06 (m, 4H, 2 x CHCHHS, 2 x COCHHCHCO), 2.49-2.37 (m, 2H, 2 x 
COCHHCHCO), 2.04 (s, 3H, NHCOCH3), 2.03 (s, 3H, NHCOCH3), 1.16-1.12 (m, 6H, 2 x 
CH2CH3).  13C NMR, CDCl3, 100 MHz:   176.7, 176.5, 174.1, 173.9, 171.1, 170.9, 
170.1, 170.0, 52.8, 52.7, 52.2, 51.2, 40.1, 38.6, 36.3, 35.6, 34.8, 34.1, 34.0, 33.9, 
23.0, 22.9. ESI-HRMS: Expected for C12H18N2O5S1 (M+Na+) = m/z 325.0829.  Found: 




cysteinate (3.7b) after TCEP reduction. Addition of alkyl azide 3.3. 
 
N-Acetyl-L-cysteine methyl ester (20.0 mg, 0.113 mmol) was dissolved in 
deoxygenated THF (2 mL) and Tris buffer (500 mM, pH = 7.2, 8 mL) and stirred 
under argon at room temperature. TCEP (5 eq., 162.7 mg, 0.565 mmol) was added 
to the stirring solution and left to stir for 30 minutes. The alkyl azide 3.3 (10 eq., 
327 mg, 1.14 mmol) was added and the reaction was stirred rapidly for 1 hour at 
room temperature. N-Ethyl maleimide (2.8, 1.1 eq., 15.5 mg, 0.124 mmol) was 
subsequently added and the reaction was stirred for 1 hour at room temperature. 
The reaction was extracted with diethyl ether (2 x 30 mL). The organic layer was 
dried (MgSO4), filtered and concentrated to dryness. The residue was purified by 
silica gel chromatography (10 % EtOAc/petroleum ether  70 % EtOAc/petroleum 
ether) to yield 3.7b as a white solid (25.4 mg, 74 %). The aqueous layer was purified 
by C-18 chromatography (100 % H2O  30 % MeOH/H2O) to yield 3.6 as a 
transparent oil (116.9 mg, 79 %). Experimental data was consistent with that 
reported in the literature [192].  1H NMR, CD3OD, 400 MHz:    3.76 (t, 2H, 
NH2CH2CH2, J = 5.1 Hz), 3.70 (m, 14H, 7 x CH2), 3.44 (t, 2H, N3CH2, J = 4.8 Hz), 3.16 (t, 
2H, NH2CH2, J = 5.1 Hz).  13C NMR, CD3OD, 100 MHz:    71.45, 71.41, 71.36, 71.35, 
71.10, 70.97, 67.97 (NH2CH2CH2), 51.77 (N3CH2), 40.68 (NH2CH2).  ESI-HRMS: 





cysteinate (3.7b) after THPP reduction. No addition of alkyl azide 3.3. 
 
N-Acetyl-L-cysteine methyl ester (20.0 mg, 0.113 mmol) was dissolved in 
deoxygenated THF (2 mL) and Tris buffer (500 mM, pH = 7.2, 8 mL) and stirred 
under argon at room temperature. THPP (5 eq., 118.2 mg, 0.568 mmol) was added 
to the stirring solution and left to stir for 30 minutes. N-Ethyl maleimide (2.8, 1.1 
eq., 15.5 mg, 0.124 mmol) was subsequently added and the reaction was stirred for 
1 hour. The reaction was extracted with diethyl ether (2 x 30 mL). The organic layer 
was dried (MgSO4), filtered and concentrated to dryness. The crude material was 
purified by silica gel chromatography: 10 % EtOAc/petroleum ether  70 % 









cysteinate (3.7b) after THPP reduction. Addition of alkyl azide 3.3. 
 
N-Acetyl-L-cysteine methyl ester (20.0 mg, 0.113 mmol) was dissolved in 
deoxygenated THF (2 mL) and Tris buffer (500 mM, pH = 7.2, 8 mL) and stirred 
under argon at room temperature. THPP (5 eq., 118.2 mg, 0.568 mmol) was added 
to the stirring solution and left to stir for 30 minutes. The alkyl azide 3.3 (10 eq., 
327.2 mg, 1.14 mmol) was added and the reaction was stirred rapidly for 1 hour at 
room temperature. N-Ethyl maleimide (2.8, 1.1 eq., 15.5 mg, 0.124 mmol) was 
subsequently added and the reaction was stirred for 1 hour at room temperature. 
The reaction was extracted with diethyl ether (2 x 30 mL). The organic layer was 
dried (MgSO4), filtered and concentrated to dryness. The residue was purified by 
silica gel chromatography (10 % EtOAc/petroleum ether  70 % EtOAc/petroleum 
ether) to yield 3.10 as a white solid (23.8 mg, 69 %). The aqueous layer was purified 
by C-18 chromatography (100 % H2O  30 % MeOH/H2O) to yield 3.6 as a 
transparent oil (105.7 mg, 71 %). 
Investigating the potential reaction of maleimide with alkyl azide 3.3. 
N-Ethyl maleimide (2.8, 5.0 mg, 0.0400 mmol) and the alkyl azide 3.3 (11.5 mg, 
0.400 mmol) were dissolved in deuterium oxide (450 L). The solution was 
immediately analysed by NMR spectroscopy. No reaction between the reagents 
was detected. The solution was left at room temperature for 16 hours then 
analysed by NMR spectroscopy. New peaks were detected in the NMR spectrum to 

























1,14-diazido-3,6,9,12-tetraoxatetradecane (3.3, 50.0 mg, 0.173 mmol) and N-ethyl 
maleimide (2.8, 1.5 eq., 32.6 mg, 0.260 mmol) were stirred in aqueous sodium 
phosphate (0.1 M, pH = 7.0, 2 mL) at room temperature for 2.5 days. The reaction 
was diluted with water (20 mL) and extracted with ethyl acetate (2 x 50 mL). The 
organic layer was dried over MgSO4, filtered and concentrated. The crude was 
purified by silica gel chromatography: 10 % EtOAc/petroleum ether  60 % 
EtOAc/petroleum ether to yield 3.8 as a transparent oil (30.1 mg, 42 %) and 3.9 as a 
transparent oil (23.4 mg, 25 %). Compound 3.8:  1H NMR, CDCl3, 400 MHz:    5.49 
(d, 1H, NCOCHNCH2, J = 11.0 Hz), 4.62 (d, 1H, NCOCHN2, J = 11.0 Hz), 4.15-4.09 (dt, 
1H, NCHHCH2O, J = 4.5 & 15.1 Hz), 4.00-3.93 (ddd, 1H, NCHHCH2O, J = 3.9, 7.9 & 
14.8 Hz), 3.86-3.81 (m, 1H, NCH2CHHO), 3.78-3.72 (m, 1H, NCH2CHHO), 3.65-3.55 
(m, 14H), 3.50 (q, 2H, NCH2CH3, J = 7.2 Hz), 3.36 (t, 2H, CH2CH2N3, J = 5.2 Hz), 1.11 
(t, 3H, CH2CH3, J = 7.2 Hz).  13C NMR, CDCl3, 100 MHz:    172.2 (NCOCHN2), 170.6 
(NCOCHNCH2), 81.2 (NCOCHNCH2), 70.58, 70.54, 70.41, 70.38, 70.32, 70.12, 69.87, 
69.1 (NCH2CH2O), 58.5 (NCOCHN2), 50.5 (CH2CH2N3), 48.1 (NCH2CH2O), 34.1 
(NCH2CH3), 12.7 (CH2CH3).  ESI-HRMS: Expected for C16H27N7Na1O6 (M+Na+) = m/z 
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436.1915.  Found: m/z 436.1946. Infrared (thin film):  2107, 1714 cm-1.  HPLC: 
column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % 
MeCN in water  100 % MeCN over 20 minutes, retention time, 13.50 mins., 
purity, 98.3 %). Detection at 254 nm.  Compound 3.9:  1H NMR, CDCl3, 400 MHz:    
5.55 (d, 1H, COCHNCH2, J = 11.0 Hz), 5.54 (d, 1H, COCHNCH2, J = 11.0 Hz), 4.67 (d, 
1H, COCHN2,J = 11.0 Hz) & 4.66 (d, 1H, COCHN2, J = 11.0 Hz), 4.19-4.12 (m, 2H, 2 x 
NCHHCH2O), 4.02-3.94 (m, 2H, 2 x NCHHCH2O), 3.89-3.83 (m, 2H, 2 x NCH2CHHO), 
3.80-3.74 (m, 2H, 2 x NCH2CHHO), 3.68-3.56 (m, 12H), 3.53 (q, 4H, 2 x NCH2CH3, J = 
7.2 Hz), 1.14 (t, 6H, 2 x CH2CH3, J = 7.2 Hz).  13C NMR, CDCl3, 100 MHz:    172.41 & 
172.39 (2 x NCOCHN2), 170.79 & 170.73 (2 x NCOCHNCH2), 81.34 & 81.33 (2 x 
COCHNCH2), 70.49, 70.36, 70.08, 69.21 & 69.06 (2 x NCH2CH2O), 58.62 & 58.59 (2 x 
NCOCHN2), 48.14 & 48.12 (2 x NCH2CH2O), 34.24 (2 x NCH2CH3), 12.76 (2 x CH2CH3).  
ESI-HRMS: Expected for C22H34N8Na1O8 (M+Na+) = m/z 561.2392.  Found: m/z 
561.2365. Infrared (thin film): 1714 cm-1.  HPLC:  column:  Waters Symmetry Shield 
RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN 
over 20 minutes (retention time, 13.53 mins., purity, 99.4 %. Detection at 254 nm. 
Reaction of N-ethyl maleimide with glutathione in a deuterated buffer 
to generate 3.10. 
 
N-Ethyl maleimide (2.8, 1 mM) was dissolved in deuterated phosphate buffer (0.5 
M, pH = 7.2) and analysed by 1H NMR spectroscopy to identify the singlet at  7 
ppm representing the alkene protons of the maleimide ring. Reduced glutathione 
(2.21, 1 mM), was added to the solution and immediately analysed by 1H NMR 
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spectroscopy. The 1H NMR spectrum showed complete disappearance of the singlet 
representing the maleimide alkene protons, confirmation of a rapid reaction 
between N-ethyl maleimide (2.8) and glutathione (2.21). The thiol alkylated peptide 
3.10 was also confirmed by HRMS (m/z 433.1381 (M-H+)). 
 
Mass spectrum of reaction of glutathione (2.21) with N-ethyl maleimide (2.8) in a 










Reaction of glutathione (2.21) with N-ethyl maleimide (2.8) in the 
presence of alkyl azide 3.3 to generate 3.10. 
 
Reduced glutathione (2.21, 1 mM) was dissolved in deuterated aqueous phosphate 
(0.5 M, pH = 7.2, 1 mL), containing alkyl azide (3.3, 50 mM). N-Ethyl maleimide (2.8, 
1 mM) was subsequently added and the reaction was immediately analysed by 1H 
NMR spectroscopy. The 1H NMR spectrum showed complete disappearance of the 
singlet representing the maleimide alkene protons. There was no evidence in the 
NMR spectrum of a pair of doublets at    4.68 and  5.61 ppm with coupling 
constants of 11 Hz, which would be a positive indication of triazoline formation. 
This evidence was verified by HRMS analysis. The positive identification of 3.10 (m/z 
433.1375 (M-H+)) and the absence of any peaks in the HRMS spectrum representing 










Mass spectrum of reaction containing glutathione (2.21), alkyl azide 3.3 and N-ethyl 
maleimide (2.8). 
NMR experiment to determine the rate of triazoline formation with 
maleimide derivatives. 
Either N-ethyl maleimide (2.8, 1 mM) or maleimide-PEG2kDa (1 mM) was dissolved 
in deuterated phosphate buffer (0.5 M, pH = 7.2, 1 mL) containing alkyl azide 3.3 
(100 mM). The reaction was monitored by 1H NMR spectroscopy at room 
temperature. The reaction was monitored through the consumption of maleimide 
(diminishing singlet representing the alkene protons) and the appearance of 








The alkyl azide 3.3 (0.11 g, 0.38 mmol) was dissolved in THF/H2O (2:8, 10 mL). 
Phenyl vinyl sulfone (2.18, 2 eq., 0.128 g, 0.763 mmol) was added and the reaction 
was stirred at room temperature for 4 days. The reaction was concentrated and 
purified silica gel chromatography: 10 % EtOAc/petroleum ether  60 % 
EtOAc/petroleum ether to yield 3.11 as a transparent oil (0.10 g, 59 %).  1H NMR, 
CDCl3, 400 MHz:    7.98-7.55 (m, 5H, Ar-H), 5.59 (dd, 1H, SCHCH2, J = 7.6 & 13.0 
Hz), 4.06 (dd, 1H, SCHCHH, J = 7.6 & 13.0 Hz), 3.80 (t, 2H, CH2CH2N3, J = 5.0 Hz), 
3.71-3.62 (m, 17H, SCHCHH & 8 x CH2), 3.37 (t, 2H, CH2NCH2, J = 5.2 Hz).  13C NMR, 
CDCl3, 100 MHz:    136.21 (ipso-Ar-C), 134.36 (para-Ar-C), 129.60 (2 x ortho-Ar-C), 
129.04 (2 x meta-Ar-C), 93.58 (SCHCH2), 70.64, 70.58, 70.54, 70.47, 69.95, 69.65, 
50.62 (CH2NCH2), 49.61 (OCH2CHHN3), 46.22 (SCHCH2N).  ESI-HRMS: Expected for 
C18H29N6O6S1 (M+H+) = m/z 457.1864.  Found: m/z 457.1907.  Infrared (thin film):  
2872, 2111, 1447 cm-1.  HPLC: column:  Waters Symmetry Shield RP8 (100 x 4.60 
mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 








Reaction of phenyl vinyl sulfone (2.18) with glutathione (2.21) in the 
presence of alkyl azide 3.3 to generate 3.12. 
 
Reduced glutathione (2.21, 1 mM) was dissolved with alkyl azide 3.3 (50 mM) in 
deuterated aqueous phosphate (0.5 M, pH = 7.2, 1 mL), followed by the addition of 
phenyl vinyl sulfone (2.18, 1 mM). The reaction was monitored by 1H NMR 
spectroscopy and HRMS. The 1H NMR spectra showed disappearance of the peaks 
representing the vinyl protons, indicating an addition reaction, which was 
confirmed as 3.12 by HRMS (m/z 476.1143 (M-H+)). There was no evidence of 




Mass spectrum of reaction containing glutathione (2.21), alkyl azide 3.3 and phenyl 





Mass spectrum of reaction containing glutathione (2.21), alkyl azide 3.3 and phenyl 
vinyl sulfone (2.18). 
TCEP and THPP oxidation by the alkyl azide 3.3 in bioconjugation 
reactions. 
TCEP (2.6, 10 mM) or THPP (2.7, 10 mM) were incubated with 3.3 (100 mM) in Tris 
buffer (0.5 M, pH = 7.2, 1 mL) at 37 °C. After 30 minutes aliquots of the reactions 









Mass spectrum of TCEP (2.6) incubated with the alkyl azide 3.3. 
 
Mass spectrum of THPP (2.7) incubated with the alkyl azide 3.3. 
Use of alkyl azide 3.3 to oxidise excess TCEP or THPP to ensure high 
protein-maleimide-fluorescein conjugate yields. 
1) Yeast enolase (1 mg/mL) was denatured in argon purged buffer (0.5 M Tris, pH = 
7.2, 5 mM EDTA) containing 8 M urea at 85 C for 15 minutes. The solution was 






experiments. Varying concentrations of TCEP or THPP (1-10 mM) were added to 
aliquots of protein solution (11 M) and incubated for 45 minutes at 25 C. 
Maleimide fluorescein (1 mM) was subsequently added to the reactions with no 
addition of 3.3 and incubated at 37 C for 18 hours. Samples that had addition of 
3.3 (100 mM) required pre-incubation for 1 hour at 37 C. Maleimide- fluorescein (1 
mM) was subsequently added to the reactions and incubated at 37 C for 18 hours. 
Samples (15 L) were taken from each of the reactions and added to Laemmli 
sample buffer (15 L). Aliquots (9 L) of these solutions were loaded into a precast 
gradient gel (4-12 % Bis-Tris, Invitrogen) along with a protein ladder (EZ-Run, Fisher 
Scientific) and resolved by SDS Page electrophoresis [MOPS running buffer 
(Invitrogen), 180 V, 60 mins]. The precast gels were stained by Coomassie solution 
and destained using a water/ethanol/acetic acid (16:3:1) solution. 
2) Sbi was diluted to 1 mg/mL in buffer (0.5 M Tris, pH = 7.2, 5 mM EDTA), followed 
by aliquoting 100 L samples for the experiments. Varying concentrations of TCEP 
or THPP (1-10 mM) were added to aliquots of protein solution (33 M) and 
incubated for 45 minutes at 25 C. Maleimide-fluorescein (1 mM) was subsequently 
added to the reactions with no addition of 3.3 and incubated at 37 C for 18 hours. 
Samples that had addition of 3.3 (100 mM) required pre-incubation for 1 hour at 37 
C. Maleimide fluorescein (1 mM) was subsequently added to the reactions and 
incubated at 37 C for 18 hours. Samples (15 L) were taken from each of the 
reactions and added to Laemmli sample buffer (15 L). Aliquots (9 L) of these 
solutions were loaded into a precast gradient gel (4-12 % Bis-Tris, Invitrogen) along 
with a protein ladder (EZ-Run, Fisher Scientific) and resolved by SDS Page 
electrophoresis [MOPS running buffer (Invitrogen), 180 V, 60 mins]. The precast 
gels were stained by Coomassie solution and destained using a 




Addition of the alkyl azide 3.3 to oxidise TCEP/THPP to ensure high 
yeast protein-PEG2kDa conjugate yields. 
1) Yeast enolase (1 mg/mL) was denatured in argon purged buffer (0.5 M Tris, pH = 
7.2, 5 mM EDTA) containing 8 M urea at 85 C for 15 minutes. The solution was 
allowed to cool to room temperature before aliquoting out 100 L samples for the 
experiments. Varying concentrations of TCEP or THPP (1-10 mM) were added to 
aliquots of protein solution (11 M) and incubated for 45 minutes at 25 C. 
Maleimide-PEG2kDa (1 mM) was subsequently added to the reactions with no 
addition of 3.3 and incubated at 37 C for 18 hours. Samples that had addition of 
3.3 (100 mM) required pre-incubation for 1 hour at 37 C. Maleimide- PEG2kDa (1 
mM) was subsequently added to the reactions and incubated at 37 C for 18 hours. 
Samples (15 L) were taken from each of the reactions and added to Laemmli 
sample buffer (15 L). Aliquots (9 L) of these solutions were loaded into a precast 
gradient gel (4-12 % Bis-Tris, Invitrogen) along with a protein ladder (EZ-Run, Fisher 
Scientific) and resolved by SDS Page electrophoresis [MOPS running buffer 
(Invitrogen), 180 V, 60 mins]. The precast gels were stained by Coomassie solution 
and destained using a water/ethanol/acetic acid (16:3:1) solution. 
2) Sbi (1 mg/mL) in Tris buffer (0.5 M, pH = 7.2, 5 mM EDTA), was aliquoted into 100 
L samples for the experiments. Varying concentrations of TCEP or THPP (1-10 mM) 
were added to aliquots of protein solution (33 M) and incubated for 45 minutes at 
25 C. Maleimide-PEG2kDa (1 mM) was subsequently added to the reactions with 
no addition of 3.3 and incubated at 37 C for 18 hours. Samples that had addition of 
3.3 (100 mM) required pre-incubation for 1 hour at 37 C. Maleimide-PEG2kDa (1 
mM) was subsequently added to the reactions and incubated at 37 C for 18 hours. 
Samples (15 L) were taken from each of the reactions and added to Laemmli 
sample buffer (15 L). Aliquots (9 L) of these solutions were loaded into a precast 
gradient gel (4-12 % Bis-Tris, Invitrogen) along with a protein ladder (EZ-Run, Fisher 
Scientific) and resolved by SDS Page electrophoresis [MOPS running buffer 
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(Invitrogen), 180 V, 60 mins]. The precast gels were stained by Coomassie solution 
and destained using a water/ethanol/acetic acid (16:3:1) solution. 
Synthesis of 4-bromo-2-methylpyridine 1-oxide (4.6). 
 
2-Methyl-4-nitropyridine 1-oxide (4.5, 0.30 g, 1.95 mmol) was dissolved in 2 mL of 
acetic acid and heated to 55 °C. Acetyl bromide (20 eq., v = 2.9 mL, 39 mmol) was 
added and the reaction was refluxed at 120 °C for 3 hours. The reaction was 
allowed to cool and then poured onto ice cold saturated NaHCO3 solution (100 mL) 
and stirred for 5 minutes. This solution was extracted with ethyl acetate (2 x 100 
mL). The organic layer was dried over MgSO4, filtered and concentrated. The 
residue was purified by silica gel chromatography: 10 % EtOAc/petroleum ether  
10 % MeOH/EtOAc to yield 4.6 as a yellow oil (216 mg, 59 %). Spectral data was 
consistent with that reported in the literature [145]. 1H NMR, CDCl3, 400 MHz:    
8.08 (d, 1H, H-6, J = 6.9 Hz), 7.39 (d, 1H, H-3, J = 2.7 Hz), 7.25 (dd, 1H, H-5, J = 2.7 & 
6.9 Hz), 2.47 (s, 3H, CH3).  13C NMR, CDCl3, 100 MHz:    150.4 (C-2), 140.1 (C-6), 
129.4 (C-3), 126.8 (C-5), 118.5 (C-4), 17.7 (CH3).  ESI-MS: Expected for C6H7Br1N1O1 






Synthesis of (4-bromopyridin-2-yl)methanol (4.7). 
 
4-Bromo-2-methylpyridine 1-oxide (4.6, 0.20 g, 1.06 mmol) was dissolved in 
anhydrous dichloromethane (10 mL) and cooled to 0 °C. Trifluoroacetic anhydride 
(5 eq., 5.3 mmol, v = 0.74 mL) was slowly added. The reaction was allowed to warm 
to room temperature then refluxed for 3 hours. The reaction was allowed to cool 
then concentrated. The crude was resuspended in 10 mL of dichloromethane and 2 
M NaOH was added until pH = 12. The reaction was rapidly stirred for 2.5 hours 
then extracted with water. The organic layer was dried over MgSO4, filtered and 
concentrated. The residue was purified by silica gel chromatography: 10 % 
EtOAc/petroleum ether  100 % EtOAc to yield 154 mg 4.7 as a yellow oil (154 mg, 
77 %). Spectral data was consistent with that reported in the literature [145]  1H 
NMR, CDCl3, 400 MHz:    8.35 (d, 1H, H-6, J = 5.3 Hz), 7.50 (d, 1H, H-3, J = 1.0 Hz), 
7.38 (dd, 1H, H-5, J = 1.0 & 5.3 Hz), 4.74 (s, 2H, CCH2OH), 3.68 (br. s, 1H, OH).  13C 
NMR, CDCl3, 100 MHz:    161.0 (C-2), 149.3 (C-6), 133.5 (C-4), 125.7 (C-3), 123.9 (C-
5), 63.9 (CCH2OH).  ESI-MS: Expected for C6H7Br1N1O1 (M+H+) = m/z 187.9706. 






Synthesis of (4-bromopyridin-2-yl)methyl acetate (4.8). 
 
(4-Bromopyridin-2-yl)methanol (4.7, 120 mg, 0.64 mmol) was dissolved in 
anhydrous pyridine (5 mL). Acetic anhydride (2 eq., 1.28 mmol, v = 0.12 mL) was 
added and the reaction was stirred at room temperature for 5 hours, while under 
N2. The reaction was cooled to 0 C and methanol (0.5 mL) was slowly added. The 
reaction was subsequently concentrated and co-evaporated with toluene (2 x 20 
mL). The crude was purified by silica gel chromatography: 10 % EtOAc/petroleum 
ether  50 % EtOAc to yield 4.8 as a slightly yellow oil (135 mg, 92 %). Compound is 
reported in the literature and is commercially available [193, 194].  1H NMR, CDCl3, 
400 MHz:    8.39 (s, 1H, H-6, J = 5.3 Hz), 7.52 (s, 1H, H-3), 7.40 (dd, 1H, H-5, J = 1.6 
& 5.3 Hz), 5.19 (s, 2H, CCH2O), 2.17 (s, 3H, OCOCH3).  13C NMR, CDCl3, 100 MHz:    
170.4 (OCOCH3), 157.4 (C-2), 150.1 (C-6), 133.5 (C-4), 126.1 (C-3), 124.9 (C-5), 66.0 
(CCH2O), 20.8 (OCOCH3).  ESI-MS: Expected for C8H9Br1N1O2 (M+H+) = m/z 229.9811. 








Synthesis of (4-ethenylpyridin-2-yl)methyl acetate (4.1). 
 
(4-Bromopyridin-2-yl)methyl acetate (4.8, 80.0 mg, 0.35 mmol) was dissolved in 5 
mL of deoxygenated toluene. Tetrakis(triphenylphosphine)palladium(0) (10 mol %, 
40.2 mg, 0.035 mmol) and tributyl(vinyl)tin (2 eq., 0.20 mL, 0.70 mmol) was added. 
The reaction was refluxed under inert atmosphere for 1.5 hours then allowed to 
cool. The reaction was loaded directly onto a silica gel column containing 10 % 
(w/w) KF. The reaction was purified by silica gel chromatography: 5 % 
EtOAc/petroleum ether  40 % EtOAc/petroleum ether to yield 4.1 as a yellow oil 
(50.5 mg, 82%).    1H NMR, CDCl3, 400 MHz: 8.53 (d, 1H, H-6, J = 5.1 Hz), 7.31 (s 1H, 
H-3), 7.21 (dd, 1H, H-5, J = 1.4 & 5.1 Hz), 6.68 (dd, 1H, CCHCH2, J = 10.8 & 17.6 Hz), 
6.00 (d, 1H, CCHCHH, J = 17.6 Hz), 5.50 (d, 1H, CCHCHH, J = 10.8 Hz), 5.21 (s, 2H, 
CCH2O), 2.16 (s, 3H, OCOCH3).  13C NMR, CDCl3, 100 MHz:    170.6 (OCOCH3), 156.1 
(C-2), 149.7 (C-6), 145.7 (C-4), 134.6 (CCHCH2), 119.9 (CCHCH2), 119.0 (C-3 & C-5), 
66.8 (CCH2O), 20.8 (OCOCH3).  ESI-MS: Expected for C10H12N1O2 (M+H+) = m/z 
178.0863. Found: m/z 178.0861. Infrared (NaCl disc):  1744, 1608, 1238 cm-1.  HPLC: 
column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % 
MeCN in water  100 % MeCN over 20 minutes, retention time, 13.03 mins., 





Synthesis of 4-bromo-2,6-dimethylpyridine 1-oxide (4.10). 
 
2,6-Dimethylpyridine 1-oxide (4.9, 200 mg, 1.19 mmol) was dissolved in 2 mL of 
glacial acetic acid and cooled to 0 °C. Acetyl bromide (20 eq., 1.76 mL) was added 
and the reaction was refluxed for 3 hours. The reaction was allowed to cool and 
poured onto ice water. The reaction was neutralised with K2CO3 and extracted with 
dichloromethane (3 x 100 mL). The organic layer was dried over MgSO4, filtered and 
concentrated. The residue was purified by silica gel chromatography: 10 % 
EtOAc/petroleum ether  10 % MeOH/EtOAc to yield 4.10 as a light yellow solid 
(173 mg, 72 %). Commercially available [195].  1H NMR, CDCl3, 400 MHz:    7.28 (s, 
2H, H-3 & H-5), 2.48 (s, 6H,2 x CCH3).  13C NMR, CDCl3, 100 MHz:    150.1 (C-2 & C-
6), 126.9 (C-3 & C-5), 117.4 (C-4), 18.2 (2 x CCH3).  ESI-MS: Expected for 








Synthesis of (4-bromo-6-methylpyridin-2-yl)methanol (4.11). 
 
4-Bromo-2,6-dimethylpyridine 1-oxide (4.10, 158 mg, 0.78 mmol) was dissolved in 
anhydrous dichloromethane and cooled to 0 °C. Trifluoroacetic anhydride (5 eq., 
3.9 mmol, 0.55 mL) was slowly added. The reaction was allowed to warm to room 
temperature then refluxed for 3 hours. The reaction was allowed to cool then 
concentrated. The crude was resuspended in 10 mL of dichloromethane and 2 M 
NaOH was added until pH = 12. The reaction was rapidly stirred for 2.5 hours then 
extracted with water. The organic layer was dried over MgSO4, filtered and 
concentrated. The residue was purified by silica gel chromatography: 10 % 
EtOAc/petroleum ether  100 % EtOAc to yield 4.11 as a pale yellow solid (130 mg, 
64 %). Commercially available [196] and spectral data consistent with that reported 
in the literature [197].  1H NMR, CDCl3, 400 MHz:    7.27 (s, 1H, H-3), 7.22, (s, 1H, H-
5), 4.74 (s, 2H, CCH2OH), 2.49 (s, 3H, CCH3).  13C NMR, CDCl3, 100 MHz:    160.2 (C-
6), 158.8 (C-2), 133.6 (C-4), 125.0 (C-5), 120.8 (C-3), 63.8 (CCH2OH), 23.8 (CCH3).  
ESI-MS: Expected for C7H8Br1N1Na1O1 = m/z 223.9681. Found: m/z 223.9691.  
Melting point:  92 C.  Infrared (thin film):  3218, 1574, 1089 cm-1. HPLC: column:  
Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in 
water  100 % MeCN over 20 minutes, retention time, 12.02 mins., purity, 90.6 %. 
Detection at 280 nm. 
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Synthesis of (4-bromo-6-methylpyridin-2-yl)methyl 4-
methylbenzenesulfonate (4.12). 
 
(4-Bromopyridin-2-yl)methanol (4.11, 100 mg, 0.53 mmol) was dissolved in dry THF 
(10 mL) and cooled to 0 °C. Tosyl chloride (2 eq., 202.8 mg, 1.06 mmol) and 1 M 
NaOH (0.7 mL) was added and the reaction was rapidly stirred for 2 hours while 
being allowed to warm to room temperature. The reaction was concentrated, 
resuspended in 100 mL of dichloromethane and extracted with water and brine. 
The dichloromethane was dried over MgSO4, filtered and concentrated. The residue 
was purified by silica gel chromatography: 10 %  50 % EtOAc/petroleum ether to 
yield 4.12 as a white solid (171 mg, yield: 94 %).  1H NMR, 400 MHz (CDCl3):    7.79 
(d, 2H, 2 x Ar-H, J = 8.3 Hz), 7.33 (m, 3H, 3 x Ar-H), 7.23 (s, 1H, 1 x Ar-H), 5.05 (s, 2H, 
CCH2O), 2.43 (s, 3H, NCCH3), 2.42 (s, 3H, CCH3).  13C NMR, 100 MHz (CDCl3):    159.5 
(pyridine-C-6), 154.4 (pyridine-C-2), 145.1 (tosyl-C-1), 133.7 (pyridine-C-4), 132.7 
(pyridine-C-2), 129.9 (tosyl-C-3 & C-5), 128.0 (tosyl-C-2 & C-6), 125.9 (pyridine-C-5), 
121.9 (pyridine-C-3), 70.9 (NCCH2O), 23.9 (NCCH3), 21.6 (tosyl CCH3).  ESI-MS:  
Expected for C14H14Br1N1Na1O3S1 (M+Na+) = m/z 377.9770 and 379.9750. Found: 
m/z 377.9779 and 379.9762. Melting point:  58 C.  Infrared (KBr):  3092, 1574, 
1187 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: 
(0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 
17.65 mins., purity, 96.6 %. Detection at 280 nm. 
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Synthesis of methyl 2-(((4-bromo-6-methylpyridin-2-
yl)methyl)thio)acetate (4.13). 
 
(4-Bromo-6-methylpyridin-2-yl)methyl 4-methylbenzenesulfonate (4.12, 170 mg, 
0.50 mmol) was dissolved in dry DMF (10 mL). Caesium carbonate (2 eq., 325.7 mg, 
1.00 mmol) and methyl thioglycolate (5 eq., 2.50 mmol, 0.23 mL) were added and 
the reaction was stirred rapidly under nitrogen at room temperature for 3 hours. 
The reaction was concentrated, resuspended in dichloromethane and extracted 
with water and brine. The dichloromethane was dried over MgSO4, filtered and 
concentrated. The residue was purified by silica gel chromatography: 10 %  50 % 
EtOAc/petroleum ether to yield 4.13 as a yellow oil (99.4 mg, 72 %).  1H NMR, 400 
MHz (CDCl3):    7.34 (d, 1H, H-5, J = 1.2 Hz), 7.21 (d, 1H, H-3, J = 1.2 Hz), 3.88 (s, 2H, 
NCCH2S), 3.70 (s, 3H, OCH3), 3.24 (s, 2H, SCH2CO), 2.50 (s, 3H, NCCH3).  13C NMR, 
100 MHz (CDCl3):    170.4 (CH2CO2), 159.6 (C-6), 158.4 (C-2), 133.3 (C-4), 124.9 (C-
5), 123.3 (C-3), 52.3 (OCH3), 37.8 (SCH2CO), 32.8 (NCCH2), 24.2 (NCCH3).  ESI-MS:  
Expected for C10H12Br1N1Na1O2S1 (M+Na+) = m/z 311.9664. Found: m/z 311.9674. 
Infrared (NaCl disc):  1740, 1573, 1283 cm-1.  HPLC:  column:  Waters Symmetry 
Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in water  100 % 





Synthesis of methyl {[(4-ethenyl-6-methylpyridin-2-
yl)methyl]sulfanyl}acetate (4.2). 
 
Methyl 2-(((4-bromo-6-methylpyridin-2-yl)methyl)thio)acetate (4.13, 85 mg, 0.29 
mmol) was dissolved in 10 mL of deoxygenated toluene. 
Tetrakis(triphenylphosphine)palladium(0) (10 mol %, 33.9 mg, 0.029 mmol) and 
tributyl(vinyl)tin (2 eq., 0.17 mL, 0.58 mmol) was added. The reaction was refluxed 
under inert atmosphere for 1 hour then allowed to cool. The reaction was loaded 
directly onto a silica gel column containing 10 % (w/w) KF. The reaction was purified 
by silica gel chromatography: 5 % EtOAc/petroleum ether  40 % EtOAc/petroleum 
ether to yield 4.2 as a yellow oil (59.8 mg, 86 %).  1H NMR, CDCl3, 400 MHz:    7.14 
(s, 1H, H-3), 7.00 (s, 1H, H-5), 6.61 (dd, 1H, CCHCH2, J = 10.9 & 17.6 Hz), 5.94 (d, 1H, 
CCHCHH, J = 17.6 Hz), 5.44 (d, 1H, CCHCHH, J = 10.9 Hz), 3.90 (s, 2H, NCCH2), 3.70 (s, 
3H, OCH3), 3.24 (s, 2H, SCH2CO), 2.52 (s, 3H, NCCH3).  13C NMR, CDCl3, 100 MHz:    
170.6 (CO2CH3), 158.7 (C-6), 157.2 (C-2), 145.7 (C-4), 134.8 (CCHCH2), 118.9 (C-5), 
118.4 (CCHCH2), 117.3 (C-3), 52.3 (OCH3), 38.3 (NCCH2), 32.9 (SCH2CO), 24.3 
(NCCH3).  ESI-MS:  Expected for C12H16N1O2S1 (M+H+) = m/z 238.0896. Found: m/z 
238.0914.  Infrared (NaCl disc):  1737, 1601, 1283 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in water 
 100 % MeCN over 20 minutes, retention time, 14.68 mins., purity, 98.48 %. 




Synthesis of methyl 3-(6-methylpyridin-2-yl)propanoate (4.16). 
 
3-(6-Methylpyridin-2-yl)propan-1-ol (4.14, 200 mg, 1.32 mmol, Ukrorgsyntez Ltd.) 
was suspended in 1 mL of CH3CN. The solution was slowly added to a rapidly stirring 
solution of RuCl3 (25 mg) and NaIO4 (2.5 eq., 707.3 mg, 3.30 mmol) in a solution of 
CCl4 (3 mL), CH3CN (3 mL) and H2O (4 mL). The reaction was sonicated for 2 minutes 
then left to rapidly stir for 2 hours. The reaction was diluted with CCl4 and MeCN 
(1:1, 50 mL) and water (50 mL), filtered through celite and the solid washed with 
CH3CN. The aqueous and organic layers were separated. The organic wash was 
filtered through celite and concentrated. The aqueous layer was concentrated to 10 
mL then filtered through celite. The solution was then concentrated to dryness. This 
crude was added to the crude from the organic layer. The combined residue was 
dried on a high vacuum pump then resuspended in anhydrous MeOH (50 mL). Four 
drops of concentrated H2SO4 were carefully added and the reaction was refluxed 
overnight. The reaction was allowed to cool then neutralised by addition of solid 
K2CO3. The mixture was filtered and concentrated. The residue was purified by silica 
gel chromatography: 10 % EtOAc/petroleum ether  50 % EtOAc/petroleum ether 
to yield 4.16 as a yellow oil (130 mg, 55 %).  1H NMR, CDCl3, 400 MHz:    7.43 (t, 1H, 
H-4, J = 7.6 Hz), 6.95 (m, dd 2H, H-3 & H-5, J = 1.5 & 7.6 Hz), 3.65 (s, 3H, OCH3), 3.05 
(t, 2H, NCCH2, J = 7.6 Hz), 2.76 (t, 2H, CH2CH2CO, J = 6.5 Hz), 2.49 (s, 3H, NCCH3).  13C 
NMR, CDCl3, 100 MHz:    173.5 (CO2CH3), 159.3 (C-2), 157.8 (C-6), 136.6 (C-4), 
120.8 (C-5), 119.7 (C-3), 51.5 (OCH3), 33.6 (NCCH2), 33.0 (CH2CH2CO), 24.4 (NCCH3).  
ESI-MS:  Expected for C10H13N1Na1O2 (M+Na+) = m/z 202.0838. Found: m/z 
202.0851.  Infrared (NaCl disc):  1744, 1460, 1163 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in water 
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 100 % MeCN over 20 minutes, retention time, 12.98 mins., purity, 93.4 %. 
Detection at 280 nm. 
Synthesis of 2-(3-methoxy-3-oxopropyl)-6-methylpyridine 1-oxide (4.17). 
 
Methyl 3-(6-methylpyridin-2-yl)propanoate (4.16, 260 mg, 1.45 mmol) was 
dissolved in 10 mL of anhydrous dichloromethane. m-CPBA (1.5 eq., 375.5 mg, 2.90 
mmol) was slowly added and reaction was stirred at room temperature for 4 hours. 
The reaction was neutralised with saturated Na2SO3. The solution was diluted with 
dichloromethane (100 mL), washed with water (50 mL) then 0.5 M NaOH solution 
(30 mL). The organic layer was dried over MgSO4, filtered and concentrated. The 
residue was purified by silica gel chromatography: 1  10 % MeOH/DCM to yield 
4.17 as a white solid (190 mg, 67 %).  1H NMR, CDCl3, 400 MHz:    7.12-7.00 (m, 3H, 
H-3, H-4 & H-5), 3.57 (s, 3H, OCH3), 3.14 (t, 2H, NCCH2, J = 7.1 Hz), 2.78 (t, 2H, 
CH2CH2CO, J = 7.1 Hz), 2.44 (s, 3H, NCCH3).  13C NMR, CDCl3, 100 MHz:    173.0 
(CO2CH3), 150.1 (C-2), 149.0 (C-6), 124.4 & 123.5 (C-3, C-4 & C-5), 51.5 (OCH3), 30.0 
(CH2CH2CO), 26.7 (NCCH2), 18.0 (NCCH3).  ESI-MS: Expected for C10H14N1O3 (M+H+) = 
m/z 196.0968. Found: m/z 196.1007.  Melting point:  70 C.  Infrared (KBr):  1733, 
1252, 1215 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), 
gradient: (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 





Synthesis of 4-bromo-2-(3-methoxy-3-oxopropyl)-6-methylpyridine 1-
oxide (4.18). 
 
2-(3-Methoxy-3-oxopropyl)-6-methylpyridine 1-oxide (4.17, 200 mg, 1.02 mmol) 
was dissolved in 1 mL of acetic acid. Br2 (0.5 mL) was added and the reaction was 
refluxed for 12 hours. The reaction was allowed to cool. The reaction was 
neutralised with 4 M NaOH solution. The solution was then extracted three times 
with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated. The 
crude was purified by silica gel chromatography: 20 % EtOAc/petroleum ether  10 
% MeOH/EtOAc to yield 4.18 as a slightly yellow solid (146 mg, 52 %).  1H NMR, 
CDCl3, 400 MHz:    7.33 (d, 1H, H-3, J = 2.6 Hz), 7.31 (d, 1H, H-5, J = 2.6 Hz), 3.67 (s, 
3H, OCH3), 3.17 (t, 2H, NCCH2, J = 7.0 Hz), 2.83 (t, 2H, CH2CH2CO, J = 7.0 Hz), 2.48 (s, 
3H, NCCH3).  13C NMR, CDCl3, 100 MHz:    172.8 (CO2CH3), 151.3 (C-2), 150.2 (C-6), 
127.3 (C-3), 127.0 (C-5), 117.5 (C-4), 51.7 (OCH3), 29.8 (CH2CH2CO), 26.8 (NCCH2), 
18.0 (NCCH3).  Melting point:  79 C.  Infrared (KBr):  1733, 1215 cm-1.  ESI-MS: 
Expected for C10H13Br1N1O3 (M+H+) = m/z 274.0074 & 276.0053. Found = m/z 
274.0073 & 276.0082.  HPLC: column:  Waters Symmetry Shield RP8 (100 x 4.60 
mm), gradient: (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 






Synthesis of methyl 3-(4-bromo-6-methylpyridin-2-yl)propanoate (4.19). 
 
4-Bromo-2-(3-methoxy-3-oxopropyl)-6-methylpyridine 1-oxide (4.18, 122 mg, 0.45 
mmol) was dissolved in 5 mL of deoxygenated toluene and cooled to 0 C while 
under N2. PBr3 (1.2 eq., 50 L, 0.53 mmol) was slowly added. The reaction was 
allowed to warm to room temperature and stirred for 1 hour. The reaction was 
cooled to 0 C and neutralised by addition of saturated NaHCO3 solution. The 
solution was suspended in excess EtOAc and washed with saturated NaHCO3 
solution. The organic layer was dried over MgSO4, filtered and concentrated. The 
crude was purified by silica gel chromatography: 10 % EtOAc/petroleum ether  40 
% EtOAc/petroleum ether to yield 4.19 as a transparent oil (100 mg, 87 %).  1H 
NMR, CDCl3, 400 MHz:    7.18 (s, 2H, H-3 & 5), 3.69 (s, 3H, OCH3), 3.05 (t, 2H, 
NCCH2, J = 7.4 Hz), 2.78 (t, 2H, CH2CH2CO, J = 7.4 Hz), 2.49 (s, 3H, NCCH3).  13C NMR, 
CDCl3, 100 MHz:    173.2 (CO2CH3), 160.8 (C-2), 159.3 (C-6), 133.1 (C-4), 124.1 (C-5), 
123.2 (C-3), 51.6 (OCH3), 33.1 (NCCH2), 32.7 (CH2CH2CO), 24.2 (NCCH3).  ESI-MS: 
Expected for C10H13Br1N1O2 (M+H+) = m/z 258.0124. Found: m/z 258.0131.  Infrared 
(thin film):  1738, 1573, 1169 cm-1.  HPLC: column:  Waters Symmetry Shield RP8 
(100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 






Synthesis of methyl 3-(4-ethenyl-6-methylpyridin-2-yl)propanoate (4.3). 
 
Methyl 3-(4-bromo-6-methylpyridin-2-yl)propanoate (4.19, 100 mg, 0.39 mmol) 
was dissolved in 10 mL of deoxygenated toluene. 
Tetrakis(triphenylphosphine)palladium(0) (10 mol %, 44.8 mg, 0.039 mmol) and 
tributyl(vinyl)tin (2 eq., 0.23 mL, 0.78 mmol) was added. The reaction was refluxed 
under inert atmosphere for one hour then allowed to cool. The reaction was loaded 
directly onto a silica gel column containing 10 % (w/w) KF. The reaction was purified 
by silica gel chromatography: 5 % EtOAc/petroleum ether  40 % EtOAc/petroleum 
ether to yield 4.3 as a transparent oil (68 mg, 86 %).  1H NMR, CDCl3, 400 MHz:    
6.99 (s, 2H, H-3 & 5), 6.62 (dd, 1H, CCHCH2, J = 10.8 & 17.6 Hz), 5.94 (dd, 1H, 
CCHCHH, J = 0.7 & 17.6 Hz), 5.44 (dd, 1H, CCHCHH, J = 0.7 & 10.8 Hz), 3.69 (s, 3H, 
OCH3), 3.09 (t, 2H, NCCH2, J = 7.5 Hz), 2.80 (t, 2H, CH2CH2CO, J = 17.7 Hz), 2.53 (s, 
3H, NCCH3).  13C NMR, CDCl3, 100 MHz:    173.5 (CO2CH3), 159.8 (C-2), 158.3 (C-6), 
145.4 (C-4), 135.1 (CCHCH2), 118.0 (CCHCH2), 117.9 & 117.0 (C-3 & 5), 51.5 (OCH3), 
33.6 (NCCH2), 33.0 (CH2CH2CO), 24.4 (NCCH3).  ESI-MS: Expected for C12H16N1O2 
(M+H+) = m/z 206.1176. Found: m/z 206.1183. Infrared (thin film):  1745, 1606, 
1201 cm-1. HPLC: column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: 
(0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 





Synthesis of 3-(6-methylpyridin-2-yl)propyl acetate (4.20). 
 
3-(6-Methylpyridin-2-yl)propan-1-ol (4.14, 0.25 g, 1.65 mmol) was dissolved in 
anhydrous pyridine (10 mL). Acetic anhydride (2 eq., 3.31 mmol, 0.31 mL) was 
added and the reaction was stirred at room temperature for 6 hours, while under 
N2. The reaction was cooled to 0 C and methanol (1 mL) was slowly added. The 
reaction was subsequently concentrated and co-evaporated with toluene (2 x 20 
mL). The crude was purified by silica gel chromatography: 10 % EtOAc/petroleum 
ether  50 % EtOAc to yield 4.20 as a transparent oil (0.31 mg, 95 %).  1H NMR, 
CDCl3, 400 MHz:    7.46 (t, 1H, H-4, J = 7.6 Hz), 6.94 (m, 2H, H-3 & 5), 4.10 (t, 2H, 
CH2CH2O, J = 6.6 Hz), 2.81 (t, 2H, NCCH2, J = 7.6 Hz), 2.51 (s, 3H, NCCH3), 2.05 (m, 
5H, CH2CH2CH2 & COCH3).  13C NMR, CDCl3, 100 MHz:    171.16 (OCOCH3), 160.28 
(C-2), 157.93 (C-6), 136.58 (C-4), 120.68 & 119.56 (C-3 & 5), 63.99 (CH2CH2O), 34.74 
(NCCH2), 28.74 (CH2CH2CH2), 24.52 (NCCH3), 20.97 (OCOCH3). ESI-MS: Expected for 
C11H15N1Na1O2 (M+Na+) = m/z 216.0995. Found: m/z 216.0994.  Infrared (thin film):  
1744, 1243 cm-1. HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), 
gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 







Synthesis of 2-(3-acetoxypropyl)-6-methylpyridine 1-oxide (4.21). 
 
3-(6-Methylpyridin-2-yl)propyl acetate (4.20, 369 mg, 1.47 mmol) was dissolved in 
10 mL of dry dichloromethane. m-CPBA (1.5 eq., 380.6 mg, 2.21 mmol) was slowly 
added and reaction was stirred at room temperature for 4 hours. The reaction was 
neutralised with saturated Na2SO3. The solution was diluted with dichloromethane 
(100 mL), washed with water (50 mL), then 0.5 M NaOH solution (30 mL). The 
organic layer was dried over MgSO4, filtered and concentrated. The residue was 
purified by silica gel chromatography: 1  10 % MeOH/DCM to yield 4.21 as a 
white solid (314 mg, 79 %).  1H NMR, CD3OD, 400 MHz:    7.50-7.45 (m, 3H, H-3, 4 
& 5), 4.22 (t, 2H, CH2CH2O, J = 6.3 Hz), 3.10 (dd, 2H, NCCH2CH2, J = 6.2 & 7.7 Hz), 
2.61 (s, 3H, NCCH3), 2.20-2.12 (m, 2H, CH2CH2CH2), 2.09 (s, 3H, OCOCH3).  13C NMR, 
CD3OD, 100 MHz:    170.9 (OCOCH3), 151.0 (C-2), 149.1 (C-6), 124.4 (C-4), 124.1 (C-
5), 123.0 (C-3), 63.7 (CH2CH2O), 27.9 (NCCH2), 25.0 (CH2CH2CH2), 20.8 (OCOCH3), 
18.1 (NCCH3).  ESI-MS: Expected for C11H16N1O3 (M+H+) = m/z 210.1125. Found: m/z 
210.1142.  Melting point:  42 C. Infrared (KBr):  1742, 1243 cm-1.  HPLC:  column:  
Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 mL/min) 5 % MeCN in 
water  100 % MeCN over 20 minutes, retention time, 10.24 mins., purity, 95.8 %. 






Synthesis of 2-(3-acetoxypropyl)-4-bromo-6-methylpyridine 1-oxide 
(4.22). 
 
2-(3-Acetoxypropyl)-6-methylpyridine 1-oxide (4.21, 436 mg, 2.08 mmol) was 
dissolved in 2 mL of acetic acid. Br2 (0.5 mL) was added and the reaction was 
refluxed for 12 hours. The reaction was allowed to cool. The reaction was 
neutralised with cold saturated NaHCO3 solution. The solution was then extracted 
three times with EtOAc. The organic layer was dried over MgSO4, filtered and 
concentrated. The crude was purified by silica gel chromatography: 20 % 
EtOAc/petroleum ether  10 % MeOH/EtOAc to yield 4.22 as a white solid (317.6 
mg, 56 %).  1H NMR, CD3OD, 400 MHz:    7.72 (d, 1H, Ar-H, J = 2.8 Hz), 7.69 (d, 1H, 
Ar-H, J = 2.8 Hz), 4.21 (t, 2H, CH2CH2O, J = 6.2 Hz), 3.06 (t, 2H, NCCH2, J = 7.4 Hz), 
2.57 s, 3H, NCCH3), 2.15 (m, 2H, CH2CH2CH2), 2.10 (s, 3H, COCH3).  13C NMR, CD3OD, 
100 MHz:    172.8 (OCOCH3), 154.4 (C-2), 152.3 (C-6), 122.4 (C-4), 64.9 (C-
CH2CH2O), 29.0 (NCCH2), 26.4 (CH2CH2CH2), 20.8 (OCOCH3), 18.1 (NCCH3).  ESI-MS: 
Expected for C11H14Br1N1O3 (M+Na+) = m/z 310.0055 & 312.0029. Found: m/z 
310.0084 & 312.0065.  Melting point:  52 C.  Infrared (KBr):  3069, 1728, 1037 cm-1.  
HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient: (0.5 
mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 12.53 






Synthesis of 3-(4-bromo-6-methylpyridin-2-yl)propyl acetate (4.23). 
 
2-(3-Acetoxypropyl)-4-bromo-6-methylpyridine 1-oxide (4.22, 200 mg, 0.69 mmol) 
was dissolved in 5 mL of deoxygenated toluene and cooled to 0 C while under N2. 
PBr3 (1.2 eq., 79 L, 0.83 mmol) was slowly added. The reaction was allowed to 
warm to room temperature and stirred for 1 hour. The reaction was cooled to 0 C 
and neutralised by addition of saturated NaHCO3 solution. The solution was 
suspended in excess EtOAc and washed with saturated NaHCO3 solution. The 
organic layer was dried over MgSO4, filtered and concentrated. The residue was 
purified by silica gel chromatography: 10 % EtOAc/petroleum ether  50 % 
EtOAc/petroleum ether to yield 4.23 as a light yellow oil (160.6 mg, 85 %).  1H NMR, 
CDCl3, 400 MHz:    7.16 (d, 1H, Ar-H, J = 1.3 Hz), 7.13 (d, 1H, Ar-H, J = 1.3 Hz), 4.10 
(t, 2H, CH2CH2O, J = 6.5 Hz), 2.78 (t, 2H, NCCH2, J = 7.6 Hz), 2.48 (s, 3H, NCCH3), 2.07-
2.00 (m, 5H, CH2CH2CH2 & COCH3).  13C NMR, CDCl3, 100 MHz:    171.1 (OCOCH3), 
161.7 (C-2), 159.3 (C-6), 133.1 (C-4), 123.9 (C-5), 122.9 (C-3), 63.7 (CH2CH2O), 34.4 
(NCCH2), 28.4 (CH2CH2CH2), 24.2 (NCCH3), 20.9 (OCOCH3).  ESI-MS: Expected for 
C11H14Br1N1Na1O2 (M+Na+) = m/z 294.0100. Found: m/z 294.0108.  Infrared (thin 
film):  1742, 1567, 1042 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 
4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 





Synthesis of 3-(4-bromo-6-methylpyridin-2-yl)propan-1-ol (4.24). 
 
3-(4-Bromo-6-methylpyridin-2-yl)propyl acetate (4.23, 382 mg, 1.4 mmol) was 
dissolved in 10 mL of anhydrous methanol. A 0.5 M solution of sodium methoxide 
(1.5 eq., 4 mL) was slowly added and the reaction was stirred under N2 for 1 hour, 
monitoring by TLC. The reaction was neutralised with 1 M HCl solution and 
concentrated. The residue was purified by silica gel chromatography: 1  10 % 
MeOH/DCM to yield 4.24 as a white solid (304 mg, 94 %).  1H NMR, CD3OD, 400 
MHz:    7.40 (s, 2H, H 3 & H-5), 3.65 (t, 2H, CH2CH2OH, J = 6.4 Hz), 2.86 (t, 2H, 
NCCH2, J = 7.7 Hz), 2.55 (s, 3H, NCCH3), 1.96 (ddd, 2H, CH2CH2CH2, J = 6.5, 7.0 & 15.2 
Hz).    13C NMR, CD3OD, 100 MHz:  164.1 (C-2), 160.6 (C-6), 135.1 (C-4), 125.4 (C-5), 
124.7 (C-3), 62.2 (CH2CH2OH), 35.1  9 (CH2CH2CH2), 33.7 (NCCH2), 23.7 (NCCH3).  ESI-
MS: Expected for C9H13Br1N1O1 (M+H+) = m/z 230.0175. Found: m/z 230.0166.  
Melting point:  39 C.  Infrared (KBr):  3302, 1570 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water 
 100 % MeCN over 20 minutes, retention time, 12.99 mins., purity, 97.7 %. 






Synthesis of ethyl 3-(3-(4-bromo-6-methylpyridin-2-
yl)propoxy)propanoate (4.25). 
 
3-(4-Bromo-6-methylpyridin-2-yl)propan-1-ol (4.24, 293 mg, 1.27 mmol) was added 
to 20 µL of Triton B (40 % in methanol) and subsequently co-evaporated with 
toluene (2 x 20 mL). The mixture was then dried under vacuum for 1 hour. The 
round bottom flask was then cooled to 0 °C and cold ethyl acrylate (0.5 mL) was 
slowly added. The reaction was allowed to warm to room temperature and left to 
stir for 4 days. The reaction was loaded directly onto a silica gel column and 
purified: 100 % DCM  10 % MeOH/DCM, which yielded 4.25 as transparent oil 
(143 mg, 34 %).  1H NMR, CDCl3, 400 MHz:    7.13 (s, 2H, H-3 & H-5), 4.15 (q, 2H, 
OCH2CH3, J = 7.2 & 14.3 Hz), 3.68 (t, 2H, OCH2CH2, J = 6.4 Hz), 3.46 (t, 2H, CH2CH2O, J 
= 6.4 Hz), 2.76 (t, 2H, NCCH2, J = 7.5 Hz), 2.54 (t, 2H, CH2CH2CO, J = 6.4 Hz), 2.47 (s, 
3H, NCCH3), 1.94 (m, 2H, CH2CH2CH2), 1.25 (t, 3H, OCH2CH3, J = 7.2 Hz).  13C NMR, 
CDCl3, 100 MHz:    171.5 (CO2CH2), 162.5 (C-2), 159.2 (C-6), 133.0 (C-4), 123.6 (C-5), 
122.9 (C-3), 70.0 (CH2CH2O), 66.1 (CO2CH2), 60.4 (OCH2CH2), 35.1 (NCCH2), 34.4 
(CH2CO2), 29.4 (CH2CH2CH2), 24.2 (NCCH3), 14.2 (OCH2CH3).  ESI-MS: Expected for 
C14H20Br1N1Na1O3 (M+Na+) = m/z 352.0519. Found: m/z 352.0539. Infrared (thin 
film):  1742, 1569, 1187 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 
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4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 
minutes, retention time, 16.37 mins., purity, 93.4 %. Detection at 280 nm.  
The compound 4.49 was also isolated as a transparent oil (65.1 mg, 18 %):  1H NMR, 
CDCl3, 400 MHz:    7.17 (s, 1H, H-5), 7.15 (s, 1H, H-3), 6.39 (dd, 1H, COCHCHH, J = 
1.3 & 17.3 Hz), 6.11 (dd, 1H, COCHCH2, J = 10.4 & 17.3 Hz), 5.82 (dd, 1H, COCHCHH, 
J = 1.3 & 10.4 Hz), 4.21 (t, 2H, CH2CH2O, J = 6.4 Hz), 2.82 (t, 2H, NCCH2, J = 7.4 Hz), 
2.50 (s, 3H, NCCH3), 2.10 (m, 2H, CH2CH2CH2).  13C NMR, CDCl3, 100 MHz:    166.2 
(OCOCH), 161.7 (C-2), 159.4 (C-6), 133.2 (C-4), 130.7 (COCHCH2), 128.4 (COCHCH2), 
124.0 (C-5), 123.0 (C-3), 63.9 (CH2CH2O), 34.5 (NCCH2), 28.5 (CH2CH2CH2), 24.2 
(NCCH3).  Infrared (thin film):  1726, 1567, 1194 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water 
 100 % MeCN over 20 minutes, retention time, 16.35 mins., purity, 97.6 %. 
Detection at 280 nm. 
Synthesis of ethyl 3-[3-(4-ethenyl-6-methylpyridin-2-
yl)propoxy]propanoate (4.4). 
 
Ethyl 3-(3-(4-bromo-6-methylpyridin-2-yl)propoxy)propanoate (4.25, 250 mg, 0.76 
mmol) was dissolved in 10 mL of deoxygenated toluene. 
Tetrakis(triphenylphosphine)palladium(0) (10 mol %, 87.5 mg, 0.076 mmol) and 
tributyl(vinyl)tin (2 eq., 0.44 mL, 1.52 mmol) was added. The reaction was refluxed 
under inert atmosphere (N2) for 1.5 hours then allowed to cool. The reaction was 
loaded directly onto a silica gel column containing 10 % (w/w) KF. The reaction was 
purified by silica gel chromatography: 5 % EtOAc/petroleum ether  50 % 
EtOAc/petroleum ether to yield 4.4 as a transparent oil (157 mg, 75 %).  1H NMR, 
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CDCl3, 400 MHz:    6.95 (s, 2H, H-3 & H-5), 6.60 (dd, 1H, CCHCH2, J = 10.9 & 17.6 
Hz), 5.92 (dd, 1H, CCHCHH, J = 0.7 & 17.6 Hz), 5.42 (dd, 1H, CCHCHH, J = 0.7 & 10.9 
Hz), 4.16 (q, 2H, OCH2CH3, J = 7.2 Hz), 3.70 (t, 2H, OCH2CH2CO, J = 6.4 Hz), 3.48 (t, 
2H, CH2CH2O, J = 6.4 Hz), 2.79 (dd, 2H, NCCH2, J = 7.6 & 9.2 Hz), 2.56 (t, 2H, 
OCH2CH2CO, J = 6.4 Hz), 2.51 (s, 3H, NCCH3), 2.00 (m, 2H, CH2CH2CH2O), 1.26 (t, 3H, 
OCH2CH3, J = 7.2 Hz).  13C NMR, CDCl3, 100 MHz:    171.7 (CO2CH2), 161.4 (C-2), 
158.1 (C-6), 145.4 (C-4), 135.2 (CCHCH2), 117.9 (CCHCH2), 117.8, 117.0 (C-3 & 5), 
70.3 (CH2CH2O), 66.1 (OCH2CH2CO), 60.4 (OCH2CH3), 35.2 (CH2CH2CO), 34.7 (NCCH2), 
29.8 (CH2CH2CH2), 24.3 (NCCH3), 14.2 (OCH2CH3).  ESI-MS: Expected for C16H24N1O3 
(M+H+) = m/z 278.1751. Found: m/z 278.1827.  Infrared (thin film): 1737, 1192 cm-1.  
HPLC: column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 
mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 16.83 
mins., purity, 87 %. Detection at 280 nm. 
Experimental determination of the pKa of the pyridine ring for 
compounds 4.1-4.4. 
The 4-VP derivatives 4.1-4.4 (4-10 mg) were dissolved in DMSO (100 µL) and 
deionised water (900 µL). The solution was sonicated for 30 s then adjusted to pH  
3 by addition of dilute HCl solution (5 mM) at 25 °C. The pH was accurately 
recorded. The solution was subsequently titrated against a dilute NaOH solution (5 
mM). The pH of the solution was recorded with the incremental addition of the 
basic solution. This data was subsequently plotted as pH vs volume of base added. 
The end point of the titration (pH 10) was accurately recorded for the start of the 
reverse titration. The solution was titrated against a dilute HCl solution (5 mM). The 
pH of the solution was recorded along with the incremental addition of the acidic 
solution. This data was subsequently plotted as pH vs volume of acid added. The 
pKa of the 4-VP analogues were determined by the intersection point between the 






(4-Ethenylpyridin-2-yl)methyl acetate (4.1, 10.0 mg, 0.0564 mmol) was dissolved in 
a solution of THF (1 mL) and aqueous sodium phosphate (0.1 M, pH = 7, 5 mL). 
Glutathione (2.21, 0.9 eq., 15.6 mg, 0.0508 mmol) was added and the reaction was 
rapidly stirred at room temperature for 3 hours. The reaction was subsequently 
purified by C-18 chromatography (100 % H2O  40 % MeCN/H2O) which yielded 
the product 4.26 as a sticky solid (19.9 mg, 81 %).  1H NMR, D2O, 400 MHz:    8.36 
(d, 1H, H-6, J = 5.2 Hz), 7.37 (s, 1H, H-3), 7.29 (dd, 1H, H-5, J = 1.3 & 5.2 Hz), 5.14 (s, 
2H, NCCH2), 4.47 (dd, 1H, NHCHCO, J = 5.1 & 8.9 Hz), 3.68 (m, 3H, NHCH2CO2H & 
CH2CHNH2), 3.00-2.74 (m, 6H, CCH2CH2S, CCH2CH2S, SCH2CH), 2.43 (t, 2H, 
COCH2CH2, J = 8.0 Hz), 2.11 (s, 3H, OCOCH3), 2.05 (m, 2H, CH2CH2CH, J = 6.9 Hz).  13C 
NMR, D2O, 100 MHz:    176.1, 174.8, 173.9, 173.8, 171.9 (5 x CO), 154.1 (C-2), 
152.7 (C-4), 148.0 (C-6), 124.3 (C-5), 123.2 (C-3), 66.2 (CCH2O), 54.1 (CH2CHCO2H), 
53.0 (NHCHCO), 43.3 (NHCH2CO2H), 34.1, 32.8, 31.43, 31.39, 26.2 (CH2CH2CHCO2H), 
20.3 (OCOCH3).  ESI-MS: Expected for C20H27N4O8S1 (M-H+). = m/z 483.1555. Found: 







Methyl {[(4-ethenyl-6-methylpyridin-2-yl)methyl]sulfanyl}acetate (4.2, 10.0 mg, 
0.0421 mmol) was dissolved in a solution of THF (1 mL) and aqueous sodium 
phosphate (0.1 M, pH = 7, 5 mL). Glutathione (2.21, 0.9 eq., 11.7 mg, 0.0379 mmol) 
was added and the reaction was rapidly stirred at room temperature for 3 hours. 
The reaction was subsequently purified by C-18 chromatography (100 % H2O  40 
% MeCN/H2O) which yielded the product 4.27 as a pale yellow sticky solid (17.8 mg, 
86 %).  1H NMR, 500 MHz (D2O):    7.01 (s, 1H, H-3), 7.00 (s, 1H, H-5), 4.45 (dd, 1H, 
NHCHCO, J = 5.0 & 8.7 Hz), 3.73 (s, 2H, NCCH2S), 3.70-3.61 (m, 3H, CH2CHNH2 & 
NHCH2CO2H), 3.47 (s, 3H, CO2CH3), 3.23 (s, 2H, SCH2CO), 2.96 (dd, 1H, SCHHCHNH, J 
= 4.9 & 14.2 Hz), 2.80-2.72 (m, 5H, CCH2CH2S, CH2CH2SCH2 & SCHHCHNH), 2.49 (t, 
2H, COCH2CH2, J = 7.5 Hz), 2.45 (s, 3H, NCCH3), 2.11 (m, 2H, CH2CH2CHNH2).  13C 
NMR, 125 MHz (D2O):    176.1, 174.9, 174.3, 173.2 & 171.8 (5 x CO), 158.3 (C-2), 
156.1 (C-6), 151.7 (C-4), 122.9 (C-5), 121.5 (C-3), 54.1 (CH2CHNH2), 53.0 (NHCHCO), 
52.9 (CO2CH3), 33.9, 32.9, 31.5, 31.4, 26.4 (CH2CH2CHNH2), 22.6 (NCCH3).  ESI-MS: 
Expected for C22H31N4O8S2 (M-H+). = m/z 543.1589. Found: m/z 543.1628.  Infrared 
(KBr):  3321, 1734, 1607 cm-1.  HPLC:  column:  Phenomenex Luna-C18 (250 x 4.60 
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mm), gradient:  (0.7 mL/min) 5 % MeCN/H2O  90 % MeCN/H2O over 20 minutes, 




Methyl 3-(4-ethenyl-6-methylpyridin-2-yl)propanoate (4.3, 10.0 mg, 0.0487 mmol) 
was dissolved in a solution of THF (1 mL) and aqueous sodium phosphate (0.1 M, pH 
= 7, 5 mL). Glutathione (2.21, 0.9 eq., 13.5 mg, 0.0438 mmol) was added and the 
reaction was rapidly stirred at room temperature for 3 hours. The reaction was 
subsequently purified by C-18 chromatography (100 % H2O  40 % MeCN/H2O) 
which yielded the product 4.28 as a transparent sticky solid (20 mg, 89 %).  1H NMR, 
400 MHz (D2O):    7.60 (s, 2H, H-3 & H-5), 4.62 (dd, 1H, NHCHCO, J = 5.1 & 8.5 Hz), 
3.82 (m, 3H, CH2CHNH2 & NHCH2CO2H), 3.73 (s, 3H, CO2CH3), 3.30 (t, 2H, NCCH2CH2, 
J = 7.2 Hz), 3.19-3.09 (m, 3H, CCH2CH2S & SCHHCHNH), 3.04-2.90 (m, 5H, 
CH2CH2CO2CH3, CH2CH2SCH2 & SCHHCHNH), 2.73 (s, 3H, NCCH3), 2.58 (t, 2H, 
COCH2CH2CHNH2, J = 7.3 Hz), 2.20 (m, 2H, CH2CH2CHNH2).  13C NMR, 100 MHz 
(D2O):    176.1, 174.9, 174.5, 173.9, 171.8 (5 x CO), 160.6 (C-4), 154.3 (C-2), 153.4 
(C-6), 125.4 (C-5), 123.8 (C-3), 54.2 (CH2CHNH2), 53.1 (NHCHCO), 52.5 (CO2CH3), 
43.4 (NHCH2CO2H), 34.7 (CCH2CH2S), 32.9 (SCH2CHNH), 32.4 (CH2CH2CO2CH3), 31.5 
(COCH2CH2CHNH2), 30.9 (CH2CH2SCH2), 28.0 (CCH2CH2CO), 26.3 (CH2CH2CHNH2), 
19.0 (NCCH3).  ESI-MS: Expected for C22H31N4O8S1 (M-H+) = m/z 511.1868 Found: 
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m/z 511.1882.  Infrared (KBr):  3299, 1732, 1610, 1419 cm-1.  HPLC: column:  
Phenomenex Luna-C18 (250 x 4.60 mm), gradient:  (0.7 mL/min) 5 % MeCN/H2O  
90 % MeCN/H2O over 20 minutes, retention time, 12.53 mins., purity, 99.0 %. 




Ethyl 3-[3-(4-ethenyl-6-methylpyridin-2-yl)propoxy]propanoate (4.4, 10.0 mg, 
0.0361 mmol) was dissolved in a solution of THF (1 mL) and aqueous sodium 
phosphate (0.1 M, pH = 7, 5 mL). Glutathione (2.21, 0.9 eq., 10.0 mg, 0.0324 mmol) 
was added and the reaction was rapidly stirred at room temperature for 3 hours. 
The reaction was subsequently purified by C-18 chromatography (100 % H2O  40 
% MeCN/H2O) which yielded the product 4.29 as a transparent sticky solid (16.2 mg, 
85 %).  1H NMR, 400 MHz (D2O):    7.42 (s, 2H, H-3 & H-5), 4.54 (dd, 1H, NHCHCO, J 
= 5.1 & 8.6 Hz), 4.14 (q, 2H, CO2CH2CH3, J = 7.1 Hz), 3.74-3.65 (m, 5H, OCH2CH2CO2, 
CH2CHNH2 & NHCH2CO2H), 3.53 (t, 2H, CH2CH2OCH2, J = 6.1 Hz), 3.07-3.01 (m, 3H, 
CCH2CH2S & SCHHCHNH), 2.97-2.81 (m, 5H, NCCH2CH2, CH2CH2SCH2 & SCHHCHNH), 
2.61 (s, 3H, NCCH3), 2.56 (t, 2H, CH2CH2CO2, J = 5.9 Hz), 2.49 (t, 2H, SCH2CHNH , J = 
7.4 Hz), 2.12 (m, 2H, CH2CH2CHNH2), 1.99 (m, 2H, CCH2CH2CH2), 1.22 (t, 3H, 
OCH2CH3, J = 4.2 Hz).  13C NMR, 100 MHz (D2O):    176.1, 174.9, 174.4, 173.9, 171.8 
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(5 x CO), 159.0 (C-4), 156.6 (C-2), 153.9 (C-6), 124.5 (C-5), 123.5 (C-3), 69.4 
(CH2CH2OCH2), 65.8 (OCH2CH2CO), 61.9 (CO2CH2CH3), 54.1 (CH2CHNH2), 53.1 
(NHCHCO), 43.4 (NHCH2CO2H), 34.7 (CH2CH2CO2), 34.6 (CCH2CH2S), 32.9 
(SCH2CHNH), 31.6 (COCH2CH2CH), 31.0 (CH2CH2SCH2), 30.5 (NCCH2CH2), 28.2 
(CH2CH2CH2O), 26.3 (COCH2CH2CH), 19.5 (NCCH3), 13.4 (OCH2CH3).  ESI-MS: 
Expected for C26H39N4O9S1 (M-H+) = m/z 583.2443 Found: m/z 583.2474.  Infrared 
(KBr):  3314, 1736, 1606 cm-1.  HPLC:  column:  Phenomenex Luna-C18 (250 x 4.60 
mm), gradient:  (0.7 mL/min) 5 % MeCN/H2O  90 % MeCN/H2O over 20 minutes, 
retention time, 13.30 mins., purity, 99.8 %. Detection at 280 nm. 
General procedure for experimentally determining the rate of thiol 
alkylation as a function of pH for 4-VP derivatives 4.1-4.4. 
An aliquot of 10 % (v/v) of DMSO-d6 was added to deuterated aqueous sodium 
phosphate (100 mM, pH = 6, 7 or 8) containing reduced glutathione (final 
concentration of 30 mM) within an NMR tube. The solution was sonicated for 10 s. 
A volume of DMSO-d6 was added to a vial containing the 4-VP analogue (4-10 mg). 
This solution was transferred to the buffered solution in the NMR tube so that a 
final concentration of 4-VP was 20 mM and the glutathione concentration was 30 
mM. The solution was vortexed for 5 seconds then transferred to the NMR 
instrument for spectroscopic analysis. The progress of the reaction was continually 
monitored over a 90 minute period at 25 C. The relative integral changes were 
plotted as a function of time which allowed the determination of a rate constant for 










N-acetyl-L-cysteine (9 mg, 0.0508 mmol, 3.9) and benzyl amine (4.30, 1 eq., 5.5 L, 
0.0508 mmol) was dissolved in argon purged 10 % THF in aqueous sodium 
phosphate (0.9 mL, 0.1 M, pH = 7 or pH = 8). A solution of 4.2 (1 eq., 12.1 mg, 
0.0508 mmol) in THF (0.1 mL) was added and the reaction was rapidly stirred at 
room temperature for 3 hours. The reaction was initially investigated by mass 
spectrometry, followed by silica gel chromatography purification (10 % 
EtOAc/petroleum ether  5 % MeOH/EtOAc) to yield 4.31 as a transparent sticky 
oil (16.0 mg, 76 %) at pH = 7 and (16.6 mg, 79 %) at pH = 8.  1H NMR, 400 MHz 
(CDCl3):    7.00 (s, 1H, H-3), 6.86 (s, 1H, H-5), 6.33 (br. d, 1H, NH, J = 7.2 Hz), 4.82 
(m, 1H, NHCHCH2S), 3.87 (s, 2H, NCCH2S), 3.75 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 
3.23 (s, 2H, SCH2CO2), 3.00 (dd, 2H, NHCHCH2S, J = 5.0 & 13.8 Hz), 2.79 (m, 4H, 
CCH2CH2S & CCH2CH2S), 2.50 (s, 3H, NCCH3), 2.04 (s, 3H, NHCOCH3).  13C NMR, 100 
MHz (CDCl3):    171.2, 170.7, 169.8 (3 x CO), 158.5 (C-6), 156.9 (C-2), 149.6 (C-4), 
121.9 (C-5), 120.3 (C-3), 52.7 (OCH3), 52.4 (OCH3), 51.9 (NHCHCH2S), 38.2 (NCCH2S), 
35.0, 34.3 (NHCHCH2S), 32.8 (2C), 24.3 (NCCH3), 23.1 (NHCOCH3).  ESI-MS: Expected 
for C18H26N2Na1O5S2 (M+Na+) = m/z 437.1175. Found: m/z 437.1246.  Infrared (thin 
film):  1737, 1664, 1292 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 
4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 




Mass spectrum of reaction containing 3.9, 4.30, and 4.2 at pH = 7. 
 



















N-acetyl-L-cysteine (3.9, 7 mg, 0.0395 mmol,) and benzyl amine (4.30, 1 eq., 5.5 L, 
0.0395 mmol) was dissolved in argon purged 10 % THF in aqueous sodium 
phosphate (0.9 mL, 0.1 M, pH = 7 or pH = 8). A solution of 4.3 (1 eq., 8.1 mg, 0.0395 
mmol) in THF (0.1 mL) was added and the reaction was rapidly stirred at room 
temperature for 3 hours. The reaction was initially investigated by mass 
spectrometry, followed by silica gel chromatography purification (10 % 
EtOAc/petroleum ether  5 % MeOH/EtOAc) to yield 4.32 as a transparent sticky 
oil (11.3 mg, 75 %) at pH = 7 and (12.2 mg, 81 %) at pH = 8.  1H NMR, 400 MHz 
(CDCl3):    6.82 (s, 2H, H-3 & H-5), 6.27 (br. d, 1H, NH, J = 6.8 Hz), 4.83 (m, 1H, 
NHCHCO2), 3.77 (s, 3H, OCH3), 3.67 (s, 3H, OCH3), 3.07-2.96 (m, 4H, NCCH2CH2 & 
NHCHCH2S), 2.77 (m, 6H, CH2CH2CO2, CCH2CH2S & CCH2CH2S), 2.49 (s, 3H, NCCH3), 
2.05 (s, 3H, NHCOCH3).  13C NMR, 100 MHz (CDCl3):    173.6, 171.3 & 169.8 (3 x 
CO), 159.3 (C-2), 158.1 (C-6), 149.3 (C-4), 121.0 (C-5), 120.0 (C-3), 52.7 (OCH3), 51.9 
(NHCHCO2), 51.6 (OCH3), 35.2, 34.4, 33.6, 32.9, 24.3 (NCCH3), 23.1 (NHCOCH3).  ESI-
MS: Expected for C18H26N2Na1O5S1 (M+Na+) = m/z 405.1455. Found: m/z 405.1489.  
Infrared (thin film): 1734, 1659, 1436 cm-1.  HPLC:  column:  Waters Symmetry 
Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % 





Mass spectrum of reaction containing 3.9, 4.30, and 4.3 at pH = 7. 
 
















2,2-diyl} dipropanoic acid (4.34). 
 
4-Vinyl pyridine (4.33, 20 mg, 0.190 mmol) and TCEP (2.6, 0.9 eq., 49.1 mg, 0.171 
mmol) was dissolved in THF (2 mL) and argon purged aqueous sodium phosphate 
(0.1 M, pH = 7.0, 8 mL) and stirred under argon at room temperature for 3 hours. 
The reaction was concentrated in vacuo to 3 mL and then loaded onto a C-18 
column for purification (100 % H2O  40 % MeCN/H2O) to yield 4.34 as a 
transparent solid (38.9 mg, 64 %).  1H NMR, D2O, 400 MHz:    8.57 (d, 2H, H-2 & H-
6, J = 6.8 Hz), 7.85 (d, 2H, H-3 & H-5, J = 6.8 Hz), 3.19 (m, 2H, CHCCH2CH2P), 2.65 (m, 
2H, CHCCH2CH2P), 2.51 (m, 12H, 3 x CH2CH2CO2).  13C NMR, D2O, 125 MHz:    176.8 
(d, 3 x CH2CH2CO2, J = 12.5 Hz), 160.2 (d, C-4, J = 16.2 Hz), 141.4 (C-2 & C-6), 126.8 
(C-3 & C-5), 27.6 (d, 3 x CH2CH2CO2, J = 4.2 Hz), 26.9 (d, CHCCH2CH2, J = 2.0 Hz), 18.3 
(d, PCH2CH2CCH, J = 48.3 Hz), 15.1 (d, 3 x CH2CH2CO2, J = 49.6 Hz).  31P NMR, D2O, 
202 MHz:  36.6.  HRMS:  C16H21N1O6P1 (M-H+) = m/z 354.1106. Found: m/z 
354.1123.  Infrared (thin film): 3407, 1716 cm-1.  HPLC:  column:  Phenomenex Luna-
C18 (250 x 4.60 mm), gradient:  (0.7 mL/min) 5 % MeCN/H2O  90 % MeCN/H2O 







4-Vinyl pyridine (4.33, 15 mg, 0.143 mmol) and THPP (2.7, 0.9 eq., 26.7 mg, 0.128 
mmol) was dissolved in THF (2 mL) and argon purged aqueous sodium phosphate 
(0.1 M, pH = 7.0, 8 mL) and stirred under argon at room temperature for 3 hours. 
The reaction was concentrated in vacuo to 3 mL and then loaded onto a C-18 
column for purification (100 % H2O  40 % MeCN/H2O) to yield 4.35 as a 
transparent solid (24.6 mg, 61 %).   1H NMR, D2O, 400 MHz:    8.48 (s, 2H, H-2 & H-
6), 7.41 (d, 2H, H-3 & H-5, J = 5.9 Hz), 3.68 (t, 6H, 3 x CH2CH2O, J = 6.0 Hz), 3.06 (m, 
2H, CHCCH2CH2), 2.72 (m, 2H, PCH2CH2C), 2.37 (m, 6H, 3 x CH2CH2CH2O), 1.75 (m, 
6H, 3 x CH2CH2CH2O).  13C NMR, D2O, 100 MHz:    149.6 & 149.5 (d, C-4, J = 13.7 
Hz), 149.0 (C-2 & C-6), 123.9 (C-3 & C-5), 60.9 (d, 3 x CH2CH2O, J = 16.8 Hz), 25.9 
(CHCCH2CH2), 23.4 (d, 3 x CH2CH2CH2O, J = 4.2 Hz), 18.4 (d, PCH2CH2C, J = 47.9 Hz), 
15.0 (d, 3 x CH2CH2CH2O, J = 49.7 Hz).  31P NMR, D2O, 162 MHz:  36.1.  HRMS:  
C16H29N1O3P1 (M+H+) = m/z 314.1880.  Found: m/z 314.1888.  Infrared (thin film):  
3361, 1613, 1424 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 
mm), gradient:  (0.5 mL/min) 5 % MeCN in water   100 % MeCN over 20 minutes, 
retention time, 12.00 mins., purity, 95.2 %. Detection at 280 nm. 
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Investigating a possible reaction of 4-VP with alkyl azide 3.3. 
4-VP (4.33, 36 mg) was dissolved in THF (1.5 mL) and aqueous sodium phosphate 
(0.25 M, pH = 7, 1.5 mL) containing the alkyl azide 3.3 (1 eq., 100 mg). The reaction 
was rapidly stirred at room temperature and monitored by TLC and HRMS. After 2 
days no evidence of triazoline formation was evident by either TLC or HRMS. The 
investigation proved that the addition of alkyl azide 3.3 for excess phosphine 
oxidation can be used in a reaction containing thiol alkylating reagents based on 4-
vinyl pyridine. 
 
Mass spectrum of reaction of 4.33 with 3.3 after 3 hours. 
 










Synthesis of 3-(4-ethenyl-6-methylpyridin-2-yl)propyl acetate (4.38). 
 
3-(4-Bromo-6-methylpyridin-2-yl)propyl acetate (4.23, 0.30 g, 1.10 mmol) was 
dissolved in 10 mL of deoxygenated toluene. 
Tetrakis(triphenylphosphine)palladium(0) (10 mol %, 127.4 mg, 0.110 mmol) and 
tributyl(vinyl)tin (2 eq., 0.64 mL, 2.20 mmol) were added. The reaction was refluxed 
under inert atmosphere (N2) for 2 hours then allowed to cool. The reaction was 
loaded directly onto a silica gel column containing 10 % (w/w) KF. The reaction was 
purified by silica gel chromatography: 5 % EtOAc/petroleum ether  50 % 
EtOAc/petroleum ether to yield 4.38 as a transparent oil (203.1 mg, 84 %).  1H NMR, 
CDCl3, 500 MHz:    6.97 (s, 1H, H-3), 2.95 (s, 1H, H-5), 6.60 (dd, 1H, CCHCH2, J = 10.9 
& 17.6 Hz), 5.93 (d, 1H, CCHCHH, J = 17.6 Hz), 5.43 (d, 1H, CCHCHH, J = 10.9 Hz), 
4.12 (t, 2H, CH2CH2O, J = 6.5 Hz), 2.83 (t, 2H, NCCH2CH2, J = 7.5 Hz), 2.52 (s, 3H, 
NCCH3), 2.07 (m, 2H, CH2CH2CH2O), 2.04 (s, 3H, OCOCH3).  13C NMR, CDCl3, 125 
MHz:    171.17 (OCOCH3), 160.62 (C-2), 158.21 (C-6), 145.68 (C-4), 135.04 
(CCHCH2), 118.27 (CCHCH2), 118.07 (C-3), 116.99 (C-5), 64.02 (CH2CH2O), 34.59 
(NCCH2CH2), 28.77 (CH2CH2CH2), 24.32 (NCCH3), 20.98 (OCOCH3).  ESI-MS: Expected 
for C13H17N1Na1O2 (M+Na+) = m/z 242.1151. Found: m/z 242.1151.  Infrared (NaCl 
disc):  1742, 1243 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 
mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 





Synthesis of 3-(4-ethenyl-6-methylpyridin-2-yl)propan-1-ol (4.39). 
 
3-(4-Ethenyl-6-methylpyridin-2-yl)propyl acetate (4.38, 0.20 g, 0.912 mmol) was 
dissolved in 10 mL of anhydrous methanol. Sodium methoxide (1.5 eq., 0.5 M, 2.7 
mL) was slowly added and the reaction was stirred under N2 for 1.5 hours, 
monitoring by TLC. The reaction was neutralised with 1 M HCl solution and 
concentrated. The residue was purified by silica gel chromatography: 1  10 % 
MeOH/DCM to yield 4.39 as a transparent oil (130.9 mg, 81 %).  1H NMR, CD3OD, 
400 MHz:    7.13 (s, 2H, H-3 & H-5), 6.68 (dd, 1H, CCHCH2, J = 10.9 & 17.6 Hz), 6.05 
(d, 1H, CCHCHH, J = 17.6 Hz), 5.48 (d, 1H, CCHCHH, J = 10.9 Hz), 3.59 (t, 2H, 
CH2CH2OH, J = 6.4 Hz), 2.80 (t, 2H, NCCH2CH2, J = 8.3 Hz), 2.48 (s, 3H, NCCH3), 1.90 
(m, 2H, CH2CH2CH2).  13C NMR, CD3OD, 100 MHz:    162.75 (C-2), 159.21 (C-6), 
148.05 (C-4), 136.11 (CCHCH2), 119.47 (CCHCH2), 119.42 & 118.68 (C-3 & C-5), 62.32 
(CH2CH2OH), 35.10 (NCCH2CH2), 34.09 (CH2CH2CH2), 23.71 (NCCH3).  ESI-MS: 
Expected for C11H15N1Na1O1 (M+Na+) = m/z 200.1046. Found: m/z 200.1053. 
Infrared (thin film): 3358, 1607, 1560 cm-1.  HPLC:  column:  Waters Symmetry 
Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % 









D-Lactose (4.40, 5.0 g, 14.6 mmol) was dissolved in anhydrous pyridine (40 mL). 
Acetic anhydride (12 eq., 175.3 mmol, 16.6 mL) was added to the stirring solution. 
The reaction was stirred over night at room temperature under N2 gas. The reaction 
was cooled to 0 C in an ice bath, followed by the slow addition of methanol (25 
mL). The reaction was left to stir for 5 minutes and then concentrated. The crude 
was co-evaporated with toluene (5 x 100 mL) then purified by silica gel 
chromatography: 10 % EtOAc/petroleum ether  70 % EtOAc/petroleum ether to 
yield 4.41 as a sticky white solid (10.8 g, 92 %). Spectral data consistent with 
literature [198]. 1H NMR, CDCl3, 400 MHz:    6.22 (d, 1H, J = 3.7 Hz), 5.43 (t, 1H, J = 
9.3 Hz), 5.33 (m, 1H), 5.09 (dd, 1 H, J = 7.9 & 10.4 Hz), 4.99-4.92 (m, 2H), 4.47-4.40 
(m, 2 H), 4.15-4.02 (m, 4H), 4.00-3.96 (m, 1H), 3.88-3.81 (m, 2H), 2.15 (s, 3H), 2.13 
(s, 3H), 2.10 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H).  
13C NMR, CDCl3, 100 MHz:    170.3, 170.2, 170.1, 170.0, 169.9, 169.5, 169.1, 168.9, 
101.1, 88.9, 75.7, 70.9, 70.6, 69.5, 69.3, 69.0, 66.5, 65.8, 61.4, 60.7, 20.9, 20.8, 20.7, 











glucopyranose (4.41, 0.50 g, 0.737 mmol) was dissolved in anhydrous methanol and 
dichloromethane (1:1, 15 mL). Hydrazine acetate (1.2 eq., 81.4 mg, 0.884 mmol) 
was added and the reaction was rapidly stirred for 6 hours at room temperature 
while under N2 gas. The reaction was concentrated then purified by silica gel 
chromatography: 10 % EtOAc/petroleum ether  80 % EtOAc/petroleum ether to 
yield 4.42 as a sticky solid (324 mg, 69 %). Spectral data was consistent with that 
reported in the literature [198]. 1H NMR (CDCl3, 400 MHz) and 13C NMR (CDCl3, 100 
MHz) data shows a /β mixture.  Expected for C26H36Na1O18 (M+Na+) = m/z 














glucopyranose (4.42, 0.85 g, 1.34 mmol) was dissolved in anhydrous 
dichloromethane (10 mL) and cooled to 0 C, while under N2 gas. 
Trichloroacetonitrile (5 eq., 6.68 mmol, 0.67 mL) was added to the stirring solution, 
followed by the addition of DBU (0.1 eq., 0.134 mmol, 20.0 µL). The reaction was 
allowed to warm to room temperature and left to stir for 2 hours. The reaction was 
concentrated and purified by silica gel chromatography: 10 % EtOAc/petroleum 
ether  50 % EtOAc/petroleum ether to yield 4.43 as a sticky solid (0.83 g, 80 %). 
Spectral data consistent with that reported in the literature [199].  1H NMR, CDCl3, 
400 MHz:    8.65 (s, 1H), 6.45 (d, 1H, J = 3.8 Hz), 5.54 (t, 1H, J = 9.8 Hz), 5.33 (dd, 
1H, J = 0.8 & 3.4 Hz), 5.11 (dd, 1H, J = 7.9 & 10.4 Hz), 5.04 (dd, 1H, J = 3.8 & 10.2 Hz), 
4.93 (dd, 1H, J = 3.4 & 10.4 Hz), 4.51-4.44 (m, 2H), 4.16-4.04 (m, 4H), 3.89-3.82 (m, 
2H), 2.13 (s, 3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.02 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H).  13C 
NMR, CDCl3, 100 MHz:    170.3, 170.2, 170.1, 170.03, 170.02, 169.3, 169.0, 160.9, 
101.2, 92.8, 90.6, 75.8, 71.0, 70.8, 70.6, 69.9, 69.5, 69.0, 66.5, 61.4, 60.7, 60.3, 21.0, 
20.8, 20.77, 20.71, 20.6, 20.5, 20.4.  ESI-MS: Expected for C28H36Cl3N1Na1O18 





Synthesis of 3-(4-ethenyl-6-methylpyridin-2-yl)propyl-β-D-lactose hepta 
acetate (4.44). 
 
2,3,4,6-Tetra-O-acetyl--lactopyranosyl trichloroacetimidate (4.43, 0.10 g, 0.128 
mmol) and 4-VP derivative 4.39 (2 eq., 45.4 mg, 0.256 mmol) were dissolved in 
anhydrous dichloromethane (3 mL) containing crushed 4 Ǻ molecular sieves (0.1 g). 
The reagents were stirred at room temperature, under N2 for 1 hour. The mixture 
was subsequently cooled to -25 oC. Trimethylsilyl triflate (2.2 eq., 51 μL, 0.282 
mmol) was added slowly. The mixture was stirred at -25oC for 1 hour, then allowed 
to warm to room temperature and left to stir for a further 1 hour. The mixture was 
then cooled to 0 oC and the reaction neutralised by the addition of triethylamine 
(2.2 eq., 39.3 μL, 0.282 mmol). The mixture was left to warm to room temperature 
and then filtered through celite. The filtrate was concentrated and residue was 
purified by silica gel chromatography: 10 % EtOAc/petroleum ether  100% EtOAc 
to yield 4.44 as a white foam (68.3 mg, 67 %).  1H NMR, CDCl3, 400 MHz:    6.96 (s, 
1H, CCHCCH3), 6.92 (s, 1H, CCHCCH2), 6.60 (dd, 1H, CCHCH2, J = 10.8 & 17.6 Hz), 
5.93 (dd, 1H, CCHCHH, J = 0.6 & 17.6 Hz), 5.43 (dd, 1H, CCHCHH, J = 0.6 & 10.8 Hz), 
5.34 (dd, 1H, H-4’, J = 1.0 & 2.5 Hz), 5.20 (t, 1H, H-3, J = 9.3 Hz), 5.11 (dd, 1H, H-2’, J 
= 7.9 &10.4 Hz), 4.97 - 4.90 (m, 2H, H-2 & 3’), 4.49 - 4.45 (m, 3H, H-1, 1’ & 6a), 4.16-
4.06 (m, 3H, H-6b, 6’a & 6’b), 3.91 – 3.85 (m, 2H, H-5’ & OCHHCH2CH2), 3.79 (t, 1H, H-
4, J = 9.6 Hz), 3.62 – 3.57 (m, 1H, H-5), 3.55-3.49 (m, 1H, OCHHCH2CH2), 2.78–2.73 
(m, 2H, NCCH2CH2), 2.51 (s, 3H, NCCH3), 2.15-1.96 (m, 23H, OCH2CH2CH2 & 7 x 
OCOCH3).  13C NMR, CDCl3, 100 MHz:    170.32, 170.23, 170.08, 169.98, 169.74, 
169.59, 169.03, 161.01 (NCCH3), 158.24 (NCCH2), 145.43 (CHCCHCH2), 135.14 
(CCHCH2), 118.00 (CCHCH2), 117.85 (CCHCCH3), 116.94 (CCHCCH2), 101.04 & 100.60 
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(C-1 & 1’), 76.35 (C-4), 72.91 (C-3), 72.64 (C-5), 71.83, 71.01, 70.73, 69.40, 69.18, 
66.68, 62.13, 60.85, 34.37, 29.66, 24.35, 20.77, 20.68, 20.56, 20.44.  ESI-HRMS:  
C37H49N1Na1O18 (M+Na+) = m/z 818.2842. Found: m/z 818.2833.  Infrared (thin film):  
1751, 1224, 1056 cm-1.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 
mm), gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 
retention time, 17.57 mins., purity, 96.31 %. Detection at 280 nm. 
Synthesis of 3-(4-ethenyl-6-methylpyridin-2-yl)propyl-β-D-lactose (4.45). 
 
3-(4-Ethenyl-6-methylpyridin-2-yl)propyl-β-D-lactose hepta acetate (4.44, 60.0 mg, 
0.0754 mmol) was dissolved in anhydrous methanol (5 mL) and stirred at room 
temperature while under N2 gas. A 0.5 M solution of sodium methoxide in MeOH 
(1.5 mL, 0.754 mmol) was added dropwise with stirring over five minutes. The 
solution was left to stir for 2 hours. The reaction was then neutralised by the slow 
addition of HCl solution (0.1 M). The solution was concentrated and the residue 
redissolved in water (2 mL) loaded onto a C-18 column for purification (100 % H2O 
 80 % MeOH/H2O) to yield 4.45 as a white amorphous solid (29.1 mg, 77 %).  1H 
NMR, D2O, 400 MHz:    7.15 (s, 1H, Ar-H), 7.14 (s, 1H, Ar-H), 6.67 (dd, 1H, CCHCH2, J 
= 11.0 & 17.7 Hz), 6.04 (d, 1H, CCHCHH, J = 17.7 Hz), 5.52 (d, 1H, CCHCHH, J = 11.0 
Hz), 4.44 (d, 2H, H-1 & 1’, J = 7.5 Hz), 3.96-3.89 (m, 3H), 3.82-3.51 (m, 10H), 3.33 (m, 
1H), 2.79 (t, 2H, H-16, J = 7.3 Hz), 2.43 (s, 3H, NCCH3), 1.97 (m, 2H, OCH2CH2).  13C 
NMR, D2O, 100 MHz:    160.67, 157.98, 146.76, 134.49, 119.34, 118.52, 117.62, 
102.92, 102.01, 78.39, 75.34, 74.73, 74.38, 72.82, 72.50, 70.93, 69.40, 68.52, 61.00, 
60.06, 33.08, 29.25, 22.52.  ESI-HRMS:  C23H35N1Na1O11 (M+Na+) = m/z 524.2102. 
Found: m/z 524.2176.  Infrared (KBr): 3415, 1076 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water 
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 100 % MeCN over 20 minutes, retention time, 12.72 mins., purity, 98.57 %. 




A solution of 4.45 (10 mg, 0.0199 mmol) and glutathione (2.21, 0.9 eq., 5.5 mg, 
0.0179 mmol) in THF (1 mL) and aqueous sodium phosphate (0.1 M, pH = 7, 3 mL) 
were stirred for 4 hours at room temperature. The solution was loaded directly 
onto a C-18 column and purified (100 % water → 30 % MeOH/water) to yield 4.46 
as a clear glassy solid (9.4 mg, 65 %).  1H NMR, CD3OD, 500 MHz:  δ  1.98 (q, 2H), 
2.15 (q, 2H), 2.48 (s, 3H), 2.55 (m, 2H), 2.78–2.87 (m, 6H), 3.09 (dd, 1H), 3.28 (dd, 
1H), 3.30-3.32 (m, 13H), 3.40 (m, 1H), 3.49-3.93 (m, 16H), 4.29 (d, 1H), 4.38 (d, 1H), 
4.58 (dd, 1H), 7.01, (s, 1H), 7.08 (s, 1H).  13C NMR, CD3OD, 100 MHz:  δ  23.57, 
27.99, 31.22, 33.11, 33.33, 34.50, 34.70, 44.55, 54.52, 55.68, 61.40, 61.91, 62.30, 
62.53, 69.66, 70.34, 72.57, 74.82, 74.85, 76.39, 76.47, 77.09, 80.64, 104.35, 105.13, 
122.31, 122.71, 152.83, 158.70, 162.08, 172.26, 174.06, 175.45, 175.96. ESI-MS: 
Expected for C33H51N4O17S1 (M-H+) = m/z 807.2975. Found: m/z 807.3025.  Infrared 
(KBr):  3444, 1644, 1402 cm-1.  HPLC:  column:  Phenomenex Luna-C18 (250 x 4.60 
mm), gradient:  (0.7 mL/min) 5 % MeCN/H2O  90 % MeCN/H2O over 20 minutes, 




HPLC of Sbi peptide thiol alkylation by 4.45. 
The reaction of the Sbi3,4-Cys 20 amino acid peptide (4.47, 0.37 mM) with 4.45 (1.1 
mM) was performed in aqueous sodium phosphate (0.1 M, pH = 7). Aliquots of the 
reaction (10 µl) were analysed by HPLC. The native peptide sequence eluted at 12.8 
minutes, while the glycosylated peptide eluted at 12.2 minutes under the elution 
conditions developed on the HPLC instrument: Phenomenex C-18 Luna column, 
detector 220 nm, elution: 10  50% MeCN/H2O (with 0.1 % TFA). A plot of the 
glycosylation reaction was performed through analysis of the integrals associated 
with the diminishing reactant peak and increasing product peak over the time 
course. The product eluting at 12.2 minutes was subsequently collected and 
analysed by mass spectrometry. The product was identified in the MS with a mass 
of m/z 2773.43 which was expected for the glycosylated product. Expected for 















Methyl {[(4-ethenyl-6-methylpyridin-2-yl)methyl]sulfanyl}acetate (4.2, 100 mg, 
0.421 mmol) was dissolved in THF (5 mL) with NaOH (1 M, 1.5 eq., v = 0.63 mL, 
0.632 mmol). The reaction was rapidly stirred at room temperature for 6 hours. The 
reaction was neutralised with 1 M HCl solution, concentrated and used directly in 
the following reaction. The residue was dissolved in anhydrous DMF (10 mL), along 
with NH2-PEG2kDa (0.5 g, 0.25 mmol, JenKem USA) and triethylamine (0.1 mL), 
while under N2. The solution was cooled to 0 C. HATU (144.5 mg, 0.38 mmol) was 
slowly added and the reaction was allowed to warm to room temperature and left 
to stir overnight. The reaction was concentrated and purified by silica gel 
chromatography (100 % CH2Cl2  15 % MeOH/CH2Cl2) to yield 4.48 as a white 
amorphous solid (0.34 g, 61 %).  1H NMR, CDCl3, 400 MHz:    7.89 (br. s, NH), 7.10 
(s, 1H, Ar-H), 7.03 (s, 1H, Ar-H), 6.61 (dd, 1H, CCHCH2, J = 10.8 & 17.6 Hz), 5.95 (d, 
1H, CCHCHH, J = 17.6 Hz), 5.46 (d, 1H, CCHCHH, J = 10.8 Hz), 3.80 (s, 2H, NCCH2S), 
3.58 (s, 188H, OCH2CH2O), 3.36 (s, 3H, OCH3), 3.12 (s, 2H, SCH2CONH), 2.52 (s, 3H, 
NCCH3).  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient:  
(0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 








Methyl 3-(4-ethenyl-6-methylpyridin-2-yl)propanoate (4.3, 100 mg, 0.487 mmol) 
was dissolved in THF (5 mL) with NaOH (1 M, 1.5 eq., v = 0.73 mL, 0.731 mmol). The 
reaction was rapidly stirred at room temperature for 6 hours. The reaction was 
neutralised with 1 M HCl solution, concentrated and used directly in the following 
reaction. The residue was dissolved in anhydrous DMF (10 mL), along with NH2-
PEG2kDa (0.5 g, 0.25 mmol, JenKem USA) and triethylamine (0.1 mL), while under 
N2. The solution was cooled to 0 C. HATU (144.5 mg, 0.38 mmol) was slowly added 
and the reaction was allowed to warm to room temperature and left to stir 
overnight. The reaction was concentrated and purified by silica gel chromatography 
(100 % CH2Cl2  15 % MeOH/CH2Cl2) to yield 4.49 as a white amorphous solid (0.31 
g, 57 %).  1H NMR, CDCl3, 400 MHz:    7.19 (s, 1H, Ar-H), 7.15 (s, 1H, Ar-H), 7.00 (br. 
s, NH), 6.65 (dd, 1H, CCHCH2, J = 10.9 & 17.7 Hz), 6.06 (d, 1H, CCHCHH, J = 17.7 Hz), 
5.57 (d, 1H, CCHCHH, J = 10.9 Hz), 3.65 (s, 170H, OCH2CH2O), 3.41 (s, 3H, OCH3), 
3.12 (t, 2H, NCCH2, J = 6.9 Hz), 2.71 (t, 2H, CCH2CH2CO, J = 6.9 Hz), 2.59 (s, 3H, 
NCCH3).  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient:  
(0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 





4-VP derivatised PEG’s as reagents for protein PEGylation. 
Yeast enolase (1 mg/mL) was denatured in argon purged buffer (0.5 M Tris, pH = 
7.2, 5 mM EDTA) containing 8 M urea at 85 C for 15 minutes. The solution was 
allowed to cool to room temperature before aliquoting out 100 L samples for the 
experiments. Varying concentrations of TCEP or THPP (1-10 mM) were added to 
aliquots of protein solution (11 M) and incubated for 45 minutes at 25 C. 4-VP-
PEG2kDa derivatives 4.48 or 4.49 (1 mM) were subsequently added to the reactions 
with no addition of alkyl azide 3.3 and incubated at 37 C for 18 hours. Samples that 
had addition of 3.3 (100 mM) required pre-incubation for 1 hour at 37 C. 4-VP-
PEG2kDa derivatives 4.48 or 4.49 (1 mM) were subsequently added to the reactions 
and incubated at 37 C for 18 hours. Samples (15 L) were taken from each of the 
reactions and added to Laemmli sample buffer (15 L). Aliquots (9 L) of these 
solutions were loaded into a precast gradient gel (4-12 % Bis-Tris, Invitrogen) along 
with a protein ladder (EZ-Run, Fisher Scientific) and resolved by SDS Page 
electrophoresis [MOPS running buffer (Invitrogen), 180 V, 60 mins]. The precast 
gels were stained by Coomassie solution and destained using a 
water/ethanol/acetic acid (16:3:1) solution. 
Time dependant PEGylation of yeast enolase by maleimide-PEG2kDa 
versus 4-VP-PEG2kDa derivatives 4.48 and 4.49. 
Yeast enolase (1 mg/mL) was denatured in argon purged buffer (0.5 M Tris, pH = 
7.2, 5 mM EDTA) containing 8 M urea at 85 C for 15 minutes. The solution was 
allowed to cool to room temperature before aliquoting out 100 L samples for the 
experiments. TCEP (5 mM) was added to aliquots of protein solution (11 M) and 
incubated for 45 minutes at 25 C. The alkyl azide 3.3 (100 mM) was added and the 
solutions were incubated for 1 hour at 37 C. Maleimide-PEG2kDa or 4-VP-PEG2kDa 
derivatives 4.48 or 4.49 (1 mM) were subsequently added to the reactions and 
incubated at 37 C for a total of 24 hours. Samples (15 L) were taken from each of 
the reactions at time points, 1 hour, 4 hours and 24 hours and added to Laemmli 
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sample buffer (15 L). Aliquots (9 L) of these solutions were loaded into a precast 
gradient gel (4-12 % Bis-Tris, Invitrogen) along with a protein ladder (EZ-Run, Fisher 
Scientific) and resolved by SDS Page electrophoresis [MOPS running buffer 
(Invitrogen), 180 V, 60 mins]. The precast gels were stained by Coomassie solution 




4-Vinyl pyridine (4.33, 200 mg, 1.90 mmol) was dissolved in 2-propanol (2 mL) and 
toluene (1 mL). Trityl thionitrite (5.10, 5 eq., 116 mg, 0.380 mmol) was added to the 
stirring solution and the reaction was heated from room temperature to 50 C. This 
temperature was maintained for 4 hours. The reaction was concentrated and the 
residue was purified by silica gel chromatography (10 % EtOAc/petroleum ether  
100 % EtOAc) to yield 5.11 as a white solid (115 mg, 74 %).  1H NMR, acetone-d6, 
400 MHz:    11.41 (s, 1H, NOH), 8.49 (dd, 2H, H-2 & H-6, J = 1.6 & 4.5 Hz), 7.53-7.26 
(m, 17H, H-3, H-5 & 3 x Ar-H), 3.43 (s, 2H, SCH2CNOH).  13C NMR, acetone-d6, 125 
MHz:    152.5 (CCNOH), 151.6 (C-2 & C-6), 146.0 (3 x ipso Ar-C), 143.9 (C-4), 131.2 
(6 x ortho Ar-C), 129.7 (6 x meta Ar-C), 128.6 (3 x para Ar-C), 121.6 (C-3 & C-5), 68.9 
(SC(Ph)3), 26.7 (SCH2CNOH).  Infrared (KBr):  3060, 1598, 948 cm-1.  ESI-MS:  
Expected for C26H23N2O1S1 (M+H+) = m/z 411.1526.  Found: m/z 411.1545.  HPLC: 
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column:  Phenomenex Luna-C18 (250 x 4.60 mm), gradient (0.7 mL/min) 100 % 
water  9:1 (acetonitrile:water) over 20 minutes, retention time, 12.19 mins., 
purity, 92 %. Detection at 300 nm. 
Synthesis of 4-[2-(tritylsulfanyl)ethyl]pyridine (5.13). 
 
4-Vinyl pyridine (4.33, 150 mg, 1.43 mmol) was dissolved in 2-propanol (6 mL) and 
toluene (3 mL). Tritylthiol (5.12, 1.1 eq., 434 mg, 1.57 mmol) was added to the 
stirring solution and the reaction was heated from room temperature to 50 C. The 
temperature was maintained for 4 hours. The reaction was concentrated and the 
crude was purified by silica gel chromatography (10 % EtOAc/petroleum ether  
100 % EtOAc) to yield 5.13 as a white solid (430 mg, 79 %).  1H NMR, CDCl3, 400 
MHz:    8.43 (d, 2H, H-2 & H-6, J = 5.8 Hz), 7.41-7.20 (m, 15H, 3 x Ar-H), 6.90 (d, 2H, 
H-3 & H-5, J = 5.8 Hz), 2.55-2.50 (m, 2H, CCH2CH2S), 2.46-2.42 (m, 2H, CCH2CH2S). 
13C NMR, CDCl3, 100 MHz:    149.6 (C-2 & C-6), 149.1 (C-4), 144.6 (3 x ipso Ar-C), 
129.5, 127.9, 126.7 (3 x para Ar-C), 123.8 (C-3 & C-5), 66.9 (SC(C)3), 34.5 (CCH2CH2S), 
32.1 (CCH2CH2S).  ESI-MS:  Expected for C26H23N1Na1S1 (M+Na+) = m/z 404.1449.  
Found: m/z 404.1464. Infrared (KBr):  3067, 1601 cm-1.  HPLC:  column:  Waters 
Symmetry Shield RP8 (100 x 4.60 mm), gradient:  (0.5 mL/min) 5 % MeCN in water 
 100 % MeCN over 20 minutes, retention time, 19.98 mins., purity, 95.8 %. 






4-VP (4.33, 500 mg, 4.76 mmol) was dissolved in 2-propanol (3 mL) and toluene (1.5 
mL). N-acetyl-S-nitroso-L-cysteinate (5.14, 5 eq., 196 mg, 0.951 mmol) was added to 
the stirring solution and the reaction was heated from room temperature to 50 C 
and maintained at this temperature for 4 hours. The reaction was concentrated and 
the crude was purified by silica gel chromatography (10 % EtOAc/petroleum ether 
 100 % EtOAc) to yield 5.15 as a white amorphous solid (127.3 mg, 43 %).  1H 
NMR, acetone-d6, 400 MHz:    11.24 (s, 1H, NOH), 8.59 (d, 2H, H-2 & H-6, J = 5.3 
Hz), 7.67 dd, 2H, H-3 & H-5, J = 1.7 & 5.3 Hz), 4.79 (m, 1H, CH2CHCO2), 4.09 (d, 1H, 
SCHHCNOH, J = 13.3 Hz), 3.86 (d, 1H, SCHHCNOH, J = 13.3 Hz), 3.69 (s, 3H, CO2CH3), 
3.03 (dd, 1H, SCHHCHNH, J = 5.1 & 13.8 Hz), 2.83 (1H, SCHHCHNH), 1.93 (s, 3H, 
NHCOCH3).  13C NMR, acetone-d6, 125 MHz:    172.8 (NHCOCH3), 170.8 
(CHCO2CH3), 153.9 (CCNOH), 151.6 (C-2 & C-6), 143.8 (C-4), 122.07 (C-3 & C-5), 53.6 
(CH2CHCO2), 53.2 (CO2CH3), 35.4 (SCH2CH), 24.6 (SCH2CNOH), 23.4 (NHCOCH3).  ESI-
MS:  Expected for C13H18N3O4S1 (M+H+) = m/z 312.1013. Found: m/z 312.1017.  IR 
(KBr): 3261, 1741, 1655, 967 cm-1. HPLC:  column:  Phenomenex Luna-C18 (250 x 
4.60 mm), gradient (0.7 mL/min) 100 % water  9:1 (MeCN:water) over 20 
minutes, purity 92 %. Detection at 300 nm. Also isolated was dimethyl N,N'-
diacetyl-L-cystinate (5.17) as a white solid (174.5 mg, 52 %). Experimental data was 
consistent with that reported in the literature [200].  1H NMR, CD3OD, 400 MHz:    
4.76 (dd, 1H, CH2CHCO2, J = 5.0 & 8.6 Hz), 3.77 (s, 3H, H-5), 3.28 (dd, 1H, SCHHCH, J 
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= 5.0 & 14.0 Hz), 3.00 (dd, SCHHCH, J = 8.6 & 14.0 Hz), 2.02 (s, 3H, NHCOCH3), 13C 
NMR, CD3OD, 100 MHz:    173.3 (NHCOCH3), 172.4 (CHCO2), 53.0 (CH2CHCO2 & 
CO2CH3), 40.5 (SCH2CH), 22.4 (NHCOCH3).  ESI-MS:  Expected for C12H21N2O6S2 
(M+H+)= m/z 353.0836. Found: m/z 353.0856. Methyl N-acetyl-S-[2-(pyridin-4-
yl)ethyl]-L-cysteinate (5.16) was identified in the mass spectrum of the crude 
reaction: ESI-MS:  Expected for C13H19N2O3S1 (M+H+) = m/z 283.1111. Found: m/z 
283.1110. Also isolated was 6 mg of 4,4'-but-1-ene-2,4-diyldipyridine (5.18) as a 
transparent oil (6 mg, yield: 3 %). 1H NMR, CD3OD, 400 MHz:    8.50 (dd, 2H, 2 x Ar-
H, J = 1.7 & 4.6 Hz), 8.39 (dd, 2H, 2 x Ar-H, J = 1.6 & 4.6 Hz), 7.50 (dd, 2H, 2 x Ar-H, J 
= 1.7 & 4.6 Hz), 7.27 (dd, 2H, 2 x Ar-H, J = 1.6 & 4.6 Hz), 5.58 (s, 1H, CH2CCHH), 5.28 
(s, 1H, CH2CCHH), 2.93 (m, 2H, CH2CH2CCH2), 2.84 (m, 2H, CCH2CH2CCH2).  13C NMR, 
CD3OD, 100 MHz:    153.22 (Ar-C), 150.52 (Ar-C), 150.40 (Ar-C), 149.87 (2 x Ar-C), 
146.19 (Ar-C), 125.75 (Ar-C), 122.58 (Ar-C), 117.77 (CH2CCH2), 35.63 (CH2CH2CCH2), 
34.63 (CCH2CH2C).  ESI-MS:  Expected for C14H15N2 (M+H+) = m/z 211.1230. Found: 
m/z 211.1253.  HPLC:  column:  Waters Symmetry Shield RP8 (100 x 4.60 mm), 
gradient:  (0.5 mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, 






















Allylamine (5.19, 0.40 g, 7.0 mmol) was dissolved in dry pyridine (10 mL). Acetic 
anhydride (2 eq., 1.32 mL, 14.0 mmol) was slowly added and the reaction was 
stirred under N2 for 6 hours. The reaction was cooled in an ice bath and MeOH (2 
mL) was slowly added. The reaction was concentrated and co-evaporated with 
toluene (2 x 20 mL). The crude was purified by silica gel chromatography (10 % 
EtOAc/petroleum ether  70 % EtOAc) to yield N-allylacetamide (5.20) as a clear oil 
(0.58 g, 84 %). The experimental is consistent with that reported in the literature 
[201].  1H NMR, 400 MHz (CDCl3):    6.26 (br. s, 1H), 5.82-5.72 (m, 1H), 5.15-5.04 
(m, 2H), 3.82-3.78 (m, 2H), 1.95 (s, 3H). 13NMR, 100 MHz (CDCl3):    170.1, 134.2, 
116.1, 42.0, 23.0.  ESI-MS:  Expected for C5H10N1O1 (M+H+)= m/z 100.0757. Found: 
m/z 100.0756. N-Allylacetamide (5.20, 0.10 g, 1.8 mmol) was dissolved in 2-
propanol (2 mL) and toluene (1 mL). Comound 5.10 (0.11 g, 0.35 mmol) was added 
to the reaction was subsequently heated from room temperature to 50 C. This 
temperature was maintained for 4 hours. The crude was analysed by HRMS which 
confirmed the presence of the oxime product 5.21. ESI-MS:  Expected for 
C24H24N2Na1O2S1 (M+Na+) = m/z 427.1451.  Found m/z 427.1435. The reaction was 
concentrated and the residue was purified by silica gel chromatography (10 % 



















Pentafluorophenyl trifluoroacetate (1.4 eq., 0.200 mL, 1.15 mmol) was added to a 
stirred solution of D-biotin (5.22, 0.20 g, 0.819 mmol) in pyridine (3 mL) and the 
mixture stirred at room temperature for 1 hour. Allylamine (5.19, 2 eq., 0.12 mL, 
1.64 mmol) was then added to the mixture and stirring continued for a further 30 
minutes. The mixture was concentrated and purified by silica gel chromatography 
(100 % EtOAc  15 % MeOH/CH2Cl2) to give 5.23 as a white amorphous powder 
(225 mg, 97 %). Spectral data was consistant with that reported in the literature 
[202].  1H NMR, CD3OD, 400 MHz:  δ  8.12 (s, 1H, NH), 5.91 (m, 1H), 5.24 (dd, 1H, J = 
1.6 & 17.2 Hz), 5.16 (dd, 1H, J = 1.6 & 10.3 Hz), 4.56 (dd, 1H, J = 5.0 & 7.8 Hz), 4.37 
(dd, 1H, J = 4.5 & 7.8 Hz), 3.86 (m, 2H), 3.28 (m, 1H), 3.0 (dd, 1H, J = 5.0 & 12.7 Hz), 
2.78 (d, 1H, J = 12.7 Hz), 2.30 (t, 2H, J = 7.4 Hz), 1.86-1.62 (m, 4H), 1.56-1.48 (m, 2H).  
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13C NMR, 100 MHz, (CD3OD):  δ  175.9, 166.2, 135.6, 116.2, 63.4, 61.7, 57.0, 42.7, 
41.1, 36.8, 29.8, 29.5, 26.9. Infrared (KBr): 3294, 1698 cm-1.  ESI-HRMS: Expected for 
C13H22N3O2S1 (M+H+) = m/z 284.1427. Found: m/z 284.1426. SNO-glutathione (5.24, 
20.0 mg, 0.0595 mmol) was dissolved in Tris buffer (2 mL, 50 mM, pH = 7). A 
solution of 5.23 (3 eq., 51.0 mg, 0.180 mmol) in DMSO (0.5 mL) was added to the 
buffered solution of 5.24. The reaction was heated from room temperature to 50 C 
and held at this temperature for 4 hours. The reaction was analysed by HRMS which 
confirmed the presence of the oxime product 5.25.  ESI-MS:  Expected for 
C23H38N7O9S2 (M+H+) = m/z 620.2167.  Found: m/z 620.2146. 
 










Triethylamine (2 eq., 28.2 L, 0.202 mmol) and allyl amine (4 eq., 30.4 L, 0.405 
mmol) were added to a stirred solution of succinimidyl-D-biotinamide hexonate 
(5.29,46.0 mg, 0.101 mmol) in dichloromethane (2 mL). The reaction was stirred for 
1.5 hours at room temperature and then concentrated. The crude was purified by 
silica gel chromatography: 100 % EtOAc  15 % MeOH/CH2Cl2) to yield 5.26 as a 
white amorphous powder (36 mg, 90 %). Spectral data was consistant with that 
reported in the literature [202].  1H NMR, 400 MHz, CD3OD:    5.89 (m, 1H), 5.23 
(dd, 1H, J = 1.6 & 17.2 Hz), 5.16 (dd, 1H, 1.6 & 10.3 Hz), 4.56 (dd, 1H, J = 5.0 & 7.8 
Hz), 4.37 (dd, 1H, J = 4.5 & 7.8 Hz), 3.85 (m, 2H), 3.30-3.21 (m, 3H), 2.99 (dd, 1H, J = 
5.0 & 12.7 Hz), 2.77 (d, 1H, J = 12.7 Hz), 2.27 (m, 4H), 1.85-1.35 (m, 12H).  13C NMR, 
100 MHz, CD3OD:    176.0, 175.9, 166.1, 135.7, 116.2, 63.4, 61.7, 57.0, 42.7, 41.1, 
40.2, 37.0, 36.9, 30.2, 29.8, 29.5, 27.6, 27.0, 26.7.  Infrared (KBr):  1710, 1641 cm-1.  











Allylamine (10 eq., 66.1 µL, 0.881 mmol) was added to a stirred solution of D-
biotinamidohexanoyl-6-amino-hexanoic acid N-hydroxysuccinimide ester (5.30, 50 
mg, 0.0881 mmol) in DMF (3 mL). The mixture was stirred for 3 hours and then 
concentrated. The crude was purified by silica gel chromatography (100 % EtOAc  
15 % MeOH/CH2Cl2) to yield 5.27 as a white amorphous powder (34 mg, 76 %).  1H 
NMR, 400 MHz, CD3OD:  δ  5.88 (m, 1H), 5.23 (dd, 1H, J = 1.5 & 17.2 Hz), 5.15 (dd, 
1H, J = 1.5 & 10.3 Hz), 4.55 (dd, 1H, J = 5.0 & 7.7 Hz), 4.37 (dd, 1H, J = 4.5 & 7.7 Hz), 
3.84 (m, 2H), 3.29-3.20 (m, 5H), 2.99 (dd, 1H, J = 4.9 & 12.7 Hz), 2.76 (d, 1H, J = 12.7 
Hz), 2.30-2.22 (m, 6H), 1.85-1.46 (m, 19H).  13C NMR, 100 MHz, CD3OD:  δ  176.1, 
176.0, 175.9, 166.1, 135.6, 116.1, 63.4, 61.7, 57.0, 42.7, 41.1, 40.2, 37.0, 36.9, 36.8, 
30.1, 29.8, 29.5, 27.6, 26.9, 26.7, 26.6. Infrared (KBr): 3298, 1706, 1636 cm-1.  ESI-
HRMS, Expected for C25H44N5O4S (M+H+) = m/z 510.3109. Found: m/z 510.3111.  
HPLC: column:  Phenomenex Luna-NH2 (250 x 4.60 mm, 5 micron) column, gradient 
(0.5 mL/min) 100 % water  9:1 (acetonitrile:water) over 20 minutes, retention 






Synthesis of D-biotin propylamide (5.28). 
 
Pentafluorophenyl trifluoroacetate (1.5 eq., 211 L, 1.16 mmol) was added to a 
stirred solution of D-biotin (5.22, 200 mg, 0.819 mmol) in pyridine (3 mL). The 
solution was stirred at room temperature for 1 hour, then propylamine (4 eq., 269 
L, 3.28 mmol) was added and the reaction was stirred for a further 60 minutes. 
The reaction was concentrated and purified by silica gel chromatography (100 % 
EtOAc  15 % MeOH/CH2Cl2) to yield 5.28 as a white amorphous powder (217 mg, 
93 %). Spectral data was consistant with that reported in the literature [203].  1H 
NMR, CD3OD, 400 MHz:    4.55 (dd, 1H, J = 5.0 & 7.8 Hz), 4.36 (dd, 1H, J = 4.5 & 7.8 
Hz), 3.27 (m, 1H), 3.18 (t, 2H, J = 7.2 Hz), 2.99 (dd, 1H, J = 5.0 & 12.8 Hz), 2.76 (d, 1H, 
J = 12.8 Hz), 2.26 (t, 2H, J = 7.3 Hz), 1.84-1.46 (m, 8H), 0.98 (t, 3H, J = 7.3 Hz).  13C  
NMR, CD3OD, 100 MHz:   176.0, 166.1, 63.4, 61.7, 57.0, 42.2, 41.1, 36.9, 29.8, 29.5, 
27.0, 23.7, 11.7.  Infrared (KBr): 1710 cm-1. ESI-HRMS:  Expected for C13H24N3O2S1 
(M+H+) = m/z 286.1584. Found: m/z 286.1584. 
Preparation of S-nitrosated BSA and Western blot analysis of allylamide 
functionalisation. 
Commercial bovine serum albumin (BSA, 2 mg/mL) was incubated with DEA 
NONOate solution (1 mM) in light limited conditions for 20 minutes, where all 
reactions were performed in physiological salt solutions containing NaCl (130 mM), 
KCl (5 mM), CaCl2 (1.5 mM), MgCl2, NaHCO3 (1 mM), KH2PO4 (1.5 mM), Hepes (25 
mM), glucose (10 mM) (pH 7.3 with NaOH). Control samples were left untreated 
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without addition of DEA NONOate. Control and S-nitrosated BSA samples were 
incubated individually with either 450 μM of compounds 5.23, 5.26, 5.27 and 5.28 
for 15 minutes at 60 ˚C under limited light conditions. For detection of protein 
biotinylation, 80 ng per protein sample were resolved alongside pre-biotinylated 
SDS-PAGE standard markers (Biorad, Hertfordshire, UK) as a positive control. 
Proteins were resolved using 4-12 % BIS-TRIS gradient gel and transferred to 
nitrocellulose membranes. Membranes were blocked with 5 % BSA and biotinylated 
proteins detected using neutravidin HRP. After washing steps, bound neutravidin 
HRP was detected by the ECL detection system (Amersham, GE Healthcare). 
LC-MS analysis of S-nitrosated BSA functionalized with compound 5.27. 
A sample of S-nitrosated BSA (120 μL, 2 mg/mL) was incubated with a solution of 
5.27 (5 μL, 10 mM) for 15 minutes at 37 °C. Peptic digestion of labelled BSA was 
then performed by addition of pepsin (50 μL, 0.3 mg/mL) in digestion buffer (1M 
NaH2PO4, pH = 2) and incubated for 2 hours at 37 °C. Biotinylated peptides were 
then separated using Captavidin biotin-binding agarose suspension. The digestion 
mixture was diluted in 0.5 mL of biotin-binding buffer (50 mM citrate phosphate 
buffer, pH 4) and applied to Captavidin resin. Biotinylated peptides were purified 
under standard conditions and eluted using 1 mL of elution buffer (50 mM sodium 
carbonate-HCl buffer, pH = 10). The eluent was then analysed by ES-LC-MS. In each 
of the MS experiments, the peptic digest was loaded onto a C-18 column (LC 
Packing, 100 Å pepMap, 1 mm × 150 mm) equilibrated with solvent A (solvent A: 
0.05 % trifluoroacetic acid and 2 % acetonitrile in water). Elution of the peptides 
was accomplished using a gradient (0 %  60 %) of solvent B over 60 min followed 
by 85 % solvent B over 20 min (solvent B: 0.045 % trifluoroacetic acid and 80 % 
acetonitrile in water). Solvents were pumped at a constant flow rate of 50 μL/min. 
Spectra were recorded in the single quadrupole scan mode (LC–MS), the 
quadrupole mass analyser was scanned over a mass-to-charge ratio (m/z) range of 
100–2200 Da with a step size of 0.5 Da and a dwell time of 1.5 ms per step. The ion 
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Appendix 1: THPP Reduction of ,β-Unsaturated 
Dicarbonyl Substrates 
A1.0) Introduction 
The rapid and mild conditions that resulted in the reduction of N-ethyl maleimide to 
N-ethyl succinimide by THPP, described previously in Chapter 2, prompted an 
investigation into the scope for THPP-mediated reduction of ,β-unsaturated 
dicarbonyl substrates. There are a number of methods available for reduction of 
1,4-dicarbonyl substrates, including hydrogenation reactions using metal catalysts 
such as Pd [1-3], Ru [4] or SnCl2/HCl [5], however, trisubstituted phosphines could 
offer an alternative method. Tributylphosphine and diethylphenylphosphine have 
been previously reported to reduce trans-dibenzoylethylene to 1,2-benzoylethane 
[6]. The reactions, however, required pre-forming the ylide intermediate in an 
anhydrous organic solvent, followed by a hydrolysis reaction by addition of water. 
The anhydrous organic solvents are probably required to dissolve the hydrophobic 
phosphines and also to prevent oxidation of the phosphines to phosphine oxides. 
Triphenylphosphine has been utilised to reduce maleimide to succinimide, although 
refluxing in an organic solvent was required [7]. The phosphorus containing 
Woollins reagent has also been reported to reduce ,β-unsaturated diketones [8]. 
THPP was investigated as a reagent for the mild reduction of ,β-unsaturated 
dicarbonyl substrates. 
A1.1) Reduction of ,β-Unsaturated Diesters and Diketones by THPP 
It was envisaged to investigate the potential of the water soluble THPP to rapidly 
reduce ,β-unsaturated diesters and diketones at room temperature and in an 
aqueous environment, with addition of minimal organic solvent (THF) to ensure 
dissolution of the 1,4-dicarbonyl substrates. 
263 
 
A selection of ,β-unsaturated dicarbonyl substrates were investigated and 
successfully reduced by THPP (Figure A1.1) at ambient temperature and complete 
within an hour. Reduction reactions were successful on unsaturated 1,4-diester and 
1,4-diketo substrates and also reduced both E and Z isomers in very good yield. 
 
Figure A1.1: Reduction of ,β-unsaturated diesters and diketones by THPP. 
Reduction reactions were also performed in deuterium oxide on a selection of 
substrates and consistently resulted in the incorporation of 3 deuterium atoms 
during saturation of the alkene (A1.3 & A1.7). The characterisation of the 
deuterated products indicated the reduction occurred through a similar mechanism 
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of reduction to that proposed for N-ethyl maleimide in Chapter 2. A general 
mechanism for reduction is illustrated in Figure A1.2. 
 
Figure A1.2: Mechanism of reduction of ,β-unsaturated diesters and diketones 
by THPP. 
A1.2) Conclusion 
THPP has been proven to be a rapid and efficient reducing agent for ,β-
unsaturated dicarbonyl substrates under very mild, aqueous conditions. The 
method is convenient as the reduced product can be isolated in high yield through a 
simple extraction with diethyl ether, while the phosphine or phosphine oxide 










Synthesis of diethyl butanedioate (A1.2). 
 
Diethyl fumarate (A1.1, 0.10 g, 0.581 mmol) was dissolved in THF/water (2:8, 4.5 
mL). A solution of THPP (2.7, 1 eq., 0.12 g, 0.581 mmol) was prepared in water (0.5 
mL) and added slowly to the rapidly stirring solution. The reaction was left to stir for 
30 minutes at room temperature. The reaction was diluted with 50 mL of diethyl 
ether and extracted with water (30 mL). The aqueous layer was extracted with 
diethyl ether (2 x 30 mL). The organic extraction layer were combined and dried 
over MgSO4. The mixture was filtered and the organic solution was concentrated. 
The residue was purified by silica gel chromatography (CH2Cl2  2 % 
acetone/CH2Cl2) to yield A1.2 as a clear oil (84.0 mg, 83 %). Spectral data consistent 
with data from commercial source [9]. 1H NMR, CDCl3, 400 MHz:    4.12 (q, 4 H, J = 
7.2 Hz), 2.59 (s, 4H), 1.23 (t, 6H, J = 7.2 Hz).  13C NMR, CDCl3, 100 MHz:    172.3, 
60.6, 29.1, 14.1. ESI-HRMS: Expected for C8H14Na1O4 (M+Na+) = m/z 197.0790.  








Synthesis of diethyl-2-dideutero-(3R,S)-deutero butanedioate (A1.3). 
 
Diethyl fumarate (A1.1, 0.10 g, 0.581 mmol) was dissolved in THF/deuterium oxide 
(2:8, 4.5 mL). A solution of THPP (2.7, 1 eq., 0.12 g, 0.581 mmol) was prepared in 
deuterium oxide (0.5 mL) and added slowly to the rapidly stirring solution. The 
reaction was left to stir for 30 minutes at room temperature. The reaction was 
extracted with 50 mL of diethyl ether. The aqueous layer was extracted with diethyl 
ether (2 x 30 mL). The organic extraction layer were combined and dried over 
MgSO4. The mixture was filtered and the organic solution was concentrated. The 
residue was purified by silica gel chromatography (CH2Cl2  2 % acetone/CH2Cl2) to 
yield A1.3 as a clear oil (82.6 mg, 71 %).  1H NMR, CDCl3, 400 MHz:    4.07 (q, 4H, J 
= 7.1 Hz), 2.51 (s, 1H), 1.18 (t, 6H, J = 7.1 Hz).  13C NMR, CDCl3, 100 MHz:    172.14, 
60.43, 28.52 (m), 13.96. ESI-HRMS: Expected for C8H11D3Na1O4 (M+Na+) = 200.0973. 
Found:  200.0972.  Infrared (thin film):  1738 cm-1.  HPLC: column: Phenomenex 
Luna-C18 (250 x 4.60 mm), gradient (0.7 mL/min) 100 % water  9:1 
(acetonitrile:water) over 20 minutes, retention time: 18.40 mins., purity: 90.4 %. 








Synthesis of diethyl butanedioate (A1.2). 
 
Diethyl maleate (A1.4, 0.11 g, 0.621 mmol) was dissolved in THF/water (2:8, 4.5 
mL). A solution of THPP (2.7, 1 eq., 0.13 g, 0.620 mmol) was prepared in water (0.5 
mL) and added slowly to the rapidly stirring solution. The reaction was left to stir for 
30 minutes at room temperature. The reaction was diluted with 50 mL of diethyl 
ether and extracted with water (30 mL). The aqueous layer was extracted with 
diethyl ether (2 x 30 mL). The organic extraction layer were combined and dried 
over MgSO4. The mixture was filtered and the organic solution was concentrated. 
The residue was purified by silica gel chromatography (CH2Cl2  2 % 












Synthesis of 1,4-diphenylbutane-1,4-dione (A1.6). 
 
Trans-1,4-diphenyl-2-butene-1,4-dione (A1.5, 0.17 mg, 0.731 mmol) was dissolved 
in THF/water (2:8, 4.5 mL). A solution of THPP (2.7, 1 eq., 0.15 g, 0.731 mmol) was 
prepared in water (0.5 mL) and added slowly to the rapidly stirring solution. The 
reaction was left to stir for 30 minutes at room temperature. The reaction was 
diluted with 50 mL of diethyl ether and extracted with water (30 mL). The aqueous 
layer was extracted with diethyl ether (2 x 30 mL). The organic extraction layer 
were combined and dried over MgSO4. The mixture was filtered and the organic 
solution was concentrated. The residue was purified by silica gel chromatography 
(10 % CH2Cl2/Petroleum ether  100 % CH2Cl2) to yield A1.6 as a white solid (155 
mg, 89 %). NMR data consistent with literature [10].  1H NMR, CDCl3, 400 MHz:    
8.06-8.03 (m, 4H), 7.60-7.56 (m, 2H), 7.50-7.46 (m, 4H), 3.47 (s, 4H).  13C NMR, 
CDCl3, 100 MHz:    198.6, 136.7, 133.1, 128.6, 128.1, 32.5.  ESI-HRMS: Expected for 








Synthesis of 1,4-diphenyl-2-dideutero-(3R,S)-deutero butane-1,4-dione 
(A1.7). 
 
Trans-1,4-diphenyl-2-butene-1,4-dione (A1.5, 0.11 mg, 0.466 mmol) was dissolved 
in THF/water (2:8, 4.5 ml). A solution of THPP (2.7, 1 eq., 96.8 mg, 0.466 mmol) was 
prepared in water (0.5 mL) and added slowly to the rapidly stirring solution. The 
reaction was left to stir for 30 minutes at room temperature. The reaction was 
diluted with 50 mL of diethyl ether and extracted with water (30 mL). The aqueous 
layer was extracted with diethyl ether (2 x 30 mL). The organic extraction layer 
were combined and dried over MgSO4. The mixture was filtered and the organic 
solution was concentrated. The residue was purified by silica gel chromatography (5 
% EtOAc/Petroleum ether  40 % EtOAc/Petroleum ether) to yield A1.7 as a white 
solid (95.5 mg, 85 %).  1H NMR, CDCl3, 400 MHz:    8.04-7.46 (m, 10H, Ar-H), 3.43 
(br. s, 1H).  13C NMR, CDCl3, 100 MHz:    198.8 & 198.7 (2 x C=O), 136.7, 133.1, 
128.6, 128.1, 32.2.  ESI-HRMS: Expected for C16H11D3Na1O2 (M+Na+) = m/z 
264.1074. Found: m/z 264.1099.  Infrared (thin film):  1676, 1451 cm-1.  HPLC: 
column: Waters Symmetry Shield RP8 (100 x 4.60 mm), gradient elution: (0.5 
mL/min) 5 % MeCN in water  100 % MeCN over 20 minutes, retention time, 17.19 







Synthesis of 1,4-bis(4-fluorophenyl)butane-1,4-dione (A1.9). 
 
Trans-1,4-(4-fluorophenyl)-2-butene-1,4-dione (A1.8, 0.13 g, 0.478 mmol) was 
dissolved in THF/water (2:8, 4.5 mL). A solution of THPP (2.7, 1 eq., 96.8 mg, 0.478 
mmol) was prepared in water (0.5 mL) and added slowly to the rapidly stirring 
solution. The reaction was left to stir for 30 minutes at room temperature. The 
reaction was diluted with 50 mL of diethyl ether and extracted with water (30 mL). 
The aqueous layer was extracted with diethyl ether (2 x 30 mL). The organic 
extraction layer were combined and dried over MgSO4. The mixture was filtered 
and the organic solution was concentrated. The residue was purified by silica gel 
chromatography (5 % EtOAc/Petroleum ether  40 % EtOAc/Petroleum ether) to 
yield A1.9 as a white solid (0.11 g, 85 %). NMR data consistent with literature [10].  
1H NMR, CDCl3, 400 MHz:    8.08-8.04 (m, 4H), 7.17-7.12 (m, 4H), 3.42 (s, 4H).  13C 
NMR, CDCl3, 100 MHz:    196.98 (2C), 165.81 (d, 2C, J = 254.72 Hz), 133.10 (d, 2C, J 
= 3.01 Hz), 130.73 (d, 4C, J = 9.31 Hz), 115.69 (d, 4C, J = 21.87 Hz), 32.39 (2C).  19F 
NMR, CDCl3, 470 MHz:    -105.10.  ESI-HRMS: Expected for C16H12F2Na1O2 (M+Na+) 
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Appendix 2: Reaction of a TCEP-Maleimide Ylene 
Adduct with Selectfluor 
A2.0) Introduction 
Chapter 2 describes the reaction of TCEP (2.6) with maleimide functionalised 
ligands 2.8 & 2.11, resulting in ylene adducts of TCEP and maleimide (2.9 & 2.12). 
The ylene adduct 2.9 was subsequently incubated with glutathione (2.21) to 
investigate the potential reaction of the nucleophilic thiol of 2.21 with 2.9. The 
reaction was performed at pH = 4, 7 and 8 and monitored by either NMR 
spectroscopy or mass spectrometry. No reaction between 2.9 and 2.21 was 
detected. The stability of 2.9 towards nucleophilic attack by a thiol over a wide pH 
range suggested that TCEP should be removed from the reaction before attempting 
a bioconjugation reaction utilising a thiol alkylation reagent based on maleimide. 
The potential reaction of 2.9 with an electrophilic reagent was subsequently 
investigated since the ylene adduct 2.9 resembles an ylide intermediate utilised in 
the Wittig reaction for the synthesis of alkene derivatives. 
A2.1) Reaction of 2.9 with Selectfluor 
The reaction of the ylene 2.9 with an electrophile was investigated by incubating 
2.9 with selectflour, a source of electrophilic fluorine (Figure A2.1). Purification of 
the reaction by silica gel chromatography yielded a racemic mixture of (3R)-1-ethyl-





Figure A2.1: Reaction of 2.9 with Selectfluor 
A1.2) Conclusion 
The ylene 2.9 reacted with Selectfluor to yield a racemate of A2.1 and A2.2. The 
isolation and characterisation of A2.1 and A2.2 suggested that 2.9 is capable of 
reacting with electrophilic reagents analogous to ylide derivatives, which react with 
electrophilic substrates in a Wittig reaction. The reaction of 2.9 with electrophilic 
Selectfluor provided further evidence for 2.9 existing as an ylene derivative, 












Synthesis of (3R)-1-ethyl-3-fluoropyrrolidine-2,5-dione (A2.1) and (3S)-
1-ethyl-3-fluoropyrrolidine-2,5-dione (A2.2) 
 
The ylene 2.9 (46 mg, 0.123 mmol) was dissolved in water (3 mL). Selectfluor (5 eq., 
217.1 mg, 0.615 mmol) was added and the reaction was stirred at 40 C for 6 hours. 
The reaction was extracted with Et2O (3 x 15 mL). The organic layer was dried 
(MgSO4), filtered and concentrated. The crude was purified by silica gel 
chromatography (10 % EtOAc/petroleum ether – 50 % EtOAc/petroleum ether) to 
yield racemic A2.1 and A2.2 as a transparent oil (6mg, 33.7 %).  1H NMR, CDCl3, 500 
MHz:    5.31 (ddd, 1H, COCFHCH2, J = 3.8, 8.1 & 51.5 Hz), 3.62 (q, 2H, NCH2CH3, J = 
7.2 Hz), 3.13 (ddd, 1H, CFHCHHCO, J = 8.1, 12.4 & 18.6 Hz), 2.87 (ddd, 1H, 
CFHCHHCO, J = 3.8, 18.6 & 45.0 Hz), 1.21 (t, 3H, NCH2CH3, J = 7.2 Hz).  13C NMR, 
CDCl3, 125 MHz:  172.2 (d, J = 5.3 Hz), 171.90 (d, J = 20.1 Hz), 84.36 (d, J = 188.7 Hz), 
35.91 (d, J = 21.6 Hz), 34.11, 12.84.  19F NMR, CDCl3, 470.5 MHz:    -190.2 (dddd, J = 
12.2, 26.1 & 52 Hz).  Infrared (NaCl disc):  1716.1, 1129.8, 1034.3 cm-1. 
 
